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Abstract 
Drug hypersensitivity reactions are an important problem for pharmaceutical industry, especially 
when reactions are observed in late phase clinical trials. Furthermore, management of patients 
with reactions leads to personal suffering and financial burden on the NHS. React ions are almost 
impossible to predict as there is no simple relationship between the dose of drug administered 
and the development of hypersensitivity. In recent years, pharmacogenetic studies identified 
strong associations between the expression of specific HLA alleles and susceptibility to different 
forms of hypersensitivity, which would explain why only a small number of drug-exposed 
patients develop hypersensitivity. Studies utilizing peripheral blood mononuclear cells have 
detected drug-specific T-cells in patients with hypersensitivity, but not drug-exposed tolerant 
controls, suggesting that the adaptive immune system plays an important role in the disease 
pathogenesis. Despite this, there remains a need to further understand mechanisms as more 
detailed knowledge will assist the development of diagnostic and predictive assays.  
Data described herein utilized hypersensitivity reactions to the β- lactam antibiotic piperacillin as 
a model to investigate the phenotype and function of drug-specific T-cells in blood and skin, 
focusing specifically on the profile of cytokines secreted. PBMC from hypersensitive patients 
were activated to proliferate in vitro with piperacillin. T-cell clones responsive to the drug were 
generated from blood of all patients studied. CD4+ clones were stimulated to proliferate with 
piperacillin in a concentration-dependent manner and the proliferative response was associated 
with secretion of Th1 and Th2 cytokines alongside IL-22. In contrast, IL-17 was not secreted 
from piperacillin-specific clones. Piperacillin-specific CD4+ clones were also isolated from 
inflamed skins of 2 piperacillin hypersensitive patients. Activation of these clones was associated 
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with secretion of Th1, Th2 cytokines and IL-22, in the absence of IL-17. Finally, CD4+ nitroso 
sulfamethoxazole (SMX-NO)-responsive clones were isolated from sulfamethoxazole 
hypersensitive patients and a similar cytokine secretion profile was observed, which suggests 
that IL-22 secretion might be a common feature of drug hypersensitivity.  
Evolution of T-cell culture methods means it is now possible to prime naïve T-cells from healthy 
donors to antigens, including drugs, which they have not previously been exposed to. Piperacillin 
and SMX-NO were found to prime naïve CD4+ and CD8+ T-cells from healthy donors, when the 
drug-derived antigens were presented in the context of autologous dendritic cells. Cloned drug-
specific T-cells secreted a similar panel of cytokines to that observed with patient cells. Of 
particular importance was the detection of IL-22 in the absence of IL-17.  
The final component of the project utilized cloned T-cells with specificity for SMX-NO, 
piperacillin and flucloxacillin to explore mechanisms of drug-specific T-cell activation and 
potential cross-reactivity. Clones responsive against all 3 drugs were activated via a hapten 
mechanism involving (1) formation of protein adducts, (2) antigen processing and (3) 
presentation of derived peptides in an MHC-restricted manner. No cross-reactivity was observed 
with the 3 drugs. 
Collectively, these data showed that drug-haptens activate T-cells from patients with clinically 
divergent forms of hypersensitivity. T-cells secrete a similar profile of cytokines including the 
tissue-specific cytokine IL-22 following stimulation through the T-cell receptor. Furthermore, it 
is possible to prime naïve T-cells with a similar function against drugs using peripheral blood 
mononuclear cells from healthy donors.   
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1.1 Adverse drug reactions 
Edwards and Aronson, (2000) define adverse drug reactions (ADRs) as: “An appreciably 
harmful or unpleasant reaction, resulting from an intervention related to the use of a medicinal 
product, which predicts hazard from future administration and warrants prevention or specific 
treatment, or alteration of the dosage regimen, or withdrawal of the product.’’  
Several studies have estimated the proportion of patients hospitalized due to the development of 
ADRs. A study by Lazarou et al (1998) in the USA used four electronic databases and showed 
that between 1966 and 1976 the total percentage of ADRs was 15.5%. The percentage of the 
patients with severe ADRs was 6.7% with 0.37% of reactions resulting in fatality.  According to 
a study by Pirmohamed et al (2004) which looked at 18,829 patients hospitalized in the two large 
hospitals in the UK, 1225 of these were classified as ADRs according to the Edwards and 
Aronson definition. The total percentage of ADRs was 6.25% with fatality rates of 0.15%. ADRs 
also extend the length of stay in hospital and enhancing the costs of hospitalization (Suh et al, 
2000). ADRs can be classified in terms of clinical and chemical characteristics (Park et al., 
1998).  
Type A (augmented): The vast majority (95%) of adverse drug reactions are classified as this 
type. They are dose-dependent and predictable from the knowledge of pharmacology of the drug, 
thus they can be prevented. When administration of the drug stops the reaction disappears. 
Examples of type A reactions include (1) gastrointestinal bleeding induced by the treatment of 
drug combinations of aspirin and warfarin; (2) gastrointestinal bleeding induced by NSAIDS; (3) 
diuretic- induced renal impairment; and (4) -blocker-induced heart block or hypertension 
(Pirmohamed et al., 2004).  
Type B (bizarre): These reactions cannot be predicted by knowledge of the drug’s 
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pharmacology. They display individual susceptibility and are non-dose-dependent, although this 
has been questioned (Uetrecht 2001). Such reactions are also referred to as idiosyncratic 
reactions as mechanisms have not been clearly defined. The reactions are believed to be related 
to drug metabolite and immunological components that maybe key to individual susceptibility. 
Because of this, reactions occur in a small percentage of patients. Despite this, type B reactions 
are extremely important because they are often severe and can lead to death (Pirmohamed et al., 
2004). Type B reactions can involve any organ, and may cause anaphylaxis, and severe skin 
inflammation such as hypersensitivity-syndromes or drug induced lupus. Exemplar drugs that 
can induce this type of reaction include antibiotics, such as amoxicillin and flucloxacillin; 
sulfonamides, such as sulfamethoxazole; non-steroidal anti- inflammatory drugs and 
anticonvulsants. 
 
Type C (chemical): These reactions can be explained by the chemical structure of the drug or 
drug metabolite. Paracetamol- induced hepatotoxicity is a well-defined example. The mechanism 
if tissue injury involves the conversion of the drug by metabolizing enzymes to a reactive 
qunioneimune intermediate, which (1) induces oxidative stress and (2) binds covalently to 
proteins. Eventually both of these processes lead to hepatotoxicity.  
 
Type D (delayed): These reactions include delayed effects such as carcinogenicity and 
teratogenicity after drug administration.  
 
Type E (end of treatment reactions): Onset of clinical symptoms of the reaction develops after 
removal of the drug, especially following a sudden removal. A well-known example is after 
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withdrawal of anxiolytics.  
1.2 Drug Hypersensitivity 
Type B ADRs are mostly dominated by antigen-specific immune responses induced following 
drug exposure. This form of reaction is often termed drug hypersensitivity.  
Drug hypersensitivity reactions involve the drug initiating an immune reaction that causes tissue 
damage in the patient. These reactions can be defined simply as “a serious adverse drug reaction 
with an immunological aetiology, to an otherwise safe and effective therapeutic agent”. 
Alternatively, drug hypersensitivity has been defined by the World Allergy Organization as "an 
immunologically mediated drug adverse reaction of which the mechanism is IgE or non-IgG 
mediated and with T-cell mediated reaction largely presented in the latter (Johansson et al., 
2004). 
 
1.2.1 Epidemiological investigation of drug hypersensitivity  
According to the definitions of drug hypersensitivity presented above, several studies tried to 
investigate the incidence of drug hypersensitivity. In France, a 6-month prospective study has 
been carried out, in which each individual inpatient was examined physically by a dermatologist 
and reviewed by a pharmacologist. The prevalence of cutaneous drug hypersensitive reactions 
was 3.6 per 1000 hospitalized patients (Fiszenson-albala et al., 2003). Among these patients, 
57% presented with maculopapular exanthema, 8% with erythroderma and 2% with severe 
conditions such as Stevens Johnson syndrome or toxic epidermal necrolysis. In Mexico in 2006, 
a 10-month prospective study showed 7 per 1000 hospitalized patients developed cutaneous 
hypersensitivity reactions (Hernandez-Salazar et al., 2006). Similar studies were carried in 
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Singapore (Thong et al., 2003) and in Korea (Park et al., 2008). In these studies, 4.2 and 20 per 
1000 hospitalized patients, respectively, developed hypersensitivity reactions.  
Risk factors of drug hypersensitivity include: gender; female: male ratio of drug hypersensitivity 
has been estimated to be approximately 2:1 (Impicciatore et al., 2001), age; the rate of drug 
hypersensitivity is more frequent in elderly people than in children. Concomitant disease may 
predispose individuals to drug hypersensitivity through altering metabolic pathways and the 
immune response to the suspect drug. For example, patients with HIV develop an increased 
number of drug hypersensitivity reactions when compared with control subjects exposed to the 
same treatment regime. In particular, reactions to the drug sulfomethoxazole are 10 times more 
common in patients with HIV infection. Environmental factors such as disease, alcohol 
consumption, smoking and diet may also be important in an individuals’ susceptibility to ADRs. 
Furthermore, environment factors may interact with genetic factors and either increase or 
decrease the risk of an ADR (Pirmohamed et al., 2001). Patients infected with virus such as 
human herpes virus (HHV) 6 have an increased likelihood of developing hypersensitivity 
reactions and it has been reported that the pathogenesis of certain drug hypersensitivity 
syndrome actually involve drug-specific reactivation of the latent virus infection (Ozcan et al., 
2010). Patients with cystic fibrosis have ten times higher rates of piperacillin hypersensitivity 
compared with normal people (Whitaker et al., 2012).  
The study of medical genetics has been focused on the associations between HLA genotypes and 
drug hypersensitivity. This part will be discussed in detail in the following section.  
1.2.2 The symptoms of drug hypersensitivity 
The term of drug hypersensitivity encompasses clinical conditions varying in severity from mild 
skin rashes to severe reactions such as drug reaction with eosinophilia and systemic symptoms 
 14 
 
(DRESS), Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). 
Hypersensitivity reactions also develop in other organs, with the most common being drug-
induced liver injury (DILI) (Pavlos et al., 2012).  
Skin rashes are the most common manifest of drug hypersensitivity. This may be because skin 
injury is more visible than other manifestations such as liver injury. Thus, even mild skin 
conditions are often reported. Furthermore, the skin is a very immunologically active organ 
(Uetrecht and Naisbitt, 2013). Skin expresses specialized antigen presenting cells such as 
Langerhans cells and cutaneous dendritic cells that are constantly surveying skin for new and 
potentially dangerous antigenic determinants. Finally, skin is rich in resident T-cells, which 
following priming will respond rapidly to antigen encounter. The following skin details the most 
common cutaneous manifestations of drug hypersensitivity.  
Maculopapular exanthema (MPE). MPE are the most common type of skin rash that develops 
following drug exposure. The reactions account for more than 90% of drug- induced immune-
mediated skin rashes (Hunziker et al., 1997). The time to onset is typically 1-2 weeks after 
treatment (Valeyrie-Allanore et al., 2007). This manifestation alone is not severe and patients 
commonly recover fullyafter drug withdrawal. Furthermore, it is also relatively safe to 
rechallenge patients suspected of developing a drug-induced maculopapular drug eruption (P-
Codrea Tigaran et al., 2005). The phenotype of T-cells that dominate in MPE are CD4+ T-cells 
that display cytolytic activity (Pichlar 2003). In comparison with the most severe drug induced 
skin reaction, toxic epidermal necrolysis, which dominated by CD8+ cytotoxic T-cells, MPE is 
mild as most cells in the inflammed site  do not express MHC-II molecules that present the drug-
derived antigen to CD4+ T-cells. In contrast, cell ubiquitously express MHC-I that presents 
antigens to CD8+ T-cells. Finally, although CD4+ and CD8+ T-cells secrete the same cytolytic 
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molecules, CD8+ T-cells display significantly higher levels of cytotoxicity when activated by the 
same antigen. 
Uriticaria is the second most common manifestation of drug- induced skin rash (Hunziker et al., 
1997). It is an IgE-mediated reactions. Penicillins are the most common inducers of urticarial 
reactions. Urticaria is characterized by relatively large, raised, pruritic skin lesions, which will 
last for several days. As with other types of drug- induced skin reactions, uriticaria reaction 
appear very quickly after inadvertent rechallenge. Clinical signs of a reaction often appear 
minutes to hours after drug exposure.  
A fixed drug eruption is a type of drug- induced skin reaction with lesions that always develop at 
the same site every time when a drug is administered. When the drug is removed, the lesion 
usually recovers with a fade hyperpigmentation, which make it easy to define the affected area. 
This reaction is thought to be mediated by cutaneous CD8+ T-cells that are limited to the site of 
inflammation (Shiohara, 2009). Fixed drug eruptions are commonly mild, but it can be more 
serious when combined with other systemic manifestations such as fever and arthralgia.  
Drug reaction with eosinophilia and systemic symptoms (DRESS) and drug- induced 
hypersensitivity syndrome (DIHS). Although these two nomenclature are not in totally 
agreement, they are used to describe drug- induced symptoms with characteristics including an 
acute onset of rash, fever, and involvement of at least one of the following: lymphadenopathy, 
hepatitis, nephritis, pneumonitis, carditis, thyroiditis, and hematologic abnormalities 
(eosinophilia, atypical lymphocytes, thrombocytopenia, or leukopenia) (Peyriere et al., 2006; Um 
et al., 2010; Walsh and Creamer, 2011). The most common drugs that lead to DRESS/DIHS are 
carbamazepine and other aromatic anticonvulsants, allopurinol and several anti-HIV drugs such 
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as abacavir and nevirapine. The onset of symptoms is commonly associated with herpes virus 
reactivation (Descamps et al., 1997). The reason for the virus association is not known but 
DRESS is associated with some specific HLA genotypes which will be discussed in detail later.  
Acute generalized exanthematous pustulosis (AGEP). AGEP is a type of drug- induced skin 
reaction with characteristics including an acute onset of a non- infectious pustular skin reaction, 
commonly affecting the face, neck, groin and axillae and manifestations of fever and 
neutrophilia (Roujeau et al., 1991; Choi et al., 2010). The main drugs that initiate AGEP are 
antibotics. AGEP is thought to be mediated by Th17 cells that have been found in the PBMCs 
and inflamed skin (Fili et al., 2014). 
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). TEN is the most severe 
type of skin rash with a fatality rate of 30% (Pereira et al., 2007; Downey et al., 2012). SJS is a 
severe skin rash that is milder than TEN with a fatality rate of 10%. Overlap of SJS/TEN has the 
fatality rate between 10% and 30%. SJS and TEN are characterized by large scale of skin 
detachment between epidermal layer and dermal layer. On histological examination, widespread 
apoptosis of keratinocytes between dermis and epidermis and mononuclear infiltration can be 
seen. The time to onset is usually 1-2 weeks, but the time is decreased if the patient is re-exposed 
to the drug (Roujeau, 2005). SJS-TEN are clearly immune mediated reactions as drug-specific T-
cells have been detected in skin in the acute phase of reactions (Nassif et al., 2002). Furthermore, 
HLA allele associations have been described for certain drugs. However, the lymphocyte 
transformation test, a simple assay for diagnosis based on the drug-specific proliferation of 
patient lymphocytes, is typically negative for SJS/TEN (Tang et al., 2012). It has been reported 
that the skin rash is mediated by cytotoxic CD8+ T-cells, (Nassif et al., 2004; Wei et al., 2012）
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and keratinocytes apoptosis is mediated by the release of Fas ligand (Downey et al., 2012) and 
tumor necrosis factor related apoptosis- inducing ligand (TRAIL) (de Araujo et al., 2011). Recent 
studies have identified granulysin as another important cytolytic mediator in patients with TEN 
(Chung et al., 2008).  
Drug induced liver injury 
Liver injury is of another major manifestation of drug hypersensitivity and is the major cause of 
drug withdrawal or black box warnings. Drug induced liver injury (DILI) can be divided into two 
types, hepatocellular and cholestatic. Specifically, if the ratio of alanine transaminase/alkaline 
phosphatase is less than two, it is considered cholestatic liver injury; if the ratio is greater than 5, 
it is considered hepatocellular liver injury; if the ratio is between 2 to 5, it is considered an 
overlap of the two types of liver injury (Danan G, Benichou C, 1993).  
Hepatocellular liver injury is characterized by death of hepatocytes. Histologically, infiltratio n of 
mononuclear cells and eosinophils can be seen (Zimmerman, 1999). Cholestatic liver injury is 
characterized by a great increase of alkaline phosphatase and bilirubin relative to alanine 
transaminase. Although hepatocellular liver injury more commonly leads to liver failure 
(Chalasani et al., 2008), cholestatic liver injury requires more time to recover, usually more than 
a month (Hussaini and Farrington, 2007).  
The time to onset of DILI is usually 1-3 months; however sometimes the time between drug 
administration and appearance of DILI can be up to a year (Bjornsson, 2010). In certain 
instances, DILI appears very rapidly after the culprit drug is rechallenged, potentially indicating 
an immonological mechanism (Maddrey and Boitnott, 1973).  
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The association between HLA genotype and susceptibility of DILI has been reported for several 
drugs, e.g., flucloxacillin [B*57:01](Daly et al., 2009), ximelagatran [DRB1*07:01 and HLA-
DQA1*02] (Kindmark et al., 2008), lapatinib [HLA-DRB1*0701-
DQA1*0202/DQB1*0203](Spraggs et al., 2011), lumiracoxib [DRB1*15:01] (Kindmark et al., 
2008), anti-tuberculosis drugs [HLA-DQB1*0502] (Chen et al., 2015), and isoniazid [HLA-
DRB1*03], rifampin [HLA-DQA1*0102], and ethambutol [HLA-DQB1*0201] (Sharma et al., 
2002). 
 
1.3 The types of hypersensitivity 
The adaptive immune response is an important component of host defense against infection. 
However, sometimes the adaptive immune system over-reacts to innocuous agents such as 
pollen, food and drugs. This type of reaction is named hypersensitivity and is harmful and may 
cause serious tissue damage. Hypersensitivity reactions have been classified into 4 broad types 
by Gell and Coombs as shown in Table 1.1   (Gell and Coombs., 1963).  
I. Type I hypersensitivity: is also called immediate hypersensitivity. It is mediated by IgE and 
occurs within minutes after challenge or re-exposure to the innocuous antigen. IgE is produced 
by plasma cells, rather than other types of Ig accumulating in the serum or tissue. IgE tightly 
binds to the surface of mast cells and basophils via the high the affinity IgE receptor, FceRI. 
Antigen binds to IgE and cross- links the receptors, leading to the release of pharmacological 
active agents such as histamine, prostaglandins, and leukotrienes, which increase vascular 
permeability and contraction of smooth muscle, inducing clinical manifestations, including 
rhinitis, asthma, and, in severe cases, anaphylaxis.  
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Figure 1.1A The mechanism of Type I hypersensitivity.  Activated B cells secreted large amount of IgG antibody, 
which binds to the FcR expressed on the surface of mast cells. When an allergen binds it cross -links two IgE on the 
cell surface, the mast cell degranulates and releases histamine and leukotrienes, thereby inducing inflammation.  
 
II. Type II hypersensitivity  is induced by the binding of IgM or IgG antibodies to antigen on 
the surface of cells and thereafter activating the complement cascade, which causes the massive 
death of the cells. For example, IgG or IgM antibody- induced destruction of red blood cells or 
platelets can be induced by some drugs, such as penicillin and cephalosporin. Drugs bind to cell 
surfaces and become a target of anti-drug IgG antibodies, which in turn activate the complement 
cascade and lead to cell damage.  
III. Type III hypersensitivity : reactions are caused by soluble antigens. The reaction occurs 
when the complex of IgM or IgG and antigen accumulate in the circulation or in the tissue and 
activates complement system. The large immune complexes can be removed by monocyte-
phagocyte system, whereas small complexes can escape and deposit in blood vessel walls, where 
they can ligate Fc receptors on leukocytes, generating local inflammatory response and increase 
vascular permeability. Fluid and cells then enter the site of inflammation from local blood 
vessels. IgG forms immune complexes by binding FcgRIII, triggering the complement cascade 
by activating complement fragment C5a and in turn causing tissue damage.  
 
Mast cell
ActivationActivated 
B cell
Inflammation 
Histamine
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Figure 1.1B The mechanism of type II and type III hypersensitivity. Type II and type III hypersensitivity are 
induced by IgG and IgM antibodies. In type II, Ig antibodies bind to the surface of innocent cells. Then the 
complement system act ivates and induces cytotoxicity.  Type III hypersensitivity is due to the accumulation of 
antigen-complex in blood vessels or tissue. The complexes activate the complement system which then causes 
massive tissue damage. 
 
  
IV. Type IV hypersensitivity is mediated by antigen-specific effector T-cells. The response can 
take many weeks to develop but symptoms appear rapidly, after the re-challenge with the 
antigen. This type of hypersensitivity is also called delayed-type hypersensitivity. When 
activated, T-cells secrete cytokines which induce infiltration of inflammatory cells and the 
release of cytokines which in turn causes local tissue damage. Type IV hypersensitivity as further 
classified into four subsets depending on the different cytokines secreted by T-cells. 
 
 
 
 
 
complement
TYPE III REACTIONS
Soluble
antigen
antibodies bind to cell 
surface proteins
complement
IgG
TYPE II REACTIONS
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Figure 1.1C The mechanism of type IV hypersensitivity.  Antigen penetrates the skin and is confronted with 
dendritic cells (DCs). DCs uptake the antigen, travel to lymph nodes where they mature and efficiently prime 
naïve T-cells. The naïve T-cells then proliferate and turn into memory T-cells which then travel into the blood 
and back to inflammatory site. There they secrete cytokines, promoting the recruitment of other inflammatory 
cells, thereby amplifying skin inflammation.  
 
 
 
Type IVa hypersensitivity is induced by Th1-type T-cell responses. Th1-type T-cells secrete IFN-
γ and TNF-α. These cytokines stimulate the expression of adhesion molecules on endothelial 
cells and increase the vessel permeability which allows plasma and inflammatory cells to the 
inflammatory site. Moreover, IFN-γ promotes macrophages to secrete TNF-α and IL-12, which 
stimulates NK cells. As macrophages contain TNF-α receptors on self-surface, they can be auto-
activated by TNF-α and then generate more TNF- and IL-12, forming a positive feedback chain 
and thereby amplifying the inflammatory response. An example of type IVa hypersensitivity is 
tuberculin skin test (Sinigaglia et al., 1985).  Type IVb correlates to Th2 type immune responses. 
Th2 secreting T-cells secrete IL-4, IL-5 and IL-13 cytokines, which stimulate B-cells to secrete 
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antibodies such as IgE and IgG4. IgE in turn activate mast cells and IgG4 is associated with 
allergy, which suggest a link with type I hypersensitivity. IL-5 secretion leads to an eosinophilic 
inflammation, which is the characteristic of many drug hypersensitivity reactions (Pichler et al., 
2003, Yawalkar et al., 2000).   
Type IVc reactions involve cytotoxic T-cell migration into the tissue and direct cytotoxicity to 
tissue cells by release of cytolytic molecules such as perforin/ granzyme B. Alternatively, T-cells 
may secrete FasL and induce apoptosis through triggering the Fas receptor. Cytotoxic T-cells 
play a role in the drug hypersensitivity reactions such as maculopapular or bullous skin diseases, 
neutrophilic inflammation and in contact dermatitis. Type IVc reactions appear to be 
predominant in severe drug hypersensitivity reactions especially SJS/TEN syndrome, in which 
keratinocytes are killed by CD8 cytotoxic T-cells (Yawalkar et al., 2000, Schnyder et al., 1998). 
In general, CD8 T cell-mediated cytotoxic skin reactions are more severe than CD4 T-cell 
mediated cytotoxicity, as MHC I is ubiquitously expressed in keratinocytes as well as other skin 
cells, leading them being potential targets of CD8+ cytotoxic T-cells. In contrast, CD4 cytotoxic 
T-cells only recognize fewer cells expressing MHC II molecules, mainly antigen presenting cells. 
Hence, the massive presence of CD8 cytotoxic T-cells found in the blister fluid of SJS/TEN is a 
characteristic of the symptom. 
Type IVd reactions involve the recruitment of neutrophils through the release of IL-8 and 
CXCL8 from T-cells. The neutrophils play an active role in the induction of pustular 
inflammation. Symptoms include pustular exanthema and acute-generalized exanthematous 
pustulosisatous (AGEP) (Pichler 2003). Kabashima et al., (2011) found a significantly higher 
percentage of Th17 cells in the patients suffering from AGEP. As IL-17 and IL-22 cooperatively 
stimulate keratinocytes to secrete IL-8, Th17 cells are considered an important T-cell subset in 
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the recruitment of neutrophils. Cytokines play a fundamental role in pathogenesis of drug 
hypersensitivity and their function is summarized in table 1.2.  
   
Table 1.1 Extended Coombs and Gell Classification Adapted from (Pichler 2003) 
 
 
Classification Type of Immune 
responses 
Pathologic 
characteristics 
Clinical systems  Cell types 
Type I IgE Mast-cell 
degranulation 
Urticaria 
anaphylaxis 
B cells/Ig 
Type II IgG and IgM FcR-dependent 
cell destruction 
Blood cell 
dyscrasia 
B cells/Ig 
Type III IgG, IgM and 
complement 
Immune complex 
deposition 
Vasculit is B cells/Ig 
Type Iva Th1 (IFN-, TNF-
) 
Monocyte 
activation 
Eczema Th1 cells 
Type IVb  Th2 
(IL-5 and IL-4) 
Eosinophilic 
inflammat ion 
Maculopapular 
exanthema, 
bullous 
exanthema 
Th2 cells 
Type IVc CTL (perforin and 
granzyme B and 
fasl) 
CD4-or CD8-
mediated killing 
of cells 
Maculopapular 
exanthema, 
eczema, bullous, 
exanthema, 
pustular 
exanthema 
Cytotoxic T-cells  
Type IVd  T-cells (IL-8) Neutrophil 
recruitment and 
activation 
Pustular 
exanthema 
T-cells 
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Table 1.2 Brief summary of cytokines and their functions (Adopted from Janeway 2012 Immunobiology) 
 
 
Family Cytokine Function Producer cells 
Interleukins IL-1 Fever, T-cell activation, macrophage 
activation  
Macrophages, epithelial 
cells 
 IL-1 Th17 differentiation, Fever, T-cell activation, 
macrophage activation  
Macrophages, epithelial 
cells 
 IL-2 T-cell proliferation  Th1 
 IL-3 Synergistic action in early haematopoiesis Th1, Th2 
 IL-4 B cell act ivation, IgE switch, induce 
differentiat ion into Th2 cells  
T-cells, mast cells 
 IL-5 Eosinophil growth, differentiation  T-cells, mast cells 
 IL-6 T- and B-cell growth and  differentiation, 
Th17 d ifferentiation, fever 
T-cells, macrophages 
 IL-8 Chemo attractant for neutrophils and T-cells Macrophages 
 IL-10 Potent suppressant of macrophage functions Monocytes 
 IL-12 Activates NK cells, induces CD4 T-cell 
differentiat ion into Th1 cells  
Macrophages, dendritic 
cells 
 IL-13 B-cell growth and differentiation, inhibits 
Th1 cells 
T-cells 
 IL-17A Induces cytokine production by epithelia, 
endothelia, and fibroblasts, proinflammatory 
Th17 cells  
 
 
IL-17F Induces cytokine production by epithelia, 
endothelia, and fibroblasts, proinflammatory 
Th17 cells, monocytes 
 IL-21 Induces proliferation of B, T and NK cells, 
promotes Th17 d ifferentiation 
Th2 
 IL-22 Epithelial barrier, pro-inflammatory agents NK cells, Th17 cells, 
Th22 cells 
 IL-23 Induces proliferation of Th17 Dendritic  cells 
 IFN- Macrophage activation, increased expression 
of MHC molecules and antigen processing 
components, Ig class switching, suppresses 
Th2 
T-cells, NK cells  
Colony-
stimulat ing 
factors 
G-CSF Stimulates neutrophil development and 
differentiat ion 
Fibroblasts and 
monocytes 
 GM-CSF Stimulates growth and differentiation of 
dendritic cells 
Macrophages, T-cells 
TNF family TNF- Promotes inflammat ion, promotes 
differentiat ion into Th22 cells  
Macrophages, NK cells, 
T-cells 
 Fas Ligand Apoptosis T-cells 
Transforming 
growth factor 
beta (TGF-β) 
superfamily  
TGF-1 Anti-inflammat ion, induces Th17 and Tregs 
differentiat ion 
T-cells, monocytes 
 TGF-3 Promotes Th17 d ifferentiation, promotes 
inflammat ion 
T-cells, monocytes 
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1.4 Immune response 
The immune system is designed to help the body to remove harmful microorganisms or viruses 
that enter it. Antigen presenting cells (APCs) can interact with other cells of the immune system, 
to achieve this.  
Dendritic cells (DCs) are the most powerful antigen presenting cell as they are the only type of 
APCs that can stimulate naïve T-cells. When they are activated, they present peptide antigens on 
the cell surface using MHC class I and MHC Class II molecules (See Figure 1.2.1). They travel 
out of the inflammatory site to the local lymph nodes where they meet naïve T-cells and prime 
them through an interaction of the MHC-peptide complex with the T-cell receptor (TCR) and by 
interactions between the costimulatory molecules. Thereafter, primed T-cells become antigen-
specific effecter T-cells that circulate the body and can return to inflammatory sites to help 
resolve the infection via cytokine secretion and recruitment of pro-inflammatory cells.  
 
1.4.1  The mechanisms of antigen presentation.  
When antigens penetrate the skin and enter the body, they may encounter APCs, such as DCs or 
macrophages. The antigen may be taken up by the APCs via phagocytosis and chopped up into 
small pieces by the proteasome, or cleaved within the endosome. The resulting peptides are 
presented on the cell surface on MHC class I and MHC class II molecules. The peptides 
displayed by MHC class I molecules are usually 8-10 amino acid residues in length and can 
activate CD8 T-cells, whereas the peptides displayed by MHC II molecules are usually 12-20 
amino acid residues in length and can activate CD4 T-cells (Janeway et al, 2012 ).  
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Figure 1.2.1 Class I MHC molecules display peptides to CD8 T-cells. Endogenous protein is cut into small 
peptides by the proteasome. These peptides are then carried by TAP (The transporter associated with antigen 
processing) and transported into endoplasmic reticulum (ER), where they will meet up with MHC I molecules. 
MHCI molecules then bind with the peptides, forming MHC I-peptide complexes. The complexes are then 
transported to surface of the cell and displayed to CD8 T-cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
proteasome 
TAP 
MHC I-peptide complex 
endogenous 
protein 
 
ER 
peptides 
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Figure 1.2.2 Class II MHC molecules display peptides derived from non-self-proteins, especially bacterial 
proteins. When pathogen is swallowed by the antigen presenting cells, they are trapped into the phagosome. 
They meet chemicals and enzymes from lysosomes and in turn are digested into small peptides. This process is 
termed phagocytosis. MHC II molecules do not load peptides in the ER. Rather, in the ER their binding 
grooves are occupied by invariant chain peptides, protected from the binding of endogenous proteins. MHC II - 
invariant chain complexes are transported from ER and enter endosomes, where the chain peptides  are 
replaced with pathogen peptides digested through phagocytosis. The MHC II-peptide complexes are then 
transported to the cell surface and displayed to CD4 T-cells.  
 
 
 
 
 
 
 
 
 
 
 
MHC II- 
Invariant chain complex 
Phagosome 
ER 
Class II MHC- peptide-complex 
Invariant chain 
Lysosome 
Endosome 
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Figure 1.3 After contacting of TCR with antigenic-peptide-MHC complex that displayed on the surface of 
dendritic cells, naïve T-cells are activated and expanded.  During priming, micro-milieu cytokines determine 
the fate of the antigen specific T-cells and consequently the role they play in the immune response.  
 
1.4.2 T-cell subsets  
During priming, naive T-cells, which have been exposed to an antigen, are activated. They 
differentiate into antigen specific effector cells over the course of 1-2 weeks. During this 
activation period, three signals are required, 1) appropriate contact with antigenic peptide 
presented by MHC molecules that are displayed on the surface of antigen presenting cells; 2) 
costimulatory molecule binding, such as the binding of B7.1 and B7.2 on the surface of T-cells 
and CD40 of APCs; 3) cytokines that are in the milieu at the time of naive T-cell priming. These 
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signals determine the nature of the T-cells that are activated and their subsequent phenotype.  
T-cells are subdivided into CD4 and CD8 T-cells according to the expression of the co-receptors 
CD4 and CD8, respectively. These co-receptors interact and stabilize MHC-peptide-T cell 
receptor complex when T-cell receptors recognize antigen. After drug priming, of the cytokine 
micro-environment determines the nature of the T-cell response. CD4+ T helper cells can 
differentiate into various subsets such as Th1, Th2, Th17, Th22, Th9 secreting cells. Each subset 
is dominant in a specific type of inflammation. In the context of drug hypersensitivity, Th1 and 
Th2 secreting T-cells are known to be involved in different forms of tissue injury. However, the 
newer subsets have not been investigated.  
1.4.2.1 CD8+ T-cell  
CD8+ T-cells have been found in SJS/TEN skin lesions and these cells are also the dominant in 
T-cell population in blister fluid (Nassif et al., 2004). Moreover, CD8+ T-cells have been shown 
induce to drug antigen-specific cytotoxicity both in vivo and in vitro (Wu et al., 2006; Rozieres 
et al., 2010). In carbamazepine- induced drug hypersensitivity, drug specific CD8+ T-cells have 
been cloned and these clones show a strong toxicity against target cells in vitro. CD8+ T-cells 
isolated from patients with abacavir- induced hypersensitivity reactions also kill target cells by 
recognizing drug-peptide-MHC I complexes displayed on surface of antigen presenting cells 
(Chessman et al., 2008).  
1.4.2.2 CD4+ T-cell and phenotypes 
As described above, CD4+ T-cells play an important role in delayed type drug hypersensitivity 
and reactions have been classified into 4 sub-types based on the effects of different CD4+ T-cell 
subsets (cytokine secretion and subsequently inflammatory cell recruitment).  
CD4+ helper T-cells play important roles for host defense and immune-mediated disease by their 
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ability to differentiate into specialized subsets. These effector T-cells are defined by the 
expression of a restricted panel of cytokines and the expression of specific master regulator 
transcription factors (Szabo et al., 2003). Initially, the understanding of distinctive populations of 
differentiated CD4+ T-cells came from analysis of T-cell clones isolated from mice (Mosmann, 
Coffman 1989). Subsequently, (Bottomly et al., 1989) identified the key cytokines of each T-cell 
subset and the T-cell populations were named Th1 and Th2 secreting cells, in which T helper 1 
(Th1) cells express T-bet and selectively produce interferon (IFN)-, while Th2 cells express 
Gata3 and produce cytokines such as IL-4 and IL-13 (Nakayamada et al., 2012). To understand 
the mechanisms of drug hypersensitivity, it is important to define the T-cell subsets involved.  
The picture is complicated by the fact that in certain circumstances, IFN- secreting T-cells also 
secrete Th2 cytokines. However, T-cell subset classification holds its value in certain 
circumstances: first, stable Th1 and Th2 lineage with typical cytokine expression can be obtained 
by cytokine polarization during naïve T-cells expansion.  Second, in terms of host defense, each 
T-cell subset plays a particular role in pathogen eradication, e.g. intracellular bacteria for Th1 
cells and helminths for Th2 cells. Third, these subsets express stable key regulators, T-bet for 
Th1 and GATA3 for Th2. Finally, the classification of T helper cell subsets renders a great 
therapeutic value in allergic and autoimmune diseases, generally Th2 cells induce allergic 
diseases, whereas Th1 and Th17 (discussed in detail below) cells induce autoimmune diseases.  
 
Th1 cells 
Th1 cells secrete IFN-, IL-2 and TNF-, inducing cell-mediated immunity and phagocytic 
inflammation. Th1 cells eradicate intracellular pathogens such as bacteria, virus and protozoa. 
IL-12 and IFN- suppresses formation of Th2 cells, increase MHC class I and MHC Class II 
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expression and promote antigen presenting cell function. IL-2 functions as a growth factor 
promoting T-cell proliferation. Th1 cells may also mediate local inflammation at sites of 
infection. Th1 cells express the CCR5 homing receptor as a character of this T-cell subset. T-bet 
is a major transcription factor involved in the inducing the release of IFN- and Th1 cell 
differentiation (Szabo et al., 2000). IFN- responses to Leishmania major are significantly 
decreased in T-bet knockout mouse (Szabo et al., 2002).  
 
Th2 cells 
Previously, it was thought that a main function of Th2 secreting T-cells was helping B cell 
antibody generation. However, recent research found that follicular B helper T-cells (Tfh) are the 
main subsets that mediate this process and Th2 cell just play a regulatory role in the antibody 
generation. Th2 cells produce IL-4, IL-5, and IL-13 which are important in the elimination of 
parasites, such as helminthes. IL-4 induces Th2 differentiation and inhibits Th1 differentiation 
together with IL-13. Th2 cells may affect eosinophils, mast cells, and basophils by cytokine 
release i.e. IL-4, IL-5, and IL-13. Th2 cells express the CCR3 homing receptor. Th2 polarization 
requires the addition of IL-4 (Le Gros et al., 1990). GATA3 is the master regulator of Th2 
(Zheng et al., 1997). GATA3 is also critical for the development of CD4+ T-cell responses (Ho et 
al., 2009). GATA3 expression is up-regulated or down-regulated during Th2 and Th1 
polarization, respectively (Zhang et al., 1997). Moreover, Th2 differentiation is completely 
blocked in vivo and in vitro in the absence of GATA3 (Zhu et al., 2004).  
 
Th17 cells 
 32 
 
Dysregulation of Th1 responses has been associated with an autoimmune response. For example, 
IFN-expression in the target tissue is associated with clinical signs of experimental 
autoimmune encephalomyelitis (EAE). Furthermore, based on the evidence of blocking one of 
the heterodimers of IL-12p40, EAE got alleviated. However, blockage of the other chain of IL-
12 did not protect from EAE, but made the condition more severe (Krakowski et al., 1996; Tran 
et al., 2000; Gran et al., 2002; Zhang et al., 2003; Gutcher et al., 2006). This confusion did not 
get resolved until the discovery of IL-23, an important inducer of Th17 secreting cells. These 
cells share a p40 chain with IL-12 and have a unique heterodimer chain of p19 (Oppmann et al., 
2000). This data implies blocking p40 blocks both Th1 and Th17 signaling and thus, the previous 
conclusion that EAE is solely Th1 induced autoimmune disorders has to be questioned.  
Depletion of p19 of IL-23 but not p35 of IL-12 was shown to block EAE, which confirms that 
EAE is dominated by Th17 but not Th1 cells (Cua et al., 2003; Langrish et al., 2005).  
 
Th17 cells were named after one of the specific cytokines they secrete (i.e., IL-17). Th17 cells do 
not express GATA3 or T-bet (Park et al., 2005, Harrington et al., 2005), instead, they express 
high level of RORt (Ivanov et al., 2006). RORt has been shown to be critical for the release of 
IL-17, as RORt deficient mice show an impaired Th17 differentiation (Lee et al., 2009). Th17 
cells were established as an independent T-cell subset due to its unique differentiation factors. IL-
23, IL-6 and TGF-  are all required to induce Th17 differentiation (Veldhoen et al., 2006; Betteli 
et al., 2006; Mangan et al., 2006). RORt is the master transcription factor of Th17 cells, 
maintaining Th17 character for a long duration of time (Ivanov et al., 2006; He et al., 1998). 
RORt is regulated by its upper signaling molecule, STAT3. STAT3 is activated by Th17 inducer 
cytokine IL-23 and IL-6, forming a positive feedback loop in Th17 differentiation (Zhou et al., 
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2007; Yang et al., 2007).   
 
Th17 cells are critical in host defense. They also play important roles in immune disorders such 
as psoriasis (Krueger et al., 2007), rheumatoid arthritis (Kirkham et al., 2006), multiple sclerosis 
(Matusevicius et al., 1999), inflammatory bowel disease (Sarra et al., 2006), asthma (Molet et al., 
2001; Barczyk et al., 2003) and EAE (as discussed above).  
 
In host defense, Th17 cells can be induced by pathogen-associated molecular patterns (PAMP) 
which are external stimuli derived from extracellu lar pathogens such as bacteria (Chtanova et al., 
2004) and fungi. 
In psoriasis, Th17 cells are the major subset of T-cells isolated from skin lesions (Pane et al., 
2008) and with CCL20/CCR signaling being important for infiltration of inflammatory cell to the 
skin. Moreover, the blockage of p40 has been shown to reduce the psoriatic skin area (Krueger et 
al., 2007). 
In patients with rheumatoid arthritis, IL-17, IL-1 and TNF have been shown to play a direct role 
in joint destruction (Kirkham et al., 2006). Furthermore, the molecule of RANKL expressed on 
the surface of Th17 induces cartilage and bone destruction directly (Kotake et al., 1999; 
Miranda-Carus et al., 2006; Sato et al., 2006). 
Evidence of involvement of Th17 cells drug hypersensitivity is lacking. Most importantly, of the 
role of Th17 cells in drug- induced mild skin reactions such as MPE has not been studied. 
However, it has been suggested that Th17 cells may play a role in neutrophilic infiltrated drug 
hypersensitivity reactions such as AGEP and SJS-TEN. These studies are discussed in more 
detail below. 
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Th22 cells 
The phenomenon that some T helper cells secrete more than one signature cytokine is called 
plasticity. A T-cell population was found as they did not secrete signature cytokines such as IFN-
, IL-4 and IL-17, but IL-22 solely (Eyerich et al., 2009). Therefore, this population is named 
after the cytokine IL-22, Th22. The specific microenvironment for differentiating Th22 cells is 
composed of TNF- and IL-6. Skin DCs have also been shown to play a critical role in Th22 
differentiation (Duhen et al., 2009). Once differentiated, the Th22 phenotype remains stable and 
does not convert to other cell types (Eyerich et al., 2009). The aryl-hydrocarbon-receptor (AHR) 
is thought to be the master transcriptional regulator for Th22 cells (Trifari et al., 2009). Th22 
express characteristic chemokine receptors such as CCR4 and CCR10 (Duhen et al., 2009), 
which suggest that they reside in normal skin and inflammatory skin, migrating following 
exposure to CCL27, a ligand of CCR10. The IL-22 receptor is expressed exclusively on tissue 
cells, mostly in epithelial cells. In contrast to many cytokine receptors, the receptor for IL-22 is 
not expressed on immune cells (Wolk et al., 2004). Therefore, tissue cells are the major target of 
IL-22. Accordingly, IL-22 secreting lymphocytes are strongly enriched in peripheral tissue 
(Eyerich et al., 2009; Anmmziato et al., 2007). In terms of host defense, both Th17 cells and 
Th22 cells are involved in protection from bacterial infection. Th17 cells play a role in bacteria 
eradication (Lin et al., 2009), whereas Th22 have a protective effect on epithelial cells, especially 
in epithelial cell regeneration, proliferation and enhancement of migration (Nograles et al., 2008; 
Wolk et al., 2006).  
 
The protective characteristic of IL-22 cells induces epithelial cell expansion. However, in 
psoriasis is IL-22 is directly involved in the disease pathogenesis. Psoriasis is a chronic 
inflammatory disease with characteristic of keratinocytes over-proliferation and impaired 
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differentiation that leads to considerable thickening and scaling of the epidermis (Nestle et al., 
2009; Perera et al., 2012). Together with IL-17 and TNF-, IL-22 induces hyper-proliferation of 
keratinocytes, leading to the maintenance of acanthosis which is a hallmark of psoriasis (Wolk et 
al., 2009; Boniface et al., 2005; Delle et al., 2007). 
 
Th22 cells also play a pathological role in inflammatory bowel disease and rheumatoid arthritis 
(Zenewicz et al., 2008; Kim et al., 2012). Moreover, serum IL-22 was reported to be elevated in 
patients with Crohn’s disease.  IL-22 elevation was thought to be induced by the activation of IL-
23/Th17 signaling (Schmechel et al., 2008).  
 
The involvement of Th17 and Th22 cells in drug hypersensitivity. 
Similar to Th17 cells, there is very limited evidence to support a role for Th22 cells in drug 
hypersensitivity. Th17 cells might play a role in AGEP and SJS/TEN, whereas IL-22 secretion 
has only been detected in patients with AGEP. 
In carbamazepine induced AGEP, drug specific IL-17 secreting T- cell clones have been shown 
to co-secrete either IL-4, IL-5 or IFN-. The Th1/ Th17 or Th2/Th17 populations may explain the 
characteristic eosinophil infiltration that induced by IL-4, keratinocyte apoptosis mediated by 
IFN-, and neutrophilic infiltration by IL-17. It is known that IL-17 and IL-22 secreting cells 
play pathological roles in psoriasis. It has been considered AGEP have a similar neutrophilic 
inflammatory processes to psoriasis since neutrophil-recruiting CXCL8/ IL-8 producing drug-
specific T-cells are found in the circulation. Furthermore, a remarkable increase in IL-17 and IL-
22 secreting cells has been described. IL-17 and IL-22 have been shown to promote 
keratinocytes to release IL-8, which is a well-known neutrophil recruitment mediator (Nakamizo 
et al., 2010). 
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In SJS/TEN, it has also been shown that the proportion of circulating Th17 cells is elevated 
among the CD4+ T-cell population in blisters and this proportion is decreased following 
improvement of the disease. In contrast, this phenomenon is not observed with Th1 or Th2 cells 
(Watanabe et al., 2011). It is not hard to understand the involvement of Th17 cells since Caproni 
et al (2006) has reported that neutrophils play a pathologic role in SJS/TEN by releasing reactive 
oxygen species and lysosomal enzymes and Th17 cells promote neutrophils recruitment. 
 
1.4.3 TCR signaling and V  receptor  
The TCR is a multiprotein transmembrane complex comprising TCR  (or TCR ), CD3, 
and CD3 dimers (Alarcon et al. 2003; Kuhns and Davis 2012). 
TCR are similar to immunoglobulin, in terms of both structure and genes. As for 
immunoglobulins, the TCR  dimers comprise both variable (V) and constant (C) regions which 
form domains that interact with antigen presented by MHC molecules on the surface of APCs. 
This interaction forms 3 complementary determining regions (CDR1, 2, and 3) on V regions. 
CD3 molecules are tightly associated with TCR  on T-cell surface. However, CD3 molecules 
do not bind to antigen. When antigen binds to ab chain of TCR, cell signaling will be transmitted 
into the cell by phosphorylation of immune-receptor tyrosine-based activation motif (ITAM) that 
is located on the cytoplasmic tail of CD3. Phosphorylation is the critical event in initiating 
downstream signaling cascades, during which, phosphorylation of phospholipase C (PLC) and 
consequently induce calcium influx into cytosol, resulting in the activation of T-cells. 
CDR3 majorly determines antigen recognition by TCR. Hyper-variability of this region enables 
the TCR to recognize a large number of antigens. The nature of this variability is the somatic 
recombination of non-contiguous V and J segments of a-chain and variable (V) and diversity 
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(D), and joining (J) segments of the b-chain (Hughes et al., 2003), among which, V  has 25 
genes, D , J , V, and J have gene numbers of 2, 12, 70, 50, respectively. One particular gene 
from each group enables the generation of 1015-20 variable TCRs that allow for recognition of 
almost all the antigens in the universe (Davis, Bjorkman 1988). TCR diversity is often associated 
with potency of antigen and is often tested by V  receptor distributions (Kimber et al., 2012a, b). 
The activated TCR repertoire can be determined by dependent on the pathway of T-cell 
activation (Currier et al., 1996). PBMCs stimulated by mitogen (PHA), super-antigen (TSST-1), 
or normal antigen (tetanus toxoid) show diverse TCR repertoires, in which both fresh blood and 
PHA stimulated PBMCs showed a normal spread distribution, whereas tetanus toxoid stimulated 
PBMCs showed a restricted profile. Finally, super-antigen stimulation resulted in a unique 
pattern of diversity (Currier et al., 1996). To explain the relationship between TCR diversity and 
potency of antigen, Moon and colleagues suggest that high TCR repertoire diversity could be 
induced by strong antigen with multiple antigen determinants and verse vice (Moon et al., 2007).  
 
In drug hypersensitivity, V  receptors have been found to be expressed in a restricted panel. For 
example, some V  receptors are expressed in a wide distribution panel. In the study by Ko et al., 
(2011), patient with genotype of HLA-B*15:02 and with carbamazepine induced SJS/TEN were 
recruited to analyze the drug-specific T-cell receptor repertoire. 16 out of 19 patients with 
carbamazepine induced SJS/TEN expressed a single clonotype of VB-11-1SGSY and this 
clonotype was not expressed in all drug-tolerant patients.  Carbamazepine specific CD8+ T-cells 
with this clonotype showed a strong cytotoxicity and this cytotoxicity was inhibited by the 
addition of anti VB-11-1SGSY antibodies. 
When testing the T-cell repertoire of abacavir specificity which is also mediated by CD8+ T-cell 
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responses and is restricted by a single HLA allele association (HL1-B*57:01), drug-specific T-
cells displayed a random distribution of V  receptors (Illing et al., 2012). These findings are in 
stark contrast to the work of Ko et al exploring carbamazepine- induced SJS. 
In my thesis, piperacillin specific T-cells displayed a random distribution of V  receptor 
repertoire. In our lab, nitroso-sulfamethoxazole (SMX-NO) T-cell clones isolated from patients 
with sulfamethoxazole hypersensitivity also displayed a random TCR V  repertoire (unpublished 
data). It is known that SMX-NO is a strong hapten that is capable of binding to both intracellular 
protein and the proteins in the serum, and wide V  receptor distribution suggests that SMX-NO 
protein binding generates a large number of peptide epitopes, which subsequently interact with 
multiple TCRs. 
 
1.4.4    Tissue homing  
Cellular tissue homing was dominanted by the interaction between chemokines and their receptor 
(Campbell & Butcher 2000). As reviewed by Charo & Ransohoff (2006), chemokines are 
divided into two groups, CC chemokines and CXC chemokines. CC chemokines have two 
adjacent cysteine residues near the amino terminus whereas in CXC chemokines, two cysteine 
residues are separated by a single amino acid. CC chemokines tend to induce the migration of 
monocytes and CXC cytokines tend to induce the migration of neutrophils. For example, CCL2 
is a chemokine that stimulates monocytes to migrate from the bloodstream to the tissue. Another 
example, CXCL8, however, attracts neutrophils out of the blood and migrates into the peripheral 
tissue.  
Chemokines have two main roles. Firstly, they act on the lymphocytes rolling along the 
endothelial cells at sites of inflammation and convert this rolling status into steady binding to the 
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endothelial cells, via changing the conformation of adhesion molecules on lymphocytes and 
thereafter binding to their ligands on endothelial cells. Next the lymphocytes squeeze between 
the endothelial cells, going out of the vessel to the tissue. Second ly, chemokines direct the 
migration of lymphocytes along a gradient of chemokine molecules bound to the extracellular 
matrix and the surface of endothelial cells. This gradient increases in concentration toward the 
site of infection. 
T-cell priming occurs in lymphoid tissue but effector cells are needed in peripheral tissue at the 
original site of infection. T-cells express specific chemokine receptors i.e., CCR4, so that release 
of CCL17 (or TARC) and it’s binding to the receptor causes T-cells to migrate; following a 
chemokine diffusion gradient and accumulation in the inflamed site.  
In immunological conditions targeting skin, antigens are transported to the draining lymph node 
by dendritic cells. Antigen specific T-cells must then be transported from the lymph node back to 
skin. When T-cells encounter antigen in the skin, they become activated and may release effector 
molecules i.e., cytolytic molecules. These cause damage to skin cells, including keratinocytes. 
Migrating immune cells reach the inflamed skin initially through a series of selectin and integrin 
contacts, including cutaneous lymphocyte antigen (CLA). CLAs function as an integrin, which 
binds to the ligand E-selectin expressed in the endothelium thereby, inducing T-cells to move 
through the endothelium into the tissue (Rossiter et al., 1994).  
Skin- infiltrating lymphocytes in patients suffering from psoriasis and allergic contact dermatitis 
express CCR10 and on the other hand, the ligand of CCR10, CCL27, is expressed by 
keratinocytes which orchestrate the migration of CCR10+ T-cells to the skin (Homey et al., 
2002). In vivo, the neutralization of CCL27-CCR10 interactions dampens lymphocyte 
recruitment to the skin leading to the suppression of skin inflammation. The results suggest an 
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important role for CCR10 in the skin inflammation. CCR4 was also demonstrated to be 
important in skin inflammation. CCR4+ T-cells were only observed in memory skin homing T-
cells and not in naïve T-cells and intestine homing T-cells. In chronic cutaneous disease, 
CLA+CCR4+ T-cells migrate following exposure to the ligands of CCR4, TARC and MDC 
(Campbell et al., 1999).  
Several studies have investigated the role of chemokines and chemokine receptors in drug 
hypersensitivity. CLA expression on T-cells, isolated from skin and blood of hypersensitive 
patients, correlated with disease severity (Leyva et al., 2000). Increased expression of CCR4, 
CCR8, and CCR10 has been implicated in allergic reactions in the skin, such as contact 
dermatitis, atopic dermatitis and psoriasis (Hudak et al., 2002, Moed et al., 2004, Vestergaard et 
al., 1999).  In patients with dermatitis, CCR4 and CCR10 are important in T-cell migration to the 
inflamed skin whereas CCR8 was important in homing of memory T-cells to healthy skin 
(Vestergaard et al., 2003, Schaerli et al., 2004).  
In patients with delayed-type drug hypersensitivity, drug-specific CCR6+ T-cells initiate reactions 
by secreting TNF- and IFN-. This leads to an acute phase response and induction of 
inflammatory chemokines such as CXCL8 or CCL20, the ligands of CCR6 in keratinocytes 
(Schaerli et al., 2004).  
Most T-cells in the skin are CCR6 T-cells; they enter the skin and secrete more pro- inflammatory 
cytokines, thereby amplifying the immunological reaction.  
 
 
 41 
 
1.5 HLA associations with drug hypersensitivity 
Over the recent years, there has been a significant increase in the volume of publications 
associating various HLA alleles with different forms of drug hypersensitivity reaction. Genetic 
association studies of both drug metabolizing genes and immune-related genes have helped to 
expand our knowledge and improve our understanding of drug hypersensitivity. HLA alleles with 
high levels of polymorphism are critical in immune surveillance because every variant molecule 
interacts with different peptides. Only a small proportion of them will stimulate T-cells. Some of 
the HLA proteins protect from disease, whereas others function as predisposing factors for 
disease  (Temajo et al., 2009; Han et al., 2012), including T cell-mediated drug hypersensitivity. 
For example, individuals expressing the HLA-B*57:01 allele are susceptible to abacavir 
hypersensitivity (Mallal et al., 2002) and flucloxacillin- induced hepatitis (Daly et al., 2009). In 
Han Chinese, carbamazepine- induced SJS and TEN are associated with expression of HLA-
B*15:02 (Chung et al., 2004). However, in Caucasians, carbamazepine- induced hypersensitivity 
reactions have recently been associated with HLA-A*31:01 (McCormack et al., 2011). 
Allopurinol induces severe cutaneous allergic reactions (SCAR) in Han Chinese patients with 
HLA-B*58:01 (Hung et al., 2005). Pre-description screening of related HLA alleles has 
significantly decreased the occurrence of hypersensitivity to abacavir and carbamazepine (Chen  
et al., 2011; Mallal et al., 2008). The strong association with HLA indicates that the drug derived 
antigens interact with high level of restriction to HLA molecules to stimulate T-cells. The nature 
of this interaction has been defined for a limited number of drugs. For example, abacavir 
interacts with the F-pocket in the peptide-binding groove of the HLA-B*57:01 molecule 
(Chessman et al., 2008). A similar mechanism was observed in the binding of carbamazepine 
with HLA-B*1502 (Illing et al., 2012). The observation that HLA-DQ A*02:01 is associated 
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with lapatinib-induced liver injury indicates MHC I and II molecules can be involved in different 
forms of hypersensitivity (Spraggs et al., 2011).  
 
 
1.6 Mechanisms of drug hypersensitivity  
There are three main theories as to how pharmaceutical drugs  can act as antigens and generate an 
immune response (See Figure 1.2).  
 
1.6.1 Hapten and Prohapten theory  
The basis of hapten theory was built up by the early research from Landsteiner and Jacobs 
(1935). They sensitized guinea pigs to the low molecular weight, chemically reactive compound, 
dinitrochlorobenezene (DNCB). The authors showed that the immune reaction resulted from the 
formation of a covalent protein adduct in skin through modification of specific nucleophilic 
residues. This leads to the hypothesis that chemicals and drugs are too small to function as 
antigens and activate an immune response directly. The hypothesis states that they bind to 
proteins forming an intact antigen to trigger an adaptive immune response; β- lactams are 
common causes of both type I and type IV hypersensitivity.  
Many more studies support a role for the binding of haptenic substances to protein in the effector 
phase of immune responses to drugs and chemicals.  Certain haptens bind spontaneously to 
protein via formation of a covalent bond with specific amino acid residues. For example, 
penicillins may induce hypersensitivity by binding directly to lysine residues on protein (see 
below). Antigen specific IgE isolated from patients with penicillin- induced anaphylaxis patients 
were found not against penicillin but against penicillin-haptenic structures formed by drug-
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protein conjugation. Furthermore, certain penicillin-specific T-cells are activated specifically 
with drug-protein adducts. Penicillins contain a 6-aminopenicillanic acid nucleus which includes 
a -lactam ring and a five numbered ring. When drug-protein conjugates form, the -lactam ring 
opens up spontaneously and acylates with lysine residue of the binding protein. A similar profile 
of binding happens with a range of antibiotics, including piperacillin and flucloxacillin, which 
are discussed in detail in the sections below. In contrast to the penicillins, other compounds only 
bind to protein after drug metabolism and the liberation of reactive species. For example, 
urushiol, an allergen contained in ivy and poison oak induces a severe contact dermatitis in both 
human and mouse models. Urushiols are oxidased into reactive quinone species and the reactive 
species binds covalently to amino acid residues on protein (Kalergis et al., 1997).  Some of drugs 
might also be metabolized into reactive intermediates prior binding to proteins. This indirect 
process is known as the pro-hapten hypothesis. A classical example is the drug halothane, which 
induces immunological hepatotoxicity in a small percentage of the population. Halothane is 
metabolized by P4502E1 (Kharasch et al., 1996) into a reactive trifluoroacetyl chloride 
intermediate, which binds covalently to lysine residues in proteins forming an antigen (Kenna et 
al., 1988). Tienilic acid an urisuric diuretic used in the treatment of hypertension was withdrawn 
from the market in 1980 due to its hepatotoxic potential. Tienilic acid is metabolized by human 
P4502C9 enzymes to yield a reactive metabolite S-oxide which binds covalently with 
nucleophilic groups on the enzyme forming an antigen. Anti-P450 antibodies have been detected 
in the serum of patients with hepatotoxicity. The most well characterized pro-hapten drug is 
sulfamethoxazole which will be discussed in the following secretion.   
1.6.2 Pharmacological inte raction of drugs with immune receptors: p.i. concept.  
 
This theory suggests that parent drugs can trigger an immune response by direct interaction with 
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MHC molecules and TCRs. The theory is based on evidence that drugs can stimulate drug 
specific T-cells in an MHC processing independent way when APCs were fixed with 
glutaraldehyde (Pichler et al., 2002).  
When a drug stimulates T-cells immediately, as shown by intracellular calcium release, then this 
response is too fast to require antigen processing (Pichler et al., 2002). Pulsing experiments show 
that T-cell responses can be inhibited by washing the antigen presenting cells, which removes the 
non-covalently bound drug. This shows that the drug is binding directly to immune receptors and 
activating T-cells by a pharmacological mechanism. Drugs that activate T-cells via a p.i. 
mechanism include carbamazepine, lidocaine, lamotrigine, and sulfamethoxazole (Farrell et al., 
2003, Zanni et al., 1998, Schnyder et al., 1998).  
 
1.6.3 Altered self-peptide repertoire model 
Certain drug hypersensitivity syndromes are highly associated with particular human leukocyte 
alleles (Mallal et al., 2002, Yun et al., 2013, Chessman et al. 2008, Mallal et al. 2008, Bharadwaj 
et al. 2012). Abacavir hypersensitivity syndrome is associated with HLA-B*57:01 and 
investigations into this syndrome have resulted in the evolution of the altered self-peptide 
hypothesis to explain how this drug interacts with the HLA molecule to activate T-cells (Mallal 
et al., 2002, Martin et al. 2005, Mallal et al. 2008). The in vitro study of abacavir- induced T-cell 
activation showed that the ability of abacavir-treated cells to stimulate T-cells could be 
completely abrogated by a single amino acid residue change at position 116 (Ser116), which 
lines an anchor pocket in the peptide-binding groove of the HLA-B*57:01 molecule. 
Collectively, the authors propose that the drug occupies specific area in the cleft of the MHC 
class I molecule, which in turn alters the configuration of the peptide that sits in the groove. This 
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altered self-peptide-MHC complex only displayed on the surface of APC in the presence of the 
drug activates CD8+ T-cells which cause tissue damage (Figure 1.4).  
Figure 1.4 Different pathways of T-cell activation in drug hypersensitivity.  
Three mechanism of drug hypersensitivity have been proposed, which are hapten/prohapten 
theory, p.i. concept and peptide alteration theory.  
 
Figure 1.4 A illustrates the hapten/prohapten hypothesis; in which  drug or drug metabolites bind covalently to 
protein to activate an immune response. Drug-protein conjugates are then taken up and processed by APC, cutting 
the protein into peptides which are then displayed on the cell surface by MHC molecule.  
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Figure 1.4 B illustrates p.i. concept. Here a drug may activate TCRs though a directly  non-covalent binding against 
TCR and MHC molecu les. Protein processing is not required. 
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Figure 1.4 C shows peptide alteration theory. When certain peptides are displayed to T-cells, they do not generate 
immune response. However, when peptides load into the groove of MHC molecules in the presence of drugs, such 
as abacavir, they may induce immune reactions, due to the drug altering the configuration of the MHC peptide -
binding groove, rendering the peptides immunogenic. 
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1.6.4 Drug metabolism and the activation of T-cells 
SMX has been used as a model to study the role of metabolism in drug hypersensitivity for 
several reasons. Firstly its metabolism is well-defined. Secondly, stable and readily metabolites 
have been synthesized and are available for functional studies. Thirdly, patient samples are 
readily available for functional studies. Most of SMX is detoxificated in the liver. The drug is 
metabolized by hepatic N-acetyltransferase enzymes to an acetylated derivative which is easily 
eliminated from the body. However, a small amount of SMX is converted to a hydroxylamine 
intermediate. A reaction is catalyzed by CYP2C9 (Cribb et al., 1995). SMX hydroxylamine is 
stable and eliminated in urine (Gill et al., 1999). This suggests that most tissues are exposed to 
the hydroxylamine after SMX administration. The hydroxylamine either undergoes reduction 
back to SMX, a reaction by catalyzing by NADH cytochrome b5 reductase and CYP3A4 or is 
spontaneously oxidized to nitroso SMX (SMX-NO). SMX-NO has been shown to bind and 
modify selective cysteine residues expressed on both cellular and protein serum (Naisbitt et al., 
1999, Naisbitt et al., 2001). Modification of cell surface proteins occurs quickly and then these 
protein conjugates are internalized through caveolae-dependent endocytosis (Elsheikh et al., 
2010). Therefore, it is possible for the transport of intermediates (i.e. the hydroxylamine) out of 
the liver, which is rich in detoxification, to remote areas (i.e. the skin) where it is converted to 
SMX-NO, which generates protein adducts and ultimately hypersensitivity. The high number of 
SMX hypersensitivity reactions in patients with HIV and cystic fibrosis might be related to the 
fact that the redox balance is tipped in favor of a pro-oxidative environment by the disease 
process (van der Ven et al., 1997, Walmsley et al., 1997).  
SMX-NO activates dendritic cells (DCs), enhancing expression of the co-stimulatory molecule 
CD40 (Sanderson et al., 2007) and generates potential antigens by bind ing to cysteine residues in 
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proteins. In rodent models, SMX-NO primed naïve CD4 and CD8 T-cells and the T-cell 
activation was antigen processing dependent (Farrell et al., 2003, Naisbitt et al., 2001, Naisbitt et 
al., 2002, Castrejon et al., 2010). On the contrary, administration of SMX does not activate 
immune cells. In vitro studies using PBMCs from drug naïve volunteers showed that SMX-NO 
generates T-cell responses in almost 100% of the volunteers (Engler et al., 2004). Application of 
a DC T-cell priming assay (Faulkner et al., 2012), using naïve T-cells from healthy volunteers 
who have never exposed to SMX, demonstrated that SMX-NO readily activates naïve T-cells. 
The newly generated memory T-cells were drug antigen specific. SMX-NO treatment resulted in 
proliferative responses and cytokine release. Several studies have shown that T-cells from blood 
and skin of all SMX hypersensitive patients are activated by SMX-NO, which suggests that 
SMX metabolites and the SMX-NO modified proteins are involved in the development of 
clinical symptoms in hypersensitive patients (Elsheikh et al., 2010, Schnyder et al., 2000, 
Burkhart et al., 2001, Nassif et al., 2004). Moreover, it has been shown that SMX-NO stimulates 
the majority of the drug responsive T-cell clones generated from patients with SMX 
hypersensitivity (Castrejon et al., 2010).  
Skin cells are known to express different CYP enzymes from the CYPs in the liver. To clarify the 
possibility that SMX (or SMX NHOH) can travel to the skin and generate SMX-NO and in turn 
induce skin inflammation, several studies (Reilly et al., 2000; Vyas et al., 2006) have shown that 
sulfonamides are metabolized by flavin-containing monooxygenase 3 and peroxidases expressed 
in human epidermal keratinocytes/cutaneous dendritic cells into SMX-NO that binds covalently 
to cellular protein. Exposure of keratinocytes to SMX promoted the secretion of pro-
inflammatory cytokines and increased expression of heat shock protein 70 (Khan et al., 2007). 
SMX-NO covalently binds to cellular proteins, which therefore may act as a source of the 
 50 
 
antigen (Naisbitt et al., 2001). A study of SMX hypersensitive patients shows that SMX-NO 
selectively binds to a single amino acid residue of human albumin (HSA), cysteine 34. It has also 
been shown that (1) SMX-NO and SMX-NO modification of protein can induce cell death when 
the levels of binding exceeds a threshold; and 2) SMX-NO metabolite modified necrotic cells 
provide a strong maturation signal to DCs (Naisbitt et al., 2002, El-Ghaiesh et al., 2012). Based 
on this discussion, it is clear that, SMX metabolites are generated in the skin and may provide 
activation signals to DCs. 
 
1.6.5 SMX and SMX-NO specific T-cell clones 
In addition to the above discussion, SMX specific T-cell clones have been isolated from blood of 
patients with different types of skin eruptions (Schnyder et al., 1998, Brander et al., 1995). T-
cells express CD4 or CD8 or both and upon stimulation by drugs, they secrete high levels of IL-5 
and perforin which induces the killing of keratinocytes (Schnyder et al., 1998). Furthermore, 
drug-specific CD8 T-cells have been isolated from patients with TEN, the most severe form of 
cutaneous hypersensitivity, and fully characterized (Yawalkar et al., 2000, Nassif et al., 2004). 
Stimulation of T-cells with SMX follows the p.i. concept. T-cells from hypersensitive patients 
stimulated by SMX bound directly to MHC and T-cell receptor in a non-covalent fashion 
(Schnyder et al., 1998, Schnyder et al., 2000, Burkhart et al., 2001, Nassif et al., 2004). The 
threshold period of drug incubation for a T-cell clone response varies from 0.1 to 4 h (Zanni et 
al., 1998) which is incompatible with the time that is required for antigen presentation. The 
response is MHC restricted, although not all of the response is restr icted to a specific HLA allele 
(Sanderson et al., 2007).  
1.7  Drugs and drug antigens 
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In this thesis I have investigated drug hypersensitivity reactions to the pro-hapten to 
sulfamethoxazole (SMX) and its metabolites nitroso-sulfamethoxazole (SMX-NO) and the β-
lactam antibiotics: piperacillin and flucloxacillin.  
1.7.1  Sulfonamides 
In 1940, Woods showed that sulfonamides prevented bacteria from growing. Sulfonamides 
prevent bacteria using para-aminobenzoic acid for folate biosynthesis, which is crucial fo r the 
synthesis of thymidine, purines and bacterial DNA (Woods, 1940). In 1960, the combination of 
sulfonamides and trimethoprim was developed based on the recognition that they both targeted 
the same pathway and double inhibition of this pathway is more e ffective than using a single 
drug (Masters, 2003). 
 Trimethoprim-SMX is available in oral and intravenous preparations. Clinically, it is used as one 
part trimethoprim to five parts SMX. SMX is primarily metabolized in the liver, with 
approximately 30% being excreted unchanged in urine. SMX is metabolized by CYP2C9 in 
human liver to a pro-reactive hydroxylamine metabolite SMX hydroxylamine then automatically 
oxidizes into nitroso sulfamethoxazole which may either bind covalently to cellular proteins, 
forming drug antigen, or may be reduced by non-protein thiols (i.e., glutathione) back to the 
hydroxylamine form (Cribb et al., 1995, Gill et al., 1999, Naisbitt et al., 2002) (See Figure 1.3).  
Skin reactions occur in 3-4% of the general population treated with SMX. Numerous skin 
reactions have been described, including maculopapular rash, urticaria, diffuse erythema, 
morbilliform lesions, erythema multiform and purpura, and photosensitivity. Severe skin 
reactions related to SMX include SJS and TEN (Kocak et al., 2006). Disorders of the blood and 
internal organs (e.g., liver) are occasionally reported.  
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Figure 1.5 Metabolis m of SMX and protein conjugate format ion (Su llivan et al, 2015)  
 
 
1.7.2  β-lactam antibiotics 
Piperacillin was developed at the end of the 1970s. It is a wide-spectrum antibacterial agent 
developed for microbes resistant to other β- lactams, such as Klebsiella pneumonia and 
Pseudomonas aeruginosa (Jones et al., 1977). Combined with tazobactam, a B- lactamase, the 
anti-bacterial effect of piperacillin has been improved especially against B- lactamase producing 
bacteria (e.g. staphylococci, Escherichia coli, Haemophilus influenza) (Speich et al., 1998). 
Piperacillin is administered via intramuscular or intravenous injection as a sodium salt because it 
is poorly absorbed by the intestine.  
Piperacillin is commonly prescribed for patients with cystic fibrosis (CF). Cystic fibrosis is the 
most common lethal autosomal recessive condition in Caucasians. Recurrent infections lead to 
airway destruction, bronchiectasis, and respiratory failure. Therefore, antibiotics, including 
piperacillin are required to maintain patients’ health. Although antibiotic therapy is necessary to 
reduce the deterioration of lung function, it results in high incidence of adverse drug reactions.  
The incidence of ADRs in patients with cystic fibrosis is 26%-50% compared with 1-10% in the 
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general population (Brock &Roach, 1984; Moss et al., 1984).  
For the formation of protein conjugates, the lactam ring is broken by nucleophilic lysine 
residues, leading to binding of the penicilloyl group (Batchelor et al., 1965). The penicillyol 
antigen can also be formed by binding of the reactive degradation product penicillenic acid 
(Levine et al., 1960). Recent advances in mass spectrometry has allowed researchers to use 
piperacillin as a model to precisely characterize the nature of the piperacillin binding interaction 
with protein (Figure 1.4.1). As for all β- lactam antibiotics, piperacillin selectively interacts with 
specific lysine residues on serum proteins such as human serum albumin (Figure 1.4.2). The 
binding interactions are dependent on the dose and incubation time (Meng et al., 2011, Whitaker 
et al., 2011). Moreover, as T-cells from hypersensitive patients are activated with piperacillin 
HSA adducts, it was possible to investigate the minimum level of modification of the drug that 
can stimulate drug-specific T-cells. At low drug concentration, only Lys541 modification was 
observed, whereas at higher concentration, up to 13 lysine modifications were detected, four of 
which (Lys 190, 195, 432, and 541) were detected in patients’ plasma (El-Ghaiesh et al., 2012, 
Whitaker et al., 2011). A synthetic β- lactam-protein conjugate mimicking the drug antigen found 
in the patients was found to stimulate PBMCs and 100% β- lactam specific T-cell clones. 
Whereas T-cell response to drug conjugates is dampened when antigen processing is inhibited, 
which suggests that the antigenic peptides are derived from drug-protein conjugates.  
 
Flucloxacillin is a narrow-spectrum β- lactam antibiotic. It is used to treat infections caused by 
susceptible Gram-positive bacteria. Unlike other penicillins, flucloxacillin is effective against 
beta-lactamase-producing organisms such as Staphylococcus aureus as it is β- lactamase stable.  
Flucloxacillin is a common cause of drug- induced liver injury in Europe, affecting about 8.5 in 
 54 
 
every 100,000 first time users of the drug. (Andrews et al., 2008). The liver injury is 
predominantly cholestatic in nature. It has now been discovered that flucloxacillin- induced liver 
injury is associated with the expression of HLA-B*57:01 (Daly AK., et al 2009) and CD8 T-cells 
play a role in liver injury (Monshi M et al., 2013). The risk of flucloxacillin induced liver injury 
is increased in females, with a high daily dosage and with increasing age (Elise Andrews et al., 
2008).                                                                                                                                                                                                                                                                                 
 
 
 55 
 
 
Figure 1.6.1 Formation of piperacillin-protein conjugated antigen (adapt from Whitaker, Meng et al., 2011). 
Piperacillin can be metabolized into desethylpiperacillin by P450 or be reduced into dioxopiperazine.  Piperacillin 
conjugated antigen can be formed either with piperacillin, via its -lactam ring opening and binding covalently to 
albumin protein  forming an intact antigen; or with its desethyl metabolite also via -lactam ring opening process; 
but not with dioxopiperacillin v ia 2,3-dioxopiperazine ring opening; nor cross -linking adduct. 
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Figure 1.6.2 Binding site of piperacillin to HSA protein, which are the modifications on lysine residues 
identified by mass spectrometry. Adapted from Whitaker, Meng et al., (2011) 
Model of albumin showing piperacillin b inding sites at positions Lys190, Lys195, Lys199, Lys212, Lys351, 
Lys432, Lys525 and Lys541. 
 
 
 
1.8 Aim of the thesis 
The primary aim of this study is to characterize the phenotype and function of piperacillin 
specific T-cells isolated from hypersensitive patients’ PBMC (chapter 3) and skin (chapter 4). 
The involvement of Th17 and Th22 cells in piperacillin hypersensitivity was also studied using a 
recently established in vitro DC T-cell priming assay (chapter 5). Finally, the priming assay was 
applied to study the mechanism(s) of drug antigen presentation and T-cell cross reactivity using 
three haptenic drugs, SMX-NO, piperacillin and flucloxacillin.  
The characterization of drug specific T-cells isolated from hypersensitive patient PBMC has been 
conducted previously; however, the involvement of new T-cell subsets, Th17 and Th22 in drug 
hypersensitivity reactions has not been investigated. Furthermore, a comparison of drug-specific 
T-cells isolated from PBMC and inflamed tissue has not been performed. These studies are 
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important because Th17 and Th22-secreting T-cells are known to play a critical role in several 
resilient and chronic immune-mediated diseases, such as psoriasis, Crohn’s disease, asthma, 
multiple sclerosis, and inflammatory bowel disease.  
The data presented in this thesis aims to answer the following questions: 
1. Are Th17 and Th22 involved in the drug hypersensitivity? And if so, which drug-specific 
cytokines do they secrete? 
2. Are there phenotypic and/or functional differences between drug-specific T-cells isolated from 
skin and PBMC? 
3. Is it possible to generate drug specific Th17 cells or Th22 cells under Th17 and Th22 under 
polarization conditions in vitro? 
4. Do APCs activate drug primed naïve T-cells via a hapten/pro-hapten pathway or a p.i. 
mechanism?                                                                                           
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Chapter 2: 
Materials and Methods 
2.1  Medium for cell culture.  
2.1.1  Preparation of the medium for T-cell cloning and culturing peripheral blood 
mononuclear cells (PBMCs) (R9 medium) 
 
R9 was used as the basic cell culture medium for all cell culture assays and for the culture of 
PBMCs and T-cells. Medium consisted of RPMI 1640 supplemented with 10% pooled heat-
inactivated human AB serum (v/v), HEPES buffer (25 mM), L-glutamine (2 mM), transferrin (25 
µg /ml), streptomycin (100 µg/ml), and penicillin (100 U/ml).  
 
2.1.2 Preparation of Epstein-Bar virus (EBV)-transformed B-lymphoblastoid cell lines (B-
LCL) culturing medium (F1 medium) 
 
F1 medium was used to culture B-LCL cell lines, but was not used in cell culture assays. consists 
of RPMI 1640 supplemented with 10% pooled heat-inactivated foetal bovine serum (FBS), 
HEPES buffer (25 mM), L-glutamine (2 mM), streptomycin (100 g/ml), and penicillin (100 
U/ml).  
Human AB serum was purchased from Innovative Research (Michigan, USA). FBS was bought 
from Invitrogen, Paisley, UK. HEPES buffer, L-glutamine, transferrin, streptomycin, and 
penicillin were purchased from Sigma-Aldrich (Dorset, UK). 
Freeze medium: 20% DMSO (v/v) with 80% of FBS (v/v).  
2.2  Preparation and the use of drugs  
The drug metabolite nitroso-sulfamethoxazole (SMX-NO) was freshly prepared at a stock 
concentration of 50mM in dimethyl sulfoxide (DMSO), and then diluted into antibiotic- free R9 
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medium at a final concentration of 50µM. Piperacillin and flucloxacillin were diluted directly 
into antibiotic- free R9 medium at a range of concentrations between 0.5-2 mM. 
SMX-NO was purchased from Dalton chemical laboratories Inc. (Toronto, Canada).  
Both piperacillin and flucloxacillin were purchased from Sigma Chemical Co. (Poole, Dorset, 
UK). DMSO was purchased from Sigma-Aldrich (Dorset, UK). Drug chemical structures are 
shown below: 
 
SMX-NO 
Piperacillin 
         Flucloxacillin 
 
Figure 2.1 Chemical structures of the focus drugs in the thesis. Although these three drugs are thought to activate T-
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cells via covalent protein binding, variat ion of their chemical structures seems to determine variat ions in drug 
hypersensitivity (Figures adapted from Wikipedia).  
2.3 Isolation of PBMCs 
Blood was taken from patients and healthy volunteers under informed consent. All protocols 
were approved by the Local Research Ethics Committee. PBMCs were isolated from fresh blood 
collected in 9 ml heparinised Vaccuette tubes (Greiner Bio-One Ltd, Stonehouse, UK) using 
Lymphoprep density gradient separation media (Axis Shield, Dundee, UK). Blood was layered 
onto an equal volume of Lymphoprep and tubes were spun at 2000 rpm for 25 mins with low 
acceleration and no brake. The cloudy layer containing PBMCs was carefully aspirated using a 
sterile Pasteur pipette. The PBMCs were washed in HBSS buffer at 1800 rpm for 15 min at room 
temperature to remove the excess Lymphoprep. After discarding the supernatant, cells were re-
suspended in 50 mL Hanks buffer and centrifuged at 1500 rpm for 10 minutes. The cells were 
then re-suspended in culture medium and counted using a Neubauer haemo-cytometer (Sigma) 
under a Wilovert Microscope (Will Wertzlar, Germany).  Cells were diluted with 10 µl 2% trypan 
blue stain and 10 µl of the cell solution was placed on the haemo-cytometer and counted. The 
cell viability was calculated using the following equation: %viability= viable cells/total number 
of cells*100%. Normally the viability was found to be higher than 95%.  
 
2.4 Lymphocyte transformation test (LTT) 
100 µl/well of isolated PBMCs at 1.5x106 cells/ml was aliquoted in 96-well U-bottomed tissue 
culture plates. 100 µl/well of medium, 10 µg /ml of Tetanus Toxoid or drug (piperacillin 0.5 mM, 
1 mM, and 2 mM) were added and incubated for 6 days at atmosphere of 37°C 5% CO2. 
Proliferation was measured by adding 0.5 µCi/well [3H]-thymidine (5 Ci/mmol, Morovek 
Biochemicals Ltd, Brea, CA, USA) for 16 hours. Plates were harvested onto glass- fibre filter 
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mats using a TomTec Harvester 96 (Receptor Technologies, Leamington Spa, UK). After drying, 
the filter mats were fused with wax scintillant MeltiLex A and counted in a MicroBeta TriLux 
1450 LSC -counter (Perkin Elmer, Cambridge, UK).  T-cell proliferation was given as cpm 
(counting per minute). The results were analyzed using Stimulation Index (SI, mean counting per 
minute (cpm) with drug/mean cpm without drug). An SI>2 was considered positive.  
 
2.5  Generation of T-cell lines and T-cell clones 
106 PBMCs from the hypersensitive patients were incubated in 48-well tissue culture plates with 
culprit drug (37°C, 5% CO2). l of fresh medium supplemented with 500U/ml IL-2 was 
added on Day 6 and Day 9 to maintain T-cell proliferation. On Day 14, the cultured cells were 
washed with medium and counted by trypan blue dye exclusion and thereafter were seeded in 
triplicate in 96-well U-bottomed plates at different cell concentrations (0.3, 1 and 3 cells/well; in 
a total volume 100 µl). Irradiated PBMCs (45 Gy) were used as feeder cells (provide stimulatory 
molecules, mainly CD28 molecules, which are required signal for T-cell activation) for 104cells 
/well and added to each well in culture medium supplemented with 200 U/ml IL-2 (maintaining 
T-cell survival) and g/ml PHA (stimulate TCR via CD3 molecule, thereby promoting T-cell 
activation). On Day 5, T-cells were fed with medium supplemented with 60 U/ml IL-2 and 
afterwards the IL-2 supplemented culture medium was fed every 48h.  
T-cell cloning cultures were re-stimulated using 45 Gy irradiated allogenic lymphocytes as 5x104 
cells/ well as feeder cells. 500 U/ml IL-2 and g/ml PHA were added to maintain the T-cell 
expansion. Wells which showed large pellets were expanded into 4 wells and fed every 2 days. 
The clones were then tested for drug specific T-cell proliferation. About 5x104 T-cell clones were 
cultured in duplicate, in the presence or absence of drug, in the addition of 60 Gy irradiated 
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autologous B-LCLs (104/well, 0.2ml) as antigen presenting cells (APCs). The cultures were 
incubated for 3 days at a temperature of 37°C and an atmosphere of 5% CO2. [
3H] thymidine was 
added at 0.5 Ci/well for the final 16h of the incubation. T-cell proliferation was measured using 
a -counter and SI>2 were considered positive.  Drug specific clones were further re-stimulated 
using the medium containing 45Gy irradiated allogenic 106 PBMCs, 500U/ml IL-2 and 10 g/ml 
PHA in the total volume of 0.66 ml. Cultures were maintained at 37°C, 5% CO2 and were fed 
with culture medium containing 60 U/ml IL-2 every two days after the second day.  
  
2.6  Generation of EBV transformed B-cell lines 
EBV-transformed B-cell lines (B-LCL) are an immortalized B-cell line used as a source of 
autologous antigen presenting cells. B-LCLs were generated by incubating isolated PBMCs from 
the donors with supernatant from the Epstein-Barr virus producing cell line B9-58 (Beatty et al., 
1998). Donor PBMCs were isolated and co-cultured with 0.2 m filtered B9-58 supernatant 
supplemented with 1 µg/ml cyclosporine A (CSA) and incubated overnight at 37°C in an 
atmosphere of 5% CO2. The next day, the supernatant was discarded and PBMCs were cultured 
in F1 medium supplemented with 1 µg/ml CSA every 3 days in 24 well plates for 3 weeks. Cells 
were then grown in F1 medium alone.  
 
2.7  Analysis the phenotype of T-cell clones by flow cytometry 
5x105 T-cell clones were incubated with anti-human CD4-FITC, CD8-PE, CXCR3-APC, CCR1-
FITC, CCR6-APC, CCR4-PE, CLA-FITC, CCR10-PE, CCR5-FITC, CCR2-PE, CCR3-FITC, 
CCR8-PE, CCR9-APC, CXCR1-APC, CXCR6-PE, and E-cad-PE antibodies (purchased from 
BD Biosciences, Oxford, UK) for 20 min on ice in the dark. Afterwards, the cells were washed 
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with 1 ml of FACS buffer (phosphate buffered saline [PBS] + 10% (v/v) FCS + 0.02% (v/v) 
[sodium azide]) by centrifuging at 1500 rpm for 5 min. The cells were re-suspended in 150 µl 
FACS buffer and analyzed by flow cytometry on a FACS Canto II (BD Biosciences).  
 
2.8  Testing drug specific T-cell proliferation 
5x104 T-cell clones were plated in duplicate, 104 autologous B-LCLs per well were added as well 
as medium in the presence or absence of the drug to a final volume of 200 µl/well. The drug was 
added at the following concentrations (piperacillin 0.5 mM, 1 mM, 2 mM, flucloxacillin 0.5 mM, 
1 mM and 2 mM, SMX-NO 12.5 µg /ml, 25 µg/ml, 50 µg /ml and PHA 5 µg/ml). The 
proliferation was measured by [3H]-thymidine incorporation as described in 2.5.  
 
2.9  Testing T-cell clones for HLA restriction 
5 µg/ml MHC class I or 5 µg/ml MHC class II blocking antibodies (from BD Bioscience Oxford, 
UK) were incubated with 104 cells/well of autologous B-LCLs for 30 min at 37°C and 
atmosphere of 5% CO2. 5x10
4 T-cell clones/well and medium or drug solution (piperacillin 2 
mM, flucloxacillin 2 mM, SMX-NO 50 µM) was then placed in each well, making up to 200 
µl/well. Proliferation was measured by [3H]-thymidine incorporation as described in 2.5.  
 
2.10  Testing T-cell-clones for antigen processing 
APCs were incubated with piperacillin (2mM), flucloxacillin (2 mM) and SMX-NO (50 M) for 
1h, 4h, 16h and then extensively washed (3 times) to discard the free drug, also known as pulsing 
the cells. 5x104 T-cell clones/well were cultured with drug pulsed B-LCLs (1x104 cells/well) and 
drugs in duplicate in 96 well plates for 3 days at 37°C in an atmosphere of 5% CO2. Proliferation 
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was measured by [3H]-thymidine incorporation as described in 2.5.  
2.11  EBV transformed B-cells cell lysate preparation. 
To test the formation of drug antigen in the medium, EBV transformed B-cell lines were 
incubated with either SMX-NO or piperacillin or flucloxacillin in a 12 well culture plate at 37°C 
in an atmosphere of 5% CO2 for 16 hours. The cells were washed 3 times with Hanks buffer (in 
the centrifugation of 1500rpm for 5 minutes) to remove free drugs. Cell pellets were suspended 
in 200 l RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCl, 2.5 mM EDTA, 10% (w/v) Glycerol, 
1% (w/v) Triton X-100, 1 mM Na3VO4, 10 μg/ml aprotinin,  g/ml  leupeptin, 1mM  PMSF, 
0.1% (w/v) SDS, and 0.5% (w/v) Na deoxycholate) and placed on ice for 30 minutes to lyse. 
Cells were given three bursts of sonication for 20 seconds each whilst on ice. The cell 
suspensions were then centrifuged at 14000 g for 10 minutes at 4°C. Supernatants were then 
collected and protein concentration was determined by Bradford assay (Bradford 1976).  
 
2.12  Bradford assay. 
A standard calibration curve was prepared using BSA (0-2000 µg/ml). Briefly, 10 µl of BSA 
standard solution/ sample solution was plated into a 96-well flat-bottom microplate. 200 µl 
Bradford reagent (from BIO-RAD Hempstead, UK) was added to each well prior to being read at 
570 nm using a microplate reader (Dynex, Technologies, Billinghurst, West Sussex). The protein 
concentration of each sample was obtained using the standard curve generated from BSA. 
Protein lysates were then standardized to 250 µg/ml.  
 
2.13  Western blotting 
The following buffers were used - TST buffer: 150 mM NaCl, 50 mM Tris-HCL, 0.05% Tween-
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20, pH 7.6 and Laemmli buffer: 63 mM Tris HCl, 10% Glycerol, 2% SDS, 0.0025% 
bromophenol blue pH 6.8. Protein lysates were added at 10 µl/lane on a 10% SDS-
polyacrylamide gel and were ran at 300 V, 60 mA for 1 hour. Separated proteins were then 
transferred from the gel onto a nitrocellulose membrane which was pre-wetted by 20% methanol, 
at 300 V, 250 mA for 1 hour. The membrane was then blocked by using TST containing 2.5% 
(w/v) non-fat dry milk and subsequently incubated with blocking buffer containing 1:1000 (v/v) 
dilution of rabbit anti-SMX-NO (Panigen, Blanchard Ville, USA) overnight at 4°C. (For anti-
piperacillin western blotting, mouse primary anti-penicillin antibody [ABCAM, UK] was diluted 
in blocking buffer in 1: 20,000 [v/v]; and for anti- flucloxacillin western-blotting, rabbit primary 
antibody, [personal gift from Frank Von Pelt, National University of Ireland] was diluted in 
blocking buffer in 1:5000 [v/v]).   
The next day, the membrane was washed five times for 5 min with TST to remove any free 
antibody. The membrane was then incubated with a 1:10,000 (v/v) dilution of secondary 
antibody: mouse anti-rabbit alkaline phosphatase-conjugated antibody (Sigma-Aldrich, 
Gillingham, UK) at room temperature for 2 hours.  [For piperacillin, goat anti-mouse HRP 
[P0447, DAKO, Ontario, Canada] was diluted in blocking buffer in 1:10,000 (v/v). For 
flucloxacillin, goat 
anti-rabbit IgG [P0448, DAKO, Ontario, Canada] were used as the secondary antibody, diluted 
in blocking buffer in 1: 2,000 [v/v]).  
 
 Afterwards, the membrane was washed five times with TST. The signal was then developed 
using enhanced chemical luminescence (Western Lightning; PerkinElmer Life and Analytical 
Sciences, Waltham, MA) by developing autoradiography film in a dark room and GS800 
calibrated scanning densitometer (Bio-Rad Laboratories, Hemel Hempstead, UK).   
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2.14  ELISpot assay 
Polyvinylidene fluoride (PVDF) membrane ELISpot plates were pre-wetted with 35% ethanol 
for 30 seconds prior to washing with 250 µl sterile ELGA distilled water 5 times. ELISpot plates 
were then coated with 100 µl/well of IFN- capture antibody (15 µg/ml) and incubated overnight 
at 4°C. The following day, wells were washed 5 times with sterile phosphate-buffered saline 
(PBS) to remove the free antibody and were then blocked with 200 µl/well of R9 medium for 30 
minutes at room temperature. Drug specific T-cell clones (5×104 cells, 50µl) were put into the 
wells alongside with autologous 60 Gy irradiated EBV-transformed B cells (1×104 cells, 50µl), 
with the addition of 100 µl of R9 medium, SMX-NO (50 µM), piperacillin (2 mM) and 
flucloxacillin (2 mM). The cells were cultured at 37°C for 48 hours.  
After 48 hours, the cells were discarded and then the wells were washed for 5 times with 250 
µl/well PBS. Biotin conjugated detection antibody (1 µg/ml) was diluted in 0.5% FBS/ PBS and 
100 µl was added to each well. Plates were incubated at room temperature for 2 hours, then wells 
were then washed 5 times with PBS. 100 µl/ well streptavidin-ALP (1:1000) in 0.5% FBS/PBS 
was added to the wells and incubated at room temperature for 1 hour. Pla tes were then washed 
with PBS for 5 times and 100 µl 0.45 µm filtered BCIP/NBT substrate was added to each well. 
Plates were incubated for 10-15 minutes in the dark at room temperature before the substrate was 
washed off with tap water. Plates were left to dry overnight prior to counting by an AID ELISpot 
reader (Cadama Medical, Stourbridge, UK).  
 
2.15  T-cell priming assay 
PBMCs were isolated from 100 ml of blood as described in 2.3. Cell populations required for the 
dendritic cell priming of naïve t-cells were isolated from PBMCs using magnetic beads, 
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according to the manufacturers’ instructions (Miltenyi Biotec Ltd, Bisley, UK). Firstly, CD14 
cells were isolated by positive selection. Secondly, T-cells were isolated from the CD14 negative 
population by negative selection and finally Tregs and memory T-cells were removed by positive 
selection leaving the naïve T-cell population.  
2.15.1  Isolation of CD14+ cells by positive selection.  
PBMCs were counted and 800 µl Macs buffer and 200 µl CD14 microbeads were added per 108 
cells. The beads were vortexed before use. The cells were incubated in the fridge for 15 minutes 
at 4°C. 15 ml of Macs buffer was added and the cells were spun at 1500 rpm for 10 minutes at 
4°C. After pipetting off the supernatant completely, cells were resuspended in 500 µl Macs 
buffer per 108 cells. An LS column was put on magnet and the column was washed with 3 ml of 
MACs buffer. The cells were then added to the column and washed 3 times with 3 ml Macs 
buffer. Non-CD14 cells were collected as the flow through and positively collected cells were 
removed from the column by adding 5ml Macs buffer to the column and immediately applying 
the plunger firmly to the column washing the cells off. The cells were counted. CD14 were used 
to culture dendritic cells or were frozen at 6-8 x 106 cells/vial in freezing medium. The non-
CD14 cells were spun down and used for T-cell selection.  
2.15.2  Naïve T-cell selections. 
T-cells were selected using the Pan-T isolation kit as follows. The non-CD14 cells were 
resuspended in 400 µl Macs buffer and 100 µl biotin-antibody cocktail added per 108 cells and 
incubated for 10 minutes in the fridge at 4°C. Then 300 µl Macs buffer and 200 µl anti-biotin 
microbeads was added per 107 cells and incubated for 15 minutes in the fridge. Then 15 ml Macs 
buffer was added and the cells spun at 1500 rpm for 10 minutes at 4°C. The cells were 
resuspended in 500 µl Macs buffer and put through an LS column as previously described. The 
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flow through from the column contained the T-cells and non-T-cells were recovered from the 
column. Tregs and memory T-cells were then removed using CD25 and CD45RO microbeads as 
described for the CD14 cells, leaving the naïve T-cells as flow through from the column. CD14-
CD3- cells (for generation of B-LCL), CD14-CD3+CD45RO-CD25- cells (naïve T-cells), and 
CD14-CD3+CD45RO+CD25- (memory T-cells) were frozen down at 107 per vial in freezing 
medium. 
2.15.3  DC culture from CD14 cells.  
6-8 x 106 CD14 cells were diluted in 6 ml of R9 medium supplemented with 800 U/ml GM-CSF 
and IL-4 and aliquoted 3 ml/well in a 6 well plate. The cells were fed every 2 days with 3 
ml/well R9 medium containing 800 U/ml GM-CSF, IL4. On day 6, the cells were matured with 1 
μg/ml LPS and 25 ng/ml TNF-α. On day 7, the mature DCs were scraped from the bottom of 
wells. After being spun at 1500 rpm, DCs were resuspended in 2 ml medium and counted.  
2.15.4  Co-culture of DCs and naïve T-cells.  
DCs were prepared at 1. 6 x 105 cells/ml in R9 medium and 0.5 ml/well added to 24-well plates. 
Naïve T-cells were thawed and washed. The cells were counted and made up 2.5 x 106 cells/ml 
in R9 medium, and 1ml/well added to 24 well plates. The drugs were added at 500 µl/well to a 
final concentration of 2 mM piperacillin, 2 mM flucloxacillin, and 50 µM SMX-NO. The co-
culture cells were incubated in the incubator in 5%CO2 at 37°C for 7 days. During this time, new 
DCs were cultured from CD14 cells as described previously.  
2.15.5 Testing the drug antigen specificity of the primed cells. 
On Day 14, the co-cultured cells and DCs were harvested. The drug primed T-cells were tested 
by ELISpot and proliferation assay using primed T-cells at 105 cells/well and autologous DCs at 
4x103 cells/well with various drug concentrations as described previously.  
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2.16  Human memory T-cell Th subsets differentiation, including Th1, Th2, Th17 and 
Th22.  
10 µg/ml of CD3 antibody was diluted in HBSS solution and pre-coated 300 µl/well in 48 sterile 
well plates over night at 4°C. On the next day, excess CD3 antibody was washed with HBSS for 
3 times. 5x105 memory T-cells were then added onto the CD3 coated wells with 500 µl of R9 
medium supplemented with 5µg/ml of anti-CD28 antibody, with or without Th17 differentiation 
cytokines including TGF-β (1 ng/ml), IL-1β (10 ng/ml), IL-6 (10 ng/ml), IL-23 (10 ng/ml). Th22 
differentiation cytokines were 50 ng/ml TNF-α, 20 ng/ml IL-6, 5 µg/ml anti IL-4 and 5 µg/ml 
anti IL-12. When differentiated into Th1 cells, the secreted cytokines were anti-IL-4 (5 µg/ml) 
and 25 ng/ml IL-12; when differentiated into Th2 cells, the secreted cytokines were 25 ng/ml IL-
4, 5 µg/ml anti-IL-12, and 5µg/ml anti-IFN-γ. The cells were incubated at atmosphere of 
37°C/5%CO2 for 5 days. On Day 6, polarized memory T-cells cytokine secretion was tested by 
ELISpot in the stimulation of PHA (5 µg/ml).  
 
2.17  T-cell isolation from skin biopsies. 
Skin biopsies were transported to the laboratory in R9 medium + 100 U/ml IL2 and on arrival 
were then removed from the R9 medium using a Pasteur pipette and spun at 1500 rpm for 10 
minutes to pellet any cells that may have migrated from the sample during transportation. A 
scalpel was used to mince the sample as finely as possible in a petri dish. The cell pellet was then 
re-suspended in 2 ml of R9-IL2 and plated in 7 ml of R9-IL2 for a combined volume of 9 ml. 3 
ml of the solution was transferred into each of the three wells on a 12 well cell culture plate and 
placed into a 37oC, 5% CO2 incubator. Skin biopsies were prone to the formation of a fat layer at 
the surface of the well. If necessary, a Pasteur pipette was used to remove the fat and the volume 
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removed was replaced with a similar amount of R9-IL2 before mixing. After 3-5 days the wells 
were aspirated and the contents passed through a 50 micron cell strainer into a 50 ml tube to 
remove any debris. The strainer was flushed with several washes of sterile PBS/Hanks and then 
spun at 1500 rpm to obtain a cell pellet. The pellet was re-suspended in 1 ml of R9 and 330 l 
was placed into each of 3 wells on a 48 well plate. l of stimulation cocktail which consisted 
of 5U of IL2, 10 g of PHA and 0.5x106 irradiated PBMC was added to each of the wells. Cells 
were fed by removing l of medium from each well on Days 5 and 9 and replaced with an 
equal volume of R9 + 100 /ml IL2. On the day 14, the wells were mixed and the contents 
aspirated into a tube and spun at 1500 RPM for 10 minutes to obtain a pellet.  
The cell pellet was re-suspended in 1 ml of freezing medium and immediately transferred to a 
cryovial, which was placed in a -80 oC freezer. After 24 hours the cryovial was removed and 
stored in either a -150 oC freezer. 
 
2.18 Glutaraldehyde APC fixation. 
Autologous B-LCLs were washed twice and re-suspended in 1 ml HBSS. Glutaraldehyde (25%, 
1 ml) was purchased from Sigma. It was then added and the cells were gently mixed for 30 s. 
Cells were then washed 3 times to remove glutaraldehyde and were re-suspended in T-cell 
culture medium. 5 x 104 T-cell clones were cultured with 104 glutaraldehyde fixed B-LCLs in 
presence or absence of drugs (50 µM SMX-NO, or piperacillin 2mM, or flucloxacillin 2 mM) in 
duplicate in 96 well plates for 3 days at 37°C in an atmosphere of 5% CO2. Proliferation was 
measured by [3H]-thymidine incorporation as described in 2.5. 
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2.19 Glutathione and NAL blocking assay 
N-Acetyl- lysine  (Sigma) was diluted in final concentration 1 mM and cultured with 1 x 104 
autologous B-LCLs and 5 x 104 T-cell clones with or without l of drug solution (piperacillin 
or flucloxacillin or SMX-NO) in a total volume of l in  well plates. Proliferation was 
measured by [3H]-thymidine incorporation as described in 2.5.  
Glutathione (Sigma) was prepared and tested in the same way as N-Acetyl- lysine. 
 
2.20 T-cell receptor Vβ expression  
TCR Vβ expression of individual clones can be typed using the IOTest kit. At least 5x104 T-cell 
clones were added into 9 FACs tubes in suspensions of 50 μl of T-cell culture medium. Tube 1 
did not contain antibodies, and the tube was used to gate the T- lymphocyte population using flow 
cytometry. TCR Vβ antibodies (5 μl) labelled A-H were then added into another 8 tubes (from 2 
to 9). Each TCR Vβ antibody cocktail was used to investigate three TCRs, twenty- four in total. 
Tubes were incubated at room temperature for 20 minutes. Unbound antibodies were washed 
with FACS buffer (1 ml), 1500 rpm for 5 minutes at room temperature. Finally, T-cell clones 
were resuspended in FACS buffer (200 μl) and samples were analyzed by flow cytometry.  
 
2.21 Statistics analysis 
Candidate screening for drug-specific clones was performed by expanding clones which had a 
stimulation index greater than 2.  A number of statistical tests were used to further this analysis 
depending on the experiment. T-cell clones were tested in triplicate with multiple doses or 
treatments. For multiple comparisons between treatments within a single clone population the 
parametric, one-way ANOVA test was applied. This method was also used to analyze chemokine 
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receptor data. Even within the same donor, there was a great variability in stimulation between 
drug-specific T-cell clones and thus the data did not follow a normal distribution. Therefore, for 
comparisons between T-cell clones, the non-parametric, Mann-Whitney test was employed. 
P<0.05 was considered statistically significant.  
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Chapter 3 
 
Characterization of peripheral T-cells in piperacillin hypersensitivity.  
 
3.1.  Introduction 
3.2 Methods 
3.3 Results 
         3.3.1    Lymphocyte transformation test (LTT) of patients with piperacillin hypersensitivity  
         3.3.2    Generation of piperacillin specific T-cell clones from patients’ PBMCs.  
         3.3.3    Piperacillin specific T-cell responses of the patients.  
         3.3.4   The cytokines and cytolytic molecule profile of the piperacillin-specific T-cell 
clones.   
         3.3.5    The surface markers of the T-cell clones.  
 
         3.3.6    V  expression of piperacillin specific T-cell clones.  
3.4 Discussion 
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3.1. Introduction 
Piperacillin hypersensitivity usually involves skin inflammation such as maculopapular 
exanthema (MPE), or delayed onset urticaria. It has been established that T-cells play an 
important role in piperacillin- induced skin inflammation (Schnyder et al., 1998; Pichler, 2002; 
Naisbitt et al., 2007; Martin et al., 2010). Cystic fibrosis (CF) patients were chosen for this study 
because of the high frequency of hypersensitivity reactions. CF patients live with a life-long 
recurrent bacterial infection and piperacillin is commonly prescribed. Unfortunately, piperacillin 
induced 10 times higher rates of drug hypersensitivity in CF patients compared with normal 
population, 26%-50% compared with 1-10% (Moss et al., 1984). Thus the CF patients’ treatment 
with antibiotics has been restricted by drug hypersensitivity.  
Hypersensitivity reactions such as MPE involve drug-specific cytotoxic CD4+T cells. In contrast, 
the presence of drug-specific CD8+T cells, which mediate severe drug hypersensitivity reactions 
such as SJS-TEN, are much more restricted. However, the role of CD8+T cells in MPE cannot be 
ruled out. Drug-specific T-cell clones have been used routinely in mechanistic studies to define 
the cellular pathophysiology of drug hypersensitivity reactions. The characterization includes T-
cell cytokine secretion, cytotoxicity, cell surface molecules such as CD4/CD8 and chemokine 
receptors, and drug specific TCR diversity.  
 
It is known that, piperacillin specific T-cell clones can be isolated from hypersensitive patients’ 
blood. Drug stimulation of the PBMC results in the secretion of IFN-, IL-5, IL-13 but not IL-10, 
which indicates a mixed panel of Th1 and Th2 cells, but not regulatory T-cells. However the 
involvement of the newly discovered CD4+ T-cell subsets Th17 and Th22 has not been 
investigated. Th17 and Th22 play important role in skin reactions and they are named after the 
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particular cytokines they secrete; IL-17 and IL-22, respectively (Infante-Duarte, et al 2000; 
Eyerich et al., 2009). Th17 cells are critical in autoimmune diseases, such as psoriasis (Kagami et 
al., 2010), Crohn’s disease (Holtta et al., 2008), and rheumatoid arthritis (Hirota et al. 2007). In 
psoriasis, IL-17 promotes chemokine secretion by keratinocytes and amplifies inflammation by 
recruiting more inflammatory cells (Harper et al., 2009). In an in vitro skin injury model, IL-22 
promoted the proliferation of keratinocytes and enhanced wound healing (Eyerich et al., 2009), 
whereas in auto- immune disease such as the very late phase of psoriasis, Th22 promotes the 
inflammatory response (Kagami et al., 2010; Michalak-Stoma et al., 2013). Thus, it is important 
to analyze the cytokine profile that T-cells secrete in drug hypersensitivity.  
 
Chemokine receptor expression directs T-cell migration and dictates the final destination of T-
cells. Cutaneous lymphocyte antigen (CLA) expressed on the T-cell surface is a hallmark of skin 
migration. CLA is an integrin that slows down T-cells rolling along the vesicular endothelium 
near the inflamed site. Subsequently, chemokines released by inflamed skin bind to chemokine 
receptors on T-cell surfaces such as CCR4, CCR8 and CCR10. T-cells then migrate following a 
chemokine diffusion gradient and accumulate at the site of inflammation. To study tissue-homing 
of drug specific T-cells, the profile of chemokine receptors has been tested including skin- and 
gut-oriented CXCR3.  
 
The aim of this chapter was to analyze the phenotypic and functional abilities of peripheral blood 
T-cells isolated from hypersensitive patients with cystic fibrosis. The data generated are used in 
chapter 4 to compare the drug-specific T-cell response induced in blood and inflamed skin of the 
same hypersensitive patients. 
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3.2 Methods  
Three patients with CF and piperacillin hypersensitivity were recruited in 2011 for this study and 
the clinical details are shown in Table 3.1. Three normal volunteers were also recruited as 
controls. Although these numbers are low and not representative of the general hypersensitive 
population, cloning is very labor intensive procedure. Cloning T-cells from three patients and 
detailed characterization of the clones takes approximately 12 months. Thus, analysis of 
additional patients was not possible.  
 
Patient Age / 
Gender 
Drug Reaction 
 
Reaction 
Time+ 
Time* Skin 
Prick Test 
Intradermal 
skin test 
P1 20/M piperacillin  MPE/fever 2 0.5 - - 
         
P2 29/F piperacillin  Fever/arthralgia  9 6 - - 
         
P3 29/M piperacillin  MPE 5 2 - + at 48 hours 
Table 3.1 The clinical history of hypersensitive patients with cystic fibrosis.  (Age in years, Reaction 
Time+: time from treatment to reaction in days, Time*: time since reaction in years, M: male, F: female, MPE: 
maculopapular exanthema, P: patient) 
 
PBMCs from patients and healthy volunteers were used to perform a lymphocyte transformation 
test (LTT) using piperacillin at 0.5 mM to 4 mM.  PBMCs were then used to set up bulk cultures 
with piperacillin which were used for isolation of drug-specific T-cell clones. Irradiated, 
autologous EBV transformed B cells were used as antigen presenting cells (APCs) in assays with 
the T-cell clones. Clones displaying a stimulation index (cpm in drug-treated cultures/cpm in 
medium control cultures) of 2 or above were used in all experiments. When available multiple 
clones from different donors were used in all mechanistic studies. However, clones have a very 
short life-span. They very rapidly become anergic to drug stimulation. Thus, several experiments 
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were limited to 3 clones. Although this number was low, it allowed us to conduct statistical 
analysis of the data. 
The phenotype and functional abilities of the T-cell clones was then assessed: proliferation was 
measured by thymidine incorporation, release of cytokines and cytolytic molecules was 
measured by ELISpot, and the surface phenotype was assessed by flow cytometry looking at 
CD4, CD8, TCR V  and chemokine receptor expression.   
 
3.3 Results 
 
Three piperacillin hypersensitive patients were recruited. They had a similar reactions to 
piperacillin, which is maculopapular exanthema (MPE). Patient 1 and 2 also showed fever and 
patient 2 showed arthralgia as side effects (Table 3.1).  The time of onset of hypersensitivity 
reaction to the drug administration was a minimum 2 days.  Skin prick tests were taken and all 
the patients were negative. Intradermal test result showed patient 1 and 2 were negat ive. Patient 
3 had a reaction to the intradermal test in 2 hours. The tests above suggest piperacillin reaction is 
delayed-type hypersensitivity. Characterization of the function of piperacillin- reactive T-cells 
was conducted in subsequent sections using peripheral blood from the hypersensitive patients.  
 
 
3.3.1 Lymphocyte transformation test (LTT) of patients with piperacillin hypersensitivity  
LTT results presented in figure 3.2 are measured by SI. All 3 patients with CF showed a positive 
LTT when PBMCs were incubated in vitro with piperacillin. The response was dose dependent 
with a maximal response at 1-2mM. PBMCs from healthy volunteers (n=3) proliferated in 
response to tetanus toxoid (5g/ml) but not to piperacillin.  
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    Piperacillin (mM)   
  cpm in control 0.5 1 2 4 TT (5g/ml) 
P1 905 1.8 2.6 4.8 2.2 16 
P2 2333 25.4 32.8 30 19.4 3.6 
P3 137 3.7 3.9 23.5 4.7 52.8 
V1 1121 1 0.8 1.3 1.3 84.1 
V2 3683 0.6 0.5 0.5 0.6 26.7 
V3 1352 0.7 0.5 0.5 0.7 7.2 
 
 
Table 3.2 Piperacillin-specific lymphocyte transformation test (LTT). LTT of the piperacillin 
hypersensitive patients and normal volunteers was performed using PBMCs at 1.5 x 10
5 
cells/well. Cells were 
incubated with piperacillin or tetanus toxoid (TT) as a control for 6 days and proliferation was measured by 
3
H-thymidine incorporation. Drug specificity of PBMCs were shown by SI (stimulation index).  
 
 
3.3.3 Piperacillin specific T-cell responses of the patients.  
After serial dilution and drug specificity test, 45 T-cell clones of patient 1, 18 clones of patient 2, 
and 15 clones of patient 3 were picked out for more detailed analysis (Table 3.3A, B and C).  The 
proliferation of clones against piperacillin was dose-dependent between 0.5-2mM piperacillin. 
  
 
 
 
Table 3.3A Piperacillin-specific proliferation (SI) of T-cell clones from patient 1 (45 clones) 
    Drug (mM) 
Clones  cpm in control 0.5 1 2 
12* 4088 3.0 3.0 2.8 
15 3889 3.5 5.2 3.5 
19 4338 11.7 6.5 5.3 
21 4804 2.4 2.3 2.4 
22 5323 4.0 4.9 4.9 
24 2911 6.5 7.0 7.8 
41 5101 8.4 8.0 8.1 
56 3583 10.7 13.0 10.9 
67 3714 3.3 5.9 4.7 
76 3794 2.8 6.4 5.3 
79 3836 7.8 10.3 10.5 
82 4778 3.2 4.8 4.1 
114 4270 6.9 6.5 8.9 
 
 80 
 
120 5186 4.8 4.6 5.1 
122 4379 5.1 3.9 10.0 
125 9799 4.3 3.7 4.6 
126 4526 10.0 8.1 9.9 
128 5059 4.2 3.3 4.3 
142 3645 4.1 5.6 5.3 
143 4370 2.6 3.3 3.4 
145 3302 4.7 8.8 7.8 
148 8642 9.7 9.3 9.4 
149 5869 6.1 6.7 6.4 
150 4037 8.3 8.2 7.3 
154 3838 2.9 4.9 5.8 
157 4105 5.2 8.3 7.8 
158 8442 3.4 3.9 4.3 
165 6171 4.1 5.2 5.3 
176 7293 23.3 27.8 31.2 
180 8702 4.7 7.3 6.6 
183 15548 5.4 4.8 5.2 
187 4511 5.3 6.3 5.2 
188 8247 5.0 5.0 6.9 
190 9131 5.7 8.4 7.3 
195 6405 16.7 27.4 27.4 
196 11283 4.9 6.8 6.2 
198 3596 2.4 4.9 3.8 
199 2848 8.3 12.3 12.0 
202 3455 23.7 28.4 25.8 
211 3680 10.4 17.3 14.8 
215 2887 67.1 71.2 81.0 
219 3798 19.7 21.2 23.5 
258 4594 2.5 2.5 2.4 
259 5571 8.7 13.2 9.6 
269 5160 8.2 6.8 6.3 
 
*Number assigned to T-cell clones throughout chapter 1 (including ELISpot test, chemokine receptor, and V 
receptor).  
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Table 3.3B Piperacillin-specific proliferation of T-cell clones from patient 2 (18 clones) 
    Drug (mM) 
Clone 
number   cpm in control 0.5 1 2 
9* 2467 29.0 44.6 45.7 
23 2547 33.7 44.3 40.9 
29 3256 4.6 5.0 5.2 
39 4012 3.6 3.9 4.6 
55 3290 8.1 13.9 11.1 
73 3181 20.6 19.1 13.4 
77 4908 11.3 11.7 11.3 
88 2757 11.4 10.4 9.7 
106 45242 2.0 2.3 2.2 
109 6117 3.1 2.9 3.3 
119 4503 2.9 5.4 4.3 
150 3077 6.0 5.9 5.8 
153 3958 10.2 10.5 10.6 
154 9422 2.5 3.3 2.7 
168 10211 2.5 2.1 2.3 
235 3441 14.9 12.1 11.9 
237 4256 10.1 8.6 10.4 
266 3948 8.6 9.0 6.7 
 
*Number assigned to T-cell clones throughout chapter 1 (including ELISpot test, chemokine receptor, and V 
receptor).  
Table 3.3C Piperacillin-specific proliferation of T-cell clones from patient 3 (15 clones) 
    Drug (mM) 
Clone 
number  cpm in control 0.5 1 2 
14* 4180 17.9 17.3 19.5 
27 3764 7.4 8.9 9.4 
146 3668 16.4 25.7 20.5 
160 3271 6.4 8.9 9.5 
171 6888 5.7 9.6 8.8 
174 5541 6.7 9.0 4.5 
182 6693 4.3 8.7 7.6 
220 3655 2.9 2.7 0.8 
222 3471 4.1 3.3 1.3 
231 7991 3.3 3.3 2.0 
239 2555 41.0 62.0 71.6 
246 2169 10.8 17.5 20.1 
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247 2257 10.7 14.1 16.0 
250 2417 25.8 32.4 36.3 
251 2791 2.9 5.2 5.4 
 
*Number assigned to T-cell clones throughout chapter 1 (including ELISpot test, chemokine receptor, and V 
receptor).  
Table 3.3 T-cell clones from 3 patients are reactive to piperacillin in a dose dependent manner. 5 x 104 T-cell  
clones were placed duplicate wells. 1x10
4 
Epstein-Barr virus (EBV) transformed B-cell  were added in the presence of 
either medium or piperacil lin to a final volume of 200 µl/well. The drug was added at the concentrations indicated. 
78 clones from 3 patients were tested. Proliferation was measured by 
3
H-thymidine incorporation for the final 16 
hours. Data is presented as SI. 
3.3.4 The cytokines and cytolytic molecules secreted by piperacillin-specific T-cell clones.   
Twenty four well-growing piperacillin-specific T-cell clones were randomly selected with SI from 3 to 40 
for the assessment of cytokine secretion. 3 million cells of a T-cell clone were required for a full scale 
experiment. Thus, it was not possible to conduct cytokine profiling experiments on all clones.  
ELISpot image results presented in Table 3.4A and Figure 3.1A-G and the result summary (Table 
3.4 B-D) show that of the 24 clones, 14 clones secreted IFN-γ, 20 clones secreted IL-5 and 18 
clones secreted IL-13 (Figure 3.1 A, B, C). Furthermore, 21 clones secreted IL-22, but no IL-17A 
secretion observed with any of these clones (Figure 3.1 D, E). 20 clones secreted the cytolytic 
molecule, granzyme B and 14 clones secreted FasL (Figure 3.1 F, G). This data suggests IL-22 
may be an important feature in hypersensitivity to piperacillin, whereas, IL-17 does not seem to 
be involved. Th1 secreting T-cells secreted mainly IFN-γ whereas Th2 T-cells secreted cytokines 
such as IL-5 and IL-13. The cytokine profiles showed that both Th1 and Th2 T-cell clones 
activated with piperacillin were generated from patients with CF. However, Th1 and Th2 
cytokine secretion in T-cell clones is not always clearly defined in that some T-cells secreted a 
mixture of Th1 and Th2 cytokines. For example, clones 176, 215, 14, and 39 express IFN-γ 
which is a Th1 cytokine, as well as IL-5 and IL-13, which are Th2 cytokines. In addition T-cell 
clones also secreted a range of cytolytic molecules such as granzyme B and Fas- ligand.  
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To characterize whether drug-specific proliferation and cytokine release after drug stimulation 
were synergistic, an attempt has been made to find a correlation between the drug specific 
secretions of Th2 cytokines, IL-13 and IL-5, by 24 clones (Figure 3.1 H).  However, no 
significant correlation (r2 =0.056, and r2>0.5) was observed. Similarly, the correlation between 
IL-22 and IFN- and the proliferative response of these clones was studied, but still, no 
correlation was observed (Appendix data).  
 
 
 Piperacillin exposure 
 0 0.5mM 0 0.5mM 0 0.5mM 
Layout of 
T-cell clones 
 
(Black = Patient 1) 
(Red = Patient 2) 
(Blue=Patient 3) 
56 56 250 250 39 39 
126 126 266 266 55 55 
176 176 235 235 73 73 
199 199 77 77 119 119 
202 202 182 182 146 146 
211 211 231 231 160 160 
215 215 14 14 171 171 
239 239 27 27 174 174 
 
Table 3.4 A. The layout of T-cell clones on ELISpot plates. 
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     Figure 3.1 A                                       Figure 3.1 B                                               Figure 3.1 C 
 
                  
                                 
 
 
 
 
 
 
 
 
               Figure 3.1 D                                                            Figure 3.1 E 
     
 
 
 
 
 
 
 
 
 
 
 
   IFN- IL-5 IL-13 
0     0.5      0      0.5      0      0.5                      
IL-22 
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  Figure 3.1 F                                    Figure 3.1 G                                      Figure 3.1 H 
  
 
 
 
 
 
                                                                                                                              
Figure 3.1 Cytokine and cytolytic molecule profile of the piperacillin-specific T-cell clones generated from 
hypersensitive patients. (A) IFN- ELISpot image. (B) IL-5 ELISpot image (C) IL-13 ELISpot image. (D) IL-22 
ELISpot image and (E) IL-17A ELISpot image. (F) granzyme B ELISpot image. (G) FasL ELISpot image. T-cell 
clones from 3 patients were plated at 5 x 10
4 
cells/well with 1 x 10
4 
cells/well irradiated autologous B cell APCs in 
the presence of  0.5 mM of p iperacillin for 2 days prior to the plate developing according to manufacturer’s 
instruction. The layout of the T-cell clones in  the ELISpot image is shown in Table 3.3A. (H) The correla tion 
between piperacillin specific IL-5 and IL-13SI.  
 86 
 
 Table 3.3B 
           
 Table 3.3 C                
 
Table 3.3 D 
 
Table 3.4 B-D. A summary of the ELIS pot results of Figure 3.3. Cytokine and cytolytic molecule profile of the 
piperacillin-specific T-cell clones generated from the 3  patients. (B) the summary result for 10 T-cell clones from 
patient 1. (B) the summary  result for 6 T-cell clones from patient 2. (C) the summary  result for 8 T-cell clones from 
patient 3. The ELISpot results were semi quantified  as follow: the numbers of spots in the non-stimulated control as 
-.   +: 40 spots more than the control.   ++:  80 spots more than the control. +++: 120 sports more than the control.  
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3.3.5 Surface markers expressed on piperacillin-specific T-cell clones 
  
The expression of CD markers on the T-cell clones was determined by flow cytometry (Figure 
3.2 and Table 3.5). Among the 78 clones isolated from the 3 patients, 77 clones were CD4+ and 
the remaining clone was CD4+CD8+ (Table 3.5). Further analysis of 12 piperacillin-specific T-
cell clones showed that all clones expressed the chemokine receptor CXCR3, 8 clones expressed 
CCR4, 3 clones expressed CCR10 and one clones expressed CCR8 (Table 3.5 and Figure 3.2). 
However, CLA was only expressed at low levels.  
 
 
 
 
 
 
 
 
 88 
 
 
 
Figure 3.2 T-cell surface molecule identification on piperacillin-specific T-cell clones. The cell surface 
molecule expression on specific T-cell clones was measured by flow cytometry. The figure shows 
representative clones. Red shaded area represents isotype control. Black line shows antibody-stained cells. 
 
 
Table 3.5 Expression of T-cell surface molecules. 5 x 10
5
 T-cell clones were incubated with anti-human CD4-
FITC, CD8-PE, CXCR3-APC, CCR4-PE, CLA-FITC, CCR10-PE, CCR5-FITC, CCR2-PE, CCR3-FITC, CCR8-PE 
antibodies (for 20 min  on ice in the dark). The cells were then washed and re-suspended in 150 µl FACS buffer and 
analyzed by flow cytometry on a FACS Canto II. Data is given as mean fluorescence index (mean fluorescence of 
test antibody/mean fluorescence of isotype control antibody). An index of <2.0 was regarded as no expression.  
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3.3.6 TCR V  expression of piperacillin specific T-cell clones. 
 
Sixteen clones were assessed for TCR V  expression by flow cytometry. These analyses were 
conducted on the best growing clones randomly selected from the three patients.  The panel of 24 
antibodies represents most of the common V  types and covers 85% of all Vs. Two T-cell 
clones (clone 27 and 199) were negative for all the TCR V  tested. The remaining 14 clones 
expressed 9 different TCR Vs, with V Vand V9 being the most common (Figure 
3.3 and 3.4). T-cell clone 174 was in fact a mixture of 2 different clones with 2 different TCR 
V , namely Vand V17 and should therefore be referred to as a drug-responsive cell line 
(Figure 3.4).  
 
 
 
 
 
 
Figure 3.3 TCR VExpression on piperacillin-specific T-cell clones from hypersensitive patients with CF.  
16 p iperacillin-specific T-cell clones were tested. Minimum of 5 x 10
4 
cells were stained with l V detecting 
antibody for 20 minutes. These cells were washed and the stained and analyzed using a FA CS Canto II. 
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Figure 3.4. Flow cytometry assessment of TCR V expression on T-cell clones. These graphs show an example 
of V receptor expression on the tested clones.  Flow cytometry profiles of 4 T-cell clones expressing single 
Vreceptors, and the profile of one clone, clone 174, which was a mixed cell population expressing V9 and 
V17. 
 
 
3.4 Discussion 
T-cell responses to piperacillin were examined in 3 patients with CF. Lymphocytes from all 3 
hypersensitive patients were stimulated to proliferate in the presence of piperacillin in a dose-
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dependent manner. In contrast, lymphocytes from healthy controls were not stimulated to 
proliferate. Collectively, these data indicate the presence of piperacillin-responsive T-cells in the 
peripheral circulation of the hypersensitive patients (Pichler et al., 2004).  
To analyze the phenotype and function of these drug-specific responses in detail, drug-
responsive T-cell lines were generated and individual T-cells were cloned. The T-cell response to 
piperacillin was dominated by CD4+ T-cells because 77 out of 78 clones expressed the TCR co-
receptor CD4. CD4+ T-cells dominate in mild skin rashes such as maculopapular exanthema, 
whereas CD8+ T-cells tended to dominate in severe drug hypersensitivity reactions such as 
Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) (Correia et al., 1993).  
Following piperacillin treatment, the majority of clones (21 out of 24 clones) secreted IL-22 but 
not IL-17. These data suggest that Th22, but not Th17, cells play a role in piperacillin 
hypersensitivity. Th22 secreting cells promote the proliferation of keratinocytes and play a role 
in healing wounds in a skin injury model, which suggests Th22 cells may be protective in skin 
injury (Eyerich et al., 2009). In contrast, Th22 cells have also been shown to promote 
inflammation. For example, in the very late phase of psoriasis, Th22 cells play an important role 
in mediating the inflammatory condition (Kagami et al., 2009; Michalak-Stoma et al., 2013). The 
role of IL-22 in the pathogenesis of piperacillin hypersensitivity is not known. Thus, in next 
chapter patient T-cells derived from inflamed skin will be isolated to further characterize the role 
of Th17 and Th22 cells in drug hypersensitivity.  
Both Th1 and Th2 cells contribute to the pathology of drug hypersensitivity. The T-cell clones 
identified in this study were a mixture of Th1 and Th2 cytokine secreting cells as shown by their 
cytokine profiles. Correlation between drug specific secretion of Th2 cytokines, IFN-, or IL-22 
and drug-specific proliferation was studied. However, significant correlation was not observed, 
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highlighting the significant variability of individual clones. These data are consistent with a 
previous study of maculopapular reactions caused by a variety of drugs in that the majority of 
clones expressed low/moderate levels of IFN-γ and high levels of IL-5 and IL-13 (Lochmatter et 
al., 2009). Lochmatter et al (2009) showed that IFN-γ and IL-13 are more sensitive marker for 
drug sensitization than IL-5. IL-5 is able to stimulate eosinophils and thereby amplify 
inflammatory conditions. IL-13 promotes B-cell IgE antibody and polarizes the alternatively 
activated macrophages, which are important in tissue remodeling and allergy. IFN-γ plays a role 
in inducing inflammatory cytokine production and inflammation. It also promotes keratinocyte 
killing by up-regulating MHC expression of the tissue cells. Some of the piperacillin-reactive 
clones may also be capable of cytotoxic activity as shown by secretion of FasL and granzyme B. 
Therefore, upon drug stimulation the piperacillin-specific T-cell clones can act as pro-
inflammatory cells. If these T-cells were present in the skin of patients with CF they could cause 
tissue damage, including the keratinocytes apoptosis (Schnyder et al., 2000).  
The homing of human T-cells in piperacillin hypersensitivity has not been previously studied. 
Chemokine receptors can regulate T-cell migration from the lymph nodes to the inflamed site. 
Once there, the T-cells may increase inflammation by secreting cytokines and cytolytic 
molecules. In this study I have analyzed the chemokine receptors expressed on 12 piperacillin-
specific T-cell clones. The T-cell clones expressed high levels of CXCR3 and CCR4, and low 
levels of CCR8 and CCR10. In patients with dermatitis, CCR4 and CCR10 were classified as 
important mediators of T-cell migration to the inflamed tissue (Reiss et al., 2001), whereas CCR8 
was important in homing of memory T-cells to healthy skin (Schaerl et al., 2004). CXCR3 is 
expressed primarily on activated T- lymphocytes and plays a role in the recruitment of 
inflammatory cells. The T-cell clones did not express CLA which is known to be important in 
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patients with drug hypersensitivity associated with exposure to carbamazepine (CBZ) (Wu et al., 
2007). Besides CLA, CBZ-reactive T-cell clones also expressed chemokine receptors such as 
CXCR4, CCR4, CCR5, and CCR8 (Wu Y et al., 2007), which suggested mechanistic differences 
between the two types of hypersensitivity.  
Piperacillin reactive T-cells express a mixed pattern of TCR Vβ receptors. If T-cell clones 
express the same Vβ receptor, it is believed that the cells may be generated from a single cell ie a 
pure clone. Furthermore, since multiple receptors were expressed, the data suggests that the 
piperacillin haptenic antigen is a strong antigen as it activates T-cells expressing multiple TCRs. 
This is likely due to the drug hapten binding to multiple sites on proteins such as HSA. For 
carbamazepine (CBZ) hypersensitivity, the CBZ specific T-cell TCRs were dominated with Vβ-
11-ISGSY, and the CD8+ T-cells isolated from the inflamed site secreted granulysin, inducing 
the killing of keratinocytes (Ko TM et al., 2007). For abacavir (ABC) hypersensitivity, the 
majority of ABC specific T-cell clones were CD8+ and they expressed broad spectrum of TCR 
V  receptors (Chessman D et al., 2008). Fourteen T-cell clones from piperacillin hypersensitive 
patients show a mixed pattern of TCR V  expression usage which is more similar to the situation 
with abacavir reactive clones. However, the importance of this similarity is limited since the 
mechanisms of T-cell activation by the two drugs differ. For example, abacavir hypersensitivity 
is associated with a specific HLA risk allele and CD8+ T-cells whereas piperacillin 
hypersensitivity is not associated with a HLA risk allele and involves CD4+ cells.  
Drug hypersensitivity can also be induced by other penicillins, such as amoxicillin and 
flucloxacillin. Susceptibility to these drugs is associated with specific HLA alleles. These 
differences suggest that different mechanisms may be involved in the hypersensitivity reaction of 
piperacillin compared to amoxicillin and flucloxacillin. Clinically, piperacillin induces milder 
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reactions compared with flucloxacillin and amoxicillin. Piperacillin-specific T-cells induce CD4-
dependent drug hypersensitivity, whereas CD8+ T-cells play a crucial role in the reaction to 
amoxicillin and flucloxacillin (Monshi et al 2013, Kim et al., 2015). Flucloxacillin-specific CD8+ 
T-cells isolated from hypersensitive patients with liver injury are activated via a hapten pathway, 
in need of protein processing and presentation by antigen presenting cells, which is restricted to 
HLA-B*57:01 (Monshi et al., 2013).  Amoxicillin specific T-cells isolated from patients with 
liver injury are also predominantly CD8 positive and the activation is again dependent on antigen 
processing (Kim et al., 2015). The hypersensitivity reaction with a greater clinical similarity to 
piperacillin is sulfamethoxazole (SMX), which is not β- lactam antibiotic. Both SMX and 
piperacillin generate similar clinical symptoms of skin rash, and the SMX inflammatory T-cells 
are mainly a CD4+ phenotype (Schnyder et al., 2000).  
The main limitation of this study is the small number of patients studied (n=3). It can be difficult 
to obtain the patient samples. Experiments were also lost due to microbial contamination. Finally 
experiments failed due to poor growth of the cells. A larger study size might show greater patient 
variation. However, the validity of my study is supported by 1) the data being consistent with 
published work showing a mixed Th1 and Th2 cytokine profile of individual clones, and 2) the 
limited variation in T-cell clones isolated from individual patients.  
In conclusion, piperacillin specific T-cells isolated from patients with cystic fibrosis were found 
to be mainly CD4+ T-cells; secreting a mixed cytokine profile of Th1, Th2 and Th22 cytokines, 
but IL-17. Expression of chemokine receptors of CXCR3, CCR4, CCR8 or CCR10 was detected 
on the clones indicating that they may migrate from blood to inflamed skin. The varied TCR V 
receptor profile suggested that piperacillin activates a variety of clones expressing different 
receptors. 
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The role of IL-17 and IL-22 producing cells in the skin from 
piperacillin hypersensitive patients with Cystic fibrosis  
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4.1  Introduction 
MPE is the mildest but the most common symptom among the immune mediated skin reactions, 
comprising more than 90% of reactions (Hunziker et al., 1997). MPE usually occurs in 1-2 
weeks after drug administration (Valeyire-Allanore et al., 2007). Piperacillin is one of the drugs 
that commonly induce MPE in patients with cystic fibrosis.  
T-cells are thought to play a critical role in inducing these skin reactions.  Immuno-histochemical 
staining of the skin and functional studies with patient blood lymphocytes reveal the presence of 
drug-specific T-cells that induce cytotoxicity and inflammation in targeted tissues when 
activated. Yawalkar N et al., (2000a) demonstrated that MPE skin is infiltrated with both CD4+ 
T-cell and CD8+ T-cells and CD4+ T-cells dominant in the inflamed tissue. Both types of T-cells 
secrete cytolytic molecules such as perforin and granzyme B and thus have the capacity to cause 
cytotoxicity.  
Secretion of IL-12 and IFN-γ suggest that cytotoxic Th1 cells play an important role in these 
reactions.  Yawalkar N et al., (2000b) also found IL-5 and exotoxin secreting in T-cells in MPE 
skin biopsies, which were capable of attracting and promoting eosinophil-mediated 
inflammation, suggesting that MPE is mediated by drug-specific T-cells that secrete Th1 and Th2 
cytokines. 
In the previous chapter, drug specific T-cells isolated from PBMCs were characterized as 
cytotoxic CD4+ T-cells that secrete Th1, Th2 and Th22 cytokine signatures. Furthermore, some 
of the clones had a tendency to migratory towards skin since they expressed skin-homing 
chemokine receptors CCR4 and CCR10. 
In this chapter, T-cells isolated from piperacillin- induced skin lesions have been studied with the 
aim of giving a complete characterization of piperacillin-specific T-cells that participate in the 
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drug hypersensitivity reaction.  
Skin biopsies were obtained following piperacillin skin testing to isolate T-cells and generate 
clones.  
Chemokines play a central role in the immune system by orchestrating the migration of immune 
cells. As introduced in previous chapter, CLA and the chemokine receptors CCR4, CCR8 and 
CCR10 are key mediators in skin homing. Gut homing receptors such as CCR9, C XCR3 and 
CXCR6 were also been tested in our study to explore whether the drug-specific T-cells 
preferentially express receptors involved in migration towards skin. Finally, CD69 a marker of 
activated T-cells (Moretta et al., 1991) and E-cadherin, which mediates the connection between 
epithelial cells and T-cells were measured (Cepek et al., 1994).  
The roles of Th17 and Th22 secreting T-cells that reside in the MPE skin biopsy of drug 
hypersensitive patients have not been studied. In this study, we characterized the T-cells in 
inflamed skin biopsies and compared the finding to the results presented in chapter 3 
characterizing drug-specific T-cells isolated from blood of piperacillin hypersensitive patients 
with CF. Importantly the two patients studied were also included in the analysis in chapter 3.  
IL-17 is the founding member of the IL-17 family of cytokines. Six IL-17 family members has 
been identified, which includes IL-17A (also called IL-17), IL-17B, IL-17C, IL-17D, IL-17E and 
IL-17F (Korn et al., 2009). IL-17A has the closest sequence homology (58% at the protein level) 
with IL-17F and they have a similar biological effect (Hurst et al., 2002). To test IL-17A 
secretion in the assay because IL-17A are secreted by T-cells (Korn et al., 2009) whereas IL-17F 
can be secreted by both Th17 and monocytes (Mcallister et al., 2005).  Therefore, in this study 
IL-17A secretion was chosen as a signature of drug specific Th17 cells.  
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4.2  Methods  
To characterize drug specific T-cells in inflamed skin and peripheral blood from the same 
patients with CF, T-cells were isolated from patients’ blood and skin biopsies (described in 
section 2.17), and cloned (described in 2.5). The T-cells were stimulated with Epstein-Barr virus 
(EBV) transformed B cells (described in 2.4) as antigen presenting cells (APCs). T-cell cytokine 
secretion was measured by ELISpot (described in 2.14). T-cell cellular surface molecule 
expression, such as CD4, CD8 and chemokine receptors, was determined by flow cytometry 
(described in 2.7). The methods for PBMC isolation and T-cell cloning are described in section 
2.3 and 2.5, respectively). Drug specificity of the T-cell response was measured using a 
proliferation assay (described in 2.8).  
Statistics 
Unless stated otherwise, the ANOVA test was applied to multiple comparisons. A p value < 0.05 
was considered statistically significant.  
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4.3  Results 
 
 
4.3.1  Characteristics of two piperacillin hypersensitive patients with CF.  
 
Patient Age / 
Gender 
Drug Reaction 
 
Reaction 
Time+ 
Time* Skin 
Prick Test 
Intradermal 
skin test 
 
P1 
 
23/M 
 
piperacillin 
 
MPE/fever 
 
2 
 
0.5 
 
- 
 
+ at 48 hours 
         
P2 32/M piperacillin MPE 5 2 - + at 48 hours 
 
 
Table 4.1 Clinical history of patients with cystic fibrosis. The table shows the age, gender and clin ical information 
of the hypersensitive patients. (Age in years, Reaction Time
+ 
= t ime from treatment to react ion in  days, Time*  = 
time since reaction in years, M: male, F: female, MPE: maculopapular exanthema, P: patient) . 
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4.3.2  Lymphocyte transformation test (LTT) of peripheral blood lymphocyte cells from 
piperacillin hypersensitive patients. 
 
In order to determine whether piperacillin-specific T-cells circulate in blood and to explore 
differences between the T-cells in the circulation and inflamed skin tissue, I firstly performed a 
LTT using PBMC from the patients. Lymphocytes from both piperacillin hypersensitive patients 
with CF proliferated when PBMCs were incubated in vitro with the drug. The response was 
dose-dependent in both patients with a maximal response observed at 2mM (Table 4.2). The LTT 
results are similar to the results we conducted on the same patients three years earlier (Table 3.2).  
 
    Piperacillin (g/ml)   
  cpm in control 0.25 0.5 1 2 4 TT (5g/ml) 
P1 370 5.3 8.4 16.8 28.0 14.6 60.8 
P2 1436 15.5 21.3 26.4 30.2 28.0 18.3 
 
 
Table 4.2    Piperacillin-specific lymphocyte transformation test (LTT). The LTT was performed using PBMCs 
at 1.5 x 10
5 
cells/well. PBMC were exposed to piperacillin 0.125-4 mM for 6 days with TT as control.  Cellular 
proliferation was measured by 
3
H-thymidine incorporation for the final 16 hours . Drug specificity is shown by SI. 
 
 
4.3.3  Characteristics of T-cell clones generated from blood of hypersensitive patients. 
Piperacillin-responsive lymphocytes were investigated for drug specific cytokine secretion 
profiles using ELISpot analysis. Piperacillin stimulation markedly enhanced IFN-γ, IL-13 and 
IL-22 secretion in both samples compared with control cultures without piperacillin (Figure 4.2). 
In contrast, piperacillin-treatment did not result in the secretion of IL-17A. In the PBMCs 
samples without piperacillin challenge, only low levels of IFN-γ were detected.  
In all cases, phytohaemagglutinin (PHA; positive control) activation of PBMCs resulted in 
cytokine secretion of cytokines including IL-17A (Lindahl-Kiessling & Book, 1964).  
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Figure 4.1. Piperacillin-s pecific cytokine secretion from PBMC of hypersensitive patients detected by 
ELIS pot. Piperacillin hypersensitive patients’ PBMCs 1.5 x 106 cells/ml were cultured in 96-well U-bottomed tissue 
culture plates with or without 5mg/ml of PHA or piperacillin (2mM) for 6 days at 37°C, 5% CO2. Antigen-specific 
cytokine production was measured by IFN-γ, IL-13, IL-17A and IL-22 ELISpot.  
 
4.3.4  Characteristics of T-cell clones generated from skin biopsies of hypersensitive 
patients. 
To phenotypically characterize the T-cells in skin of the two drug hypersensitive patients, 
piperacillin-specific T-cell clones were generated. The skin biopsy samples were obtained 
through 3mm puncturing, after a positive dermal prick test. T-cells residing in the skin were 
isolated according to the protocol described in chapter 2 (section 2.17).  Flow cytometric analysis 
was carried out on T-cell clones obtained from hypersensitive patient skin. In total, 690 CD4+ or 
CD8+ T-cell clones were isolated from inflamed skin of the 2 piperacillin hypersensitive patients 
with CF. Nighty six of the clones tested were piperacillin responsive (Table 4.3). 89% of the 
piperacillin responsive clones from patient 1 and 82% from patient 2 were CD4 positive T-cells. 
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All other clones were CD8+ T-cells.  
 
 
Patient ID 
 
Tested 
 
 
Piperacillin 
specific 
 
% CD4
+
 
 
% CD8
+
 
 
Patient 1 
 
 
354 
 
48 
 
89 
 
11 
 
Patient 2 
 
 
336 
 
48 
 
82 
 
18 
 
Table 4.3. Phenotypic characteristics of T-cell clones obtained from skin of hypersensitive patient 1 and 2. T-cells 
were isolated from skin  biopsies as described in the Material and Methods (2.17) and piperacillin-specific T-cells 
were cloned. The phenotype of the - cells (CD4
+
 or CD8
+
) was further characterized by flow cytometry.    
 
 
4.3.5  IFN-γ, IL-13, IL-17A, and IL-22 secretory profile of skin-derived T-cell clones.  
In total, 96 piperacillin specific clones were generated from a total of 690 T-cell clones tested 
with the majority expressing the CD4+ receptor. Drug-specific CD8+ T-cell clones were observed 
at lower numbers. Piperacillin specific cytokine and cytotoxic molecule secretion in 3 T-cell 
clones from patient 1 and 6 clones from the patient 2 was measured by ELISpot. As shown in the 
figure 4.3a-b and Table 4.3 A-B, a similar pattern of drug-specific cytokine and cytotoxic protein 
secretion was observed with all the clones from the two patients. High levels of IFN-γ and IL-22 
secretion was detected after the clones were cultured with antigen presenting cells and 
piperacillin. IL-13 was detected to a lesser extent when drug-treated and control wells were 
compared.  Production of cytolytic molecules such as Fas ligand, granzyme B and perforin was 
also observed with clones from patient 2, while only granzyme B was detected with the clones 
derived from patient 1. IL-17 was not secreted from the piperacillin-specific clones.  
 
 
 
 
 
 103 
 
 
 
 
Figure 4.2a Cytokine and cytolytic protein secretion from piperacillin specific T-cell clones (clones 59, 295 and 
300) generated from inflamed skin of drug hypersensitive patient 1.  5 x 10
4 
T-cell clones were placed  duplicate 
wells. 1x10
4 
autologous APCs per well were added as well as medium or 2 mM piperacillin. The cultures were 
incubated for 6 days in an atmosphere of 37°C 5% CO2. The production of IFN-, IL-13, IL-17A, IL-22, perforin, 
granzyme B, and fas-ligand were determined by ELISpot.  
 
 
 
 
 
 
 
Table 4.4 A. Cytokine and cytolytic protein secretion from piperacillin s pecific T-cell clones . 
The ELISpot results were quantified as follow: the numbers of spots in the non -stimulated control as -. +: 40 spots 
more than the control. ++:  80 spots more than the control. +++: 120 sports more than the control. 
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Figure 4.2b Cytokine and cytolytic protein secretion from piperacillin specific skin T-cell clones (clones 122, 
295, 311, 109, 157 and 223) isolated from inflamed skin of drug hypersensitive patient 2  with CF. As described 
in Figure 4.2a, 5 x 10
4
 T-cell clones were p laced duplicate each well in 2 wells, 10
4
 autologous B cell APCs per well 
were added as well as medium -/+ 2mM piperacillin to a final volume of 200 µl/well. The cultures were incubated 
for 6 days at an atmosphere of 37°C 5% CO2. ELISpot was applied to measure the productions of IFN-, IL-13, IL-
17A, IL-22, perforin, granzyme B, and Fas-ligand. 
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Table 4.4 B. Cytokine and cytolytic protein secretion from piperacillin s pecific T-cell clones . 
The ELISpot results were semi quantified as follow: the numbers of spots in the non -stimulated control as -. +: 40 
spots more than the control.   ++:  80 spots more than the control. +++: 120 sports more than the control.  
 
 
 
4.3.6  Chemokine receptors expressed on piperacillin-specific T-cell clones.  
 
To further characterize the drug specific T-cells isolated from skin of hypersensitive patients, 
chemokine receptor expression was measured using flow cytometry. Comparisons were made 
between blood- and skin-derived clones responsive towards piperacillin, along with piperacillin 
non-specific skin-derived clones (Figure 4.4). Significant differences in the expression of 
receptors were observed for multiple chemokines. Blood derived T-cell clones were shown to 
express high level of CCR1, CCR9, CCR10, CXCR6, CD69 and CLA when compared with 
piperacillin non-specific skin-derived T-cell clones, and with significant expression of CCR9, 
CCR10 and CD69 when compared with piperacillin-specific skin-derived clones. Piperacillin-
specific skin clones showed significant expression of CCR1, CXCR6 and CLA when compared 
to non-specific skin-derived clones, whereas in comparison to T-cell clones isolated from 
PBMCs, piperacillin-specific clones expressed significantly higher levels of CCR2, CCR3, 
CCR4, CXCR1, CLA and E-cadherin. 
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Figure 4.3  Comparison of the chemokine receptors expressed on piperacillin-specific blood- and skin-derived 
T-cell clones. T-cell clones were also compared with skin-derived clones that were not-responsive to piperacillin. 5 
x 10
5
 T-cell clones were incubated with anti-human CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR8, CD9, CCR 
10, CXCR1, CXCR3, CXCR6, CLA, CD69 and E-cadherin antibodies labelled with  either APC, FITC or PE for 20 
min  on ice in the dark. The cells were washed and re-suspended in 150l FACS buffer and analyzed  by flow 
cytometry on a FACS Canto II. The expression of surface molecules is presented as mean fluorescence index, 
calculated as mean fluorescence of test antibody/ mean fluorescence of isotype control antibody. The average MFI 
was used to compare the expression of chemokine receptors for each population of T-cell clones. ANOVA tests were 
used to compare variab les between groups. *p<0.05, **p<0.01, ***p<0.001.  
 
 
4.4 Discussion 
 
In order to study whether piperacillin-specific T-cell responses are detectable several years after 
an adverse event, two of the piperacillin hypersensitive patients recruited in 2010 (Chapter 3) 
were re-recruited in 2013 in this study. For patient 1 was intradermal skin test negative at the 
earlier time-point, but positive three years later. The LTT and ELISpot results suggest that there 
is no marked difference in terms of the T-cell proliferation, key cytokine profile and cytotoxic 
molecules produced when PBMC were cultured with the drug. This suggests that memory T-cells 
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with drug specificity circulated in the blood of hypersensitive patients for several years.  
In order to compare the drug-specific T-cells in inflamed skin biopsies and in the peripheral 
blood of the same piperacillin hypersensitive patients, T-cell clones were generated and analyzed 
in terms of cellular phenotype, function and the involvement of Th17 and Th22 cytokines and 
cytolytic molecules. Skin samples were taken from patients following a positive dermal test, 
mimicking the pathogenesis of drug induced MPE which is the most commonly observed 
symptom induced by piperacillin. T-cell clones generated from patient PBMCs as well as non-
drug specific skin-derived clones were studied for comparisons.  
The drug-specific T-cell clones isolated from skin were generally CD4+ T-cells. This observation 
is consistent with the immuno-chemical staining of MPE biopsies, showing that the majority of 
MPE infiltrated T-cells are CD4+. However, CD8+ T-cell clones displaying piperacillin 
specificity were also isolated from inflamed skin; hence, their role in the disease pathogenesis 
cannot be excluded. The profile of piperacillin-specific cytokine secretion from T-cell clones 
isolated from skin was generally consistent with the blood-derived drug-specific clones 
described earlier in chapter 3.  
 
The clones secreted a mixed profile of Th1 and Th2 cytokines, with high levels of IFN-γ and IL-
13 detected when activated with piperacillin. However, the newly discovered T-cell subsets 
(Th17 and Th22) render this classification incomplete. Utilizing ELISpot, drug-specific IL-22 
secretion was detected from patient PBMCs and skin-derived T-cell clones. The nature and 
function of the IL-22 secreting T-cells in piperacillin hyperactive is less understood and warrants 
further investigation.  In contrast, IL-17 secretion was not observed, suggesting that Th17 cells 
are less important in piperacillin hypersensitivity. A similar cytokine profile between piperacillin-
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specific T-cells isolated from PBMCs and inflamed skin are consistent with recent research 
which suggests that every memory T-cell clone generated in the skin bears an identical TCR that 
was presented in the lymph node and they are considered to be derived from a common naïve T-
cell after immunization (Gaide et al., 2015).  
 
Chemokine receptors are critically involved in the drug hypersensitivity reactions. To understand 
how chemokine receptor expression effects the migration of piperacillin-specific T-cells into the 
inflamed skin, cell surface chemokine receptor expression was measured by flow cytometry. 
Three populations of clones were selected: drug specific and non-drug specific T-cell clones 
from inflamed skin of piperacillin hypersensitive patients along with drug-specific T-cell clones 
isolated from patient PBMCs.  
Naïve T-cells take 12-24 hours for DC priming in the lymph nodes (von Andrian & Mempel, 
2003). Those cells that recognize the specific antigen become activated and expand. One naïve T-
cell grows up to tens of thousands of progeny (Tubo et al., 2013, von Andrian et al., 2000). 
Although these T-cells that derived from a single naïve T-cell have the same TCR, the expanded 
cells are different in terms of their chemokine receptor expression (Liu et al., 2006). Thus, in 
consideration of variations of these cells, the expression of chemokine receptors in each T-cell 
clone was compared. Piperacillin specific T-cell clones from skin expressed significant levels of 
CLA, CCR2, CCR4, CXCR1 and E-cadherin when compared to the other two types of clone. In 
contrast, piperacillin specific T-cell clones isolated from PBMCs expressed higher level of 
CCR1, CCR9, CCR10 and CXCR6. Finally non-drug reactive skin-derived T-cell clones 
expressed higher levels of CCR3 than the other two groups.  
Cutaneous lymphocyte antigen (CLA), binds selectively to the vascular lectin endothelial cell-
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leukocyte adhesion molecule 1 (ELAM-1), acting as a skin homing receptor (Berg et al., 1991). 
In this study, only piperacillin specific T-cell clones isolated from inflamed skin expressed high 
level of CLA but neither circulating clones nor non-drug specific clones expressed CLA, which 
suggests that CLA is required for the migration of drug-specific T-cells from peripheral blood to 
inflamed skin, which may play a critical role in piperacillin- induced MPE. CCR4 also mediates 
migration of T-cells to skin (Campbell et al., 1999); CXCR1 mediates T-cell homing to inflamed 
tissue (Hess et al., 2004). Thus each of these chemokine receptors may be involved in drug 
specific T-cell homing to the site of MPE.  
When naïve T-cells get primed against antigen, they become effector T-cells or memory T-cells 
and go into the blood, traveling to the inflamed site (e.g. skin) or remain in the circulation. After 
the inflammation resolves, the majority of effector cells die and the survivors are memory T-cells 
that can live for decades. Furthermore, when skin located memory T-cells have not been exposed 
to this antigen for a long time, the number decreases, and migrate into the blood (Watanabe et al., 
2015, Rosa et al., 2015). 
 
Memory T-cells provide rapid and highly effective immunity when an individual is re-exposed to 
an antigen. They are classified into three subsets, effector memory T-cells, central memory T-
cells and resident memory T-cells (Chang & Kupper, 2015). Central memory T-cells express 
lymph node homing chemokine receptor CCR7 that enable them to enter lymph nodes from 
blood. Effector memory T-cells express low level of CCR7 but highly express CLA, which 
allows them access to the skin. Resident memory T-cells can be activated rapidly by antigens at 
inflamed sites independent of recruitment of T-cells from the blood (Jiang et al., 2012, Clark et 
al., 2015). 
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In a recent study, four populations of CD4 resident antigen specific memory T-cells have been 
identified, CCR7+ with or without CD62L expression that are transient skin homing T-cells; 
CD69+ with or without CD103 expression are true resident memory T-cells (Watanabe et al., 
2015). Significant expression of CD69 expression was detected on piperacillin-specific T-cells 
isolated from skin suggesting they are long term skin resident cells that play a critical role in 
drug hypersensitivity. 
When effector T-cells infiltrate into the skin, they do not only accumulate at the inflamed site, 
they spread throughout the skin (Jiang et al., 2012, Gaide et al., 2015). Non- inflamed skin 
contains post-capillary venues that express low levels of E-selectin, chemokines and intracellular 
adhesion molecules that allow skin-homing T-cells escape from blood vessels and locate to non-
inflamed skin (Chong et al., 2004). 
 
Drug specific T-cell clones isolated from circulating PBMCs expressed CCR9 and CCR10. 
CCR9 mediates migration of T-cells to lamina propria of the intestine, while CCR10 promotes T-
cell skin migration (Agace 2006). This suggests these circulating T-cells may migrate to various 
sites in the body. 
To conclude, skin resident drug specific T-cells are considered primary mediators of the drug 
hypersensitivity reaction. Drug specific T-cells from both peripheral blood and MPE inflamed 
skin were found to secrete IFN-γ, IL-22 and IL-13, but IL-17 secretion was not detected. T-cell 
cloning suggests that drug-specific T-cells induce inflammation either though cell killing by 
granzyme B/perforin or through inducing Fas- ligand dependent cell apoptosis directly. 
 
 
 113 
 
Chapter 5 
 
Priming and characterization of drug-specific T-cells from naive CD4+ T-cells  
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            5.3.3 SMX-NO selectively polarizes drug specific IL-22 but not IL-17 producing cells 
from naïve T-cells  
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hypersensitive patients and SMX-NO primed naïve T-cell of normal donors 
 
5.3.5  Cytokine profile of the SMX-NO specific T-cell clones isolated from patients or 
drug primed T-cell populations  
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5.1 Introduction 
Drug hypersensitivity is a major clinical problem. Reactions are unpredictable in nature and 
when they develop they tend to be severe. In the last decade, genome-wide association studies 
have identified the expression of particular HLA alleles as risk factors for certain reactions 
(Phillips et al., 2011; Daly et al., 2012). Since drug-antigen specific T-cells have been detected in 
blood/tissue of patients with mild and severe skin reactions (Nassif et al., 2002) and liver injury 
(Monshi et al., 2013), they are believed to play an important role in the disease pathogenesis. 
Even though certain HLA alleles are associated with drug hypersensitivity, only a limited number 
of individuals with the allele develop hypersensitivity. Thus, additional approaches are required 
to compensate HLA screening to predict why certain individuals develop hypersensitivity to a 
particular drug. Naïve T-cell priming assays using blood from HLA typed donors have been used 
as a highly valuable resource to enhance drug hypersensitivity investigations. (Faulkner et al., 
2012, 2016).  
In this study, we investigated the possible immune mechanism by which drugs like piperacillin 
and nitroso-sulfamethoxazole (SMX-NO) induce hypersensitivity in vitro. SMX-NO is a 
metabolite of sulfamethoxazole that binds to the cellular proteins at the cysteine residues 
(Naisbitt et al., 2001). Piperacillin is associated with a high incidence of skin rash (El-Ghaiesh et 
al., 2012). As discussed in chapter 3, piperacillin bind to the lysine residues on serum proteins to 
form an antigen that activates T-cells. Both compounds activate T-cells via a hapten mechanism 
involving adduct formation and processing of the derived adduct by APCs.  
How drugs induce hypersensitivity is not fully understood. Furthermore, how to modulate and 
control the drug-mediated pathogenic response is an important clinical issue. Current evidence 
suggests that T-cells play a pivotal role in allergy, including drug allergy. Originally, Th1 and 
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Th2 cells are critically involved in the pathogenesis and modulation of allergic diseases. 
Recently, Th17 cells have been implicated in the pathogenesis of asthma and other inflammatory 
diseases, such as psoriasis (Nestle FO et al., 2009), Crohn’s disease (Kobayashi et al., 2008; 
Andoh et al., 2005).  
Th22 cells are a CD4+ T-cell population found in humans and secrete IL-22 but not IL-17. IL-22 
is a cytokine that mediates tissue response by stimulation of epithelial barrier t issues such as gut, 
lungs and skin, promoting the antimicrobial defense and epithelial barrier integrity. Also, IL-22 
secreting cells have been found in patients with allergic contact dermatitis (Dyringanderson et 
al., 2013).  
Th17 cells can produce both IL-17 and IL-22 which have been implicated in tissue inflammation 
(Kolls et al., 2004, Xie et al., 2000). However, there exist functional differences between 
cytokines. IL-17 is more pro-inflammatory and destructive, whereas IL-22 alone often functions 
in a protective way that promotes the proliferation of fibroblasts in tissue repair (Eyerich et al., 
2010). When IL-22 acts synergistically with IL-17, TNF-α and IFN-γ, it might be pro-
inﬂammatory (Michalak-Stoma et al., 2013). Since the microenvironment determines T-cell 
differentiation which in turn induces different types of inflammation, the possibility that drugs 
induce T-cell differentiation to Th1, Th2, Th17 and Th22 secreting cells was tested, especially 
Th17 and Th22 polarization, to ascertain their involvement of in drug hypersensitivity.  
 
The aim of this chapter was to further elucidate the underlying mechanism by which Th17 and 
Th22 subsets are involved in the cutaneous reactions following drug exposure. We focused on 
how drug initiates a drug-specific T-cell response and the involvement of T-cell subsets and 
related cytokines, in particular the Th17 and Th22 cytokines, in drug hypersensitivity using an 
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established in vitro T-cell priming assay. 
5.2 Methods. 
5.2.1 Isolation and priming of naïve T-cells from normal donor PBMCs. 
PBMCs isolation and the purification of naïve T-cells (CD14-CD3+CD45RO-CD25-) was 
performed according to the protocols described in chapter 2.  PBMCs were isolated from 
peripheral blood of healthy volunteers. Different populations of cell were selected by magnetic 
bead separation. These populations include naïve T-cells (CD3+CD45RO-CD14-), monocytes 
(CD14+), and memory T-cells (CD3+CD45RO+CD14-). Naïve T-cells were then cultured with 
both drug antigens, in the presence of mature monocyte-derived DCs as APCs. After 7 days 
culture under an atmosphere of 37°C 5% CO2, a number of the naïve T-cells turn into drug 
specific memory effector T-cells and can be tested for antigen specificity when re-exposed to the 
drug. This assay has been applied to prime naïve T-cells against a number of drug haptens, 
including nitroso sulfamethoxazole and β- lactam antibiotics. 
 
5.2.2 Memory T-cell polarization 
T-cell activation requires three signals which are TCR activation, costimulatory molecule 
signalling and the cytokine micro-environment. Therefore, we used an anti-CD3 antibody to 
activate TCR, and an anti-CD28 antibody to stimulate costimulatory signalling. Finally we 
explored whether culturing the naïve and memory T-cells with desired cytokine cocktails induced 
differentiation of T-cells into different cytokine producing populations. If these cytokine 
combinations were found to induce T-cell differentiation, the aim was to apply them to study the 
effect of the cytokine microenvironment on the priming of naïve T-cells to drugs. 
Memory T-cells (CD14-CD3+CD45RO+CD25-) were isolated as described in 2.15. 10 µg/ml of 
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anti-CD3 antibody was diluted in HBSS solution and pre-coated (300 µl/well) in sterile ELISpot 
plates over night at 4°C. The next day, excessive anti-CD3 antibody was washed by HBSS for 3 
times. Then 1.5 x 105 memory T-cells were added into anti-CD3 coated wells with 200 µl of R9 
medium which was supplemented with 5 µg/ml of anti-CD28 antibody and different cytokine 
cocktail for Th cell polarizations. Th17 differentiation cytokines were TGF-β (1 ng/ml), IL-1β 
(10 ng/ml), IL-6 (10 ng/ml), IL-23 (10 ng/ml). Th22 differentiation cytokines were 50 ng/ml 
TNF-α, 20 ng/ml IL-6, 5 µg/ml anti-IL-4 and 5 µg/ml anti-IL-12. When differentiated into Th1 
cells, the cytokines were anti- IL-4 (5 µg/ml) and 25 ng/ml IL-12; when differentiated into Th2 
cells, the cytokines are 25 ng/ml IL-4, 5 µg/ml anti- IL-12, and 5 µg/ml anti-IFN-γ. The cells 
were incubated at atmosphere of 37°C/5%CO2 for 5 days. On day 6, polarized memory T-cells 
cytokine secretion was tested by ELISpot.  
 
5.2.3 Naïve T-cell priming and Th17/Th22 differentiation from naïve T-cells. 
The T-cell priming assay is described in detail in 2.15. Naïve T-cells (2 x 106) and mature DCs 
(8000) were cultured with Th17 polarizing cytokines (IL-1 β, IL-6, TGF-β), 10 ng/ml alongside 
SMX-NO (50 µM). Additional cytokines were added on days 4 and 9. Polarization of naïve T-
cells was then determined by ELISpot.  
 
5.2.4 Characterization of SMX-NO-specific T-cells from hypersensitive patients and normal 
volunteers. 
PBMCs from drug hypersensitive patients were isolated and T-cell clones were generated as 
described in chapter 2.5. The patients’ clinical information is presented in Table 5.1.  
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Patient Age / 
Gender 
Drug Reaction 
 
Reaction 
Time+ 
Time* 
P1 30/F SMX-NO MPE 2 7 
       
P2 25/F SMX-NO MPE 4 5 
       
P3 34/F SMX-NO MPE 6 8 
 
  P4                
 
    23/M 
 
      SMX-NO 
 
              MPE                           
 
 10          
 
       20 
Table 5.1 The clinical h istory of patients with sulfamethoxazole hypersensitive patients with cystic fibrosis. (Age in 
years, Reaction Time
+ 
= time from treatment to reaction in days, Time* = time since reaction in years, M: male, F: 
female, MPE: maculopapular exanthema, P: patient) 
 
5.2.5 Statistics analysis 
Experiments were performed in duplicate or triplicate, based on the availability of cells. Mean 
values and SDs were calculated and statistical analysis was performed by paired t test or ANOVA 
when appropriate. 
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5.3 Results: 
5.3.1 The polarization of human memory T-cells. 
 
The results in Chapter 3 and 4 shows that T-cells isolated from piperacillin hypersensitivity 
patients can respond to the drug antigen when re-challenge in vitro, suggesting the presence of 
piperacillin-memory T-cells in the patients. It will be therapeutically important to know how to 
modulate the drug-specific T-cells. To address the aim of this chapter, we investigated if memory 
T-cells can be further polarized into different Th cell subsets.   
Memory T-cells secreted IFN- and IL-13 and a low level of IL-22 under Th1 polarization 
conditions. The same cells secreted IFN- and IL-13 under Th2 polarization. Upon culturing 
memory T-cells with Th17 polarizing cytokines, they secreted IL-17A, IFN-, and IL-22. Under 
Th22 polarization, memory T-cells secreted IFN-, IL-13 and IL-22 (figure 5.1). The controls 
wells without the addition of antibodies or cytokines did not secrete cytokines. These data 
suggests that memory T-cells can be further polarized into different Th subsets depending on 
cytokine environment. 
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Figure 5.1 Memory T-cell polarization. Memory T-cells were isolated from normal individuals and then 5 x 10
5
 
memory T-cells were stimulated with anti-CD3, anti-CD28 antibody and different cytokine cocktail for Th cell 
polarization. The cells were incubated for 6 days at an atmosphere of 37°C 5% CO2. On day seven, upon the 
stimulat ion of PHA, the production of IFN-γ, IL-13, IL-17A and IL-22 were determined by ELISpot. Red shaded 
squares indicate cytokine polarizat ion. Spots counting was shown. 
 
5.3.2 Priming of drug-specific T-cells from naïve precursors  
In chapter 4, piperacillin-specific T-cell clones isolated from the blood and skin of hypersensitive 
patients were found to secrete mainly IFN-, IL-13 and IL-22, but not IL-17A. Thus, to 
investigate the mechanism of drug specific IL-22 secretion and further determine the potential of 
drug-specific secretion of IL-17A, priming assays were applied to test the origin of drug-specific 
T-cells. SMX-NO and piperacillin were used as a model drug haptens in the T-cell priming assay. 
In initial experiments, naive CD3+ T-cells were cultured with dendritic cells and SMX-NO or 
piperacillin in the absence of polarizing cytokines. These cells were then harvested, re-stimulated 
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with the drugs and assayed for IFN-γ, IL-13, IL-17 and IL-22 secretion. As showed in Figure 
5.2A, SMX-NO-specific T-cells were polarized, and secreted IFN-γ, IL-13 and IL-22. However, 
IL-17 release was not detected (Figure 5.2A). Piperacillin (Figure 5.2B) primed naïve T-cell 
population showed a similar pattern, secreting IFN-, IL-13 and IL-22 but not IL-17A.  
               A                                                 B 
 
Figure 5.2 Drug-s pecific cytokine secretion from S MX-NO- or piperacillin-primed naïve T-cells from normal 
donors. CD3
+
 naïve T-cells from normal volunteers were co-cu ltured with dendritic  cells in the presence of different 
drug concentrations, (A) SMX-NO (12.5 µM to 50 µM) and (B) piperacillin (0.5mM to 2mM) ,in an atmosphere of  
37 °C/5% CO2 for 7 days. Drug-specific cytokine secretion was measured by ELISpot. 
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5.3.3 SMX-NO selectively polarizes drug specific IL-22 producing, but not IL-17 
producing, T-cells from naïve precursors  
To investigate the polarization of naïve T cells further, we cultured naïve T-cells with SMX-NO 
under Th22 and Th17 polarization conditions. When the priming assay was performed under 
Th22 polarizing conditions, a drug specific IL-22 secretion was observed (Figure 5.3 B). In 
contrast, SMX-NO-specific IL-17 secretion was not detected (Figure 5.3 A). When the naïve T-
cells were primed with SMX-NO under Th17 polarizing conditions drug-specific IL-17 or IL-22 
secretion was not detected. (Figure 5.3 A, B).  
 
 
               A                                                 B 
Figure 5.3 Cytokine secretion by T-cells primed to SMX-NO under Th17 and Th22 polarizing 
conditions. Naïve CD3
+
 T-cells were co-cultured with SMX-NO and dendritic cells at a ratio of 25:1 in 
the presence or absence of Th17 or Th22 polarizing cytokines for 8 days. The cultures were then plated 
and re-stimulated with fresh dendritic cells and SMX-NO. Antigen-specific T-cell responses were 
measured by IFN-, IL-13, IL-17 and IL-22 ELISpot. Cells were incubated for 48h and spots developed 
by ELISpot according to manufacturer’s instruction.  
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5.3.4 Characterization of SMX-NO specific T-cell clones isolated from SMX hypersensitive 
patients PBMC and normal donors following T-cell priming.  
 
SMX-NO-specific TCCs were generated from 4 SMX hypersensitive patients and 1 drug-naïve 
donor. We next characterized and compared the drug specific T-cell clones generated from 
hypersensitive patients to those generated from normal donors using the thymidine proliferation 
assay. All the clones tested showed a significant proliferation when exposed to SMX-NO (Figure 
5.4 a). The number of clones generated from hypersensitive patients, their CD phenotype and the 
SMX-NO-specific proliferative response are summarized in Table 5.2. All the clones generated 
expressed the CD4 cell surface marker. Two hundred and eighty three T-cell clones were 
generated from drug-naïve donors following SMX-NO priming. SMX-NO responsive clones 
secreted high levels of IFN-γ, and to lesser extent, IL-5 and IL-13 following activation (Figure 
5.4 b). There was no major difference in the drug-specific cytokine secretion profile when clones 
isolated from patients and volunteers were compared. The drug-specific proliferation of 68 T-cell 
clones from 4 patients and of 10 clones from naïve volunteers is shown in Figure 5.4.  
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Figure 5.4 Activation of SMX-NO-responsive CD4+ clones generated from drug naïve 
donors (n = 1) after in vitro priming and from hypersensitive patients (n-4). The Antigen-
specific responses were measured by [3H]-thymidine proliferation (a) and IFN-, IL-13, IL-17 
and IL-22 ELISpot (b). The data shows mean and the standard deviation of triplicate cultures and 
paired t test has been used to perform comparisons. *p<0.05 was considered positive.  
 
(a) 
(b) 
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Patient 
ID 
Clone 
tested  
(n) 
SMX-
NO 
specific 
clones 
Phenotype 
(%)  
CD4+ 
Phenotype 
(%)  
CD8+ 
Proliferation (cpm) 
Control SMX-NO 
 
1 
 
336 
 
21 
 
100 
 
- 
 
6840 ±7406 
 
14837 ±13224 
2 394 29 100 - 3899 ±5522 23970 ±18651 
3 216 6 100 - 1058 ±203 2740 ±469 
4 240 2 100 - 1584 ±493   7613±5294 
       
Table 5.2.   The origin, phenotype and specificity of T-cell clones generated from PBMCs of 
the 4 SMX hypersensitive patients.  
 
 
5.3.5  Cytokine profile of SMX-NO specific T-cell clones isolated from patients or drug 
primed T-cell populations  
 
Since hypersensitive patient clones and clones isolated from in vitro priming secreted similar 
Th1 and Th2 cytokines a panel of 17 clones (from multiple donors) with a strong growth pattern 
were selected to study their cytokine secretion profile. While approximately all the clo nes 
produced IFN-, IL-5 and IL-13, about 50% of clones were found to secrete IL-22 following 
exposure to SMX-NO. In contrast, IL-17 secretion was only detected with 1 clone (Figure 5.5 
A). IL-22 secreting low and high clones were isolated from PBMC of hypersensitive patients and 
following in vitro priming (Figure 5.5 B). Importantly, the isolation of SMX-NO responsive, IL-
22 secreting clones from the priming assay was not dependent on the presence of Th22 
polarizing cytokines and clones were not maintained under Th22 polar izing conditions.  Most of 
the clones also produced granzyme B and FasL but not the perforin (Figure 5.5).  
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Figure 5.5  A Cytokine secretion by S MX-NO responsive CD4
+
T cell clones. Analysis of SMX-NO–specific 
cytokine and cytolytic molecule secretion fro m 17 clones using the ELISpot 
 
 
 
Figure 5.5 B Representative T-cell clones with IL-22 high or low secretion, generated from S MX-NO primed 
naïve T-cell population and drug hypersensitive patients. Cytokine profile of representative SMX-NO–
responsive IL-22
high– and IL-22low–secreting clones generated from drug-naive donors after in vitro priming and 
hypersensitive patients. 
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5.4 Discussion 
 
Previous immuno-histological studies have characterized the phenotype of T-cells infiltrating 
inflamed skin of patients with maculopapular rashes, and have reported a larger numbers of 
CD4+ T-cells and lower numbers of CD8+ T-cells (Pichler 2003; Pichler et al., 2002). Studies 
focusing on SMX-specific T-cell response indicate that CD4+ and CD8+ T-cells secrete cytolytic 
molecules in response to culprit drug and keratinocytes can be specifically killed by CD4+ T-cells 
(Schnyder et al., 1998). Consistent with the these findings, several studies have demonstrated 
that most SMX-NO-specific T-cells isolated from hypersensitive patients are CD4+, and secrete  
mixed panel of Th1/Th2 cytokines including IFN-γ, IL-5 and IL-13 (Schnyder et al., 1998; 
Elsheikh et al., 2011; Schyder et al., 2000). However, the discovery of new T-cell populations, 
such as Th17, Th22 renders this classification obsolete, and the importance of these new Th cell 
subsets in drug hypersensitivity is still unknown. For this reason, we characterized SMX-NO 
specific CD4+ T-cells in terms of cytokine profiling from hypersensitive patients and healthy 
donors following priming. Following antigen re-challenge, the SMX-NO primed T-cells from 
healthy donors and drug hypersensitive patients were found to secrete IFN-γ, IL-13 and IL-22, 
but IL-17 secretion was not detected. CD4+ clones isolated from the priming assay also secreted 
drug-specific IFN-γ, IL-13 and IL-2, but not IL-17.  
IL-22 secretion was detected from approximately 50% of the clones from patients (Figure 5.5A).  
A similar pattern of cytokine secretion was seen with drug-specific T-cell clones (IFN-γhigh IL-
5high IL-13high IL-22low and IFN-γhigh IL-5high IL-13high IL-22high) isolated from SMX 
hypersensitive patients (Figure 5.5B). IL-22 is a cytokine that modulates tissue epithelia 
responses as expression of the IL-22 receptor is restricted to the non-haematopoietic cells. In 
skin, the IL-22 receptor is expressed at high levels on keratinocytes and IL-22 has been found to 
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enhance keratinocyte proliferation and inhibit terminal differentiation (Boniface et al., 2005). 
Furthermore, IL-22 has been shown to mediate inflammatory responses in patients with psoriasis 
and IL-22 secreting cells have been identified in patients with allergic contact dermatitis (Cavani 
et al., 2012; Eyerich et al., 2010). Thus, IL-22 is a pleotropic cytokine and its functions are likely 
context-dependent. Our data is, however, the first to demonstrate the production of IL-22 
alongside IFN-γ by antigen-specific T-cells from drug hypersensitive patients. More works are 
required to reveal the physiological and pathological function of IL-22 in drug hypersensitivity. 
In particular, it will be interesting to know if the detection of IL-22 is dependent on the different 
cytokine-specific transcription factors or signaling pathways.  
However, there was only one IL-17 secreting clone being detected out of 17 clones. Therefore 
these result of my project indicate that IL-17 may not play an important in drug induced MPE. 
Typically, IL-17 play important roles in chronic or/and autoimmune disease with a recruitment of 
neutrophils by stimulating keratinocytes to produce neutrophilia chemokines such as IL-
8/CXCR8 and CXCR1 (Schroder et al., 1992, Nograles et al., 2008). It has been shown that IL-
17 secreting cells are involved in severe drug hypersensitivity such as carbamazepine induced 
AGEP (Kabashima et al., 2011) and SJS/TEN (Kang et al., 2011).  Our results are consistent with 
the signature of MPE, in which there is a mild skin rash with less infiltration of neutrophils and a 
quick recovery after drug withdrawal. Polarization condition has been known to determine the 
fate of T-cells from naïve T-cells. In my study, although strong signal of Th17 polarization were 
exerted, drug specific IL-17 secretion was not detected, which indicates this drug-antigen-MHC-
complex displayed by DCs may not tend to stimulate a Th17 response.  
The low ratio of IL-17 secretion was also consistent with Lochmatter study in 2009 in which 
they showed IFN- and IL-13 are sensitive markers of drug hypersensitivity but not IL-17. They 
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cultured PBMCs of 6 patient with MPE with culprit drug for 72 hours, all the patients showed 
high fold (dozens to hundreds) of drug specific cytokine secretion of IL-13 and IFN- but only 3 
patients showed drug specific IL-17 secretion, with low fold of 6 to 8 (Lochmatter et al., 2009).   
 
To summarize, drugs such as SMX-NO and piperacillin can polarize drug-specific T-cells in vitro 
and in vivo in the presence of antigen-presenting cells. These T-cells express drug specific 
cytokines, in particular IL-22, which suggests that IL-22 may play a critical role in drug 
hypersensitivity.  
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Chapter 6 
 
Priming naïve T-cells to drug haptens and the characterization of drug-specific antigen 
presentation 
 
6.1  Introduction 
6.2  Methods 
6.3  Results 
6.3.1   Priming of Naïve T-cells with SMX-NO, piperacillin and flucloxacillin  
6.3.2   Mechanism of activation of drug-specific T-cell clones  
6.4 Discussion 
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6.1 Introduction 
Delayed-type drug hypersensitivity is mediated by T-cells, has an onset time of more than one 
hour after drug administration (Bousquet et al., 2007), and is considered pharmacologically 
unpredictable and unrelated to the concentration of the drug administered. These adverse 
reactions can target a wide range of organs and therefore pose a serious threat to patient health as 
they can induce potentially fatal responses including drug- induced liver injury (DILI) and severe 
cutaneous reactions such as toxic epidermal necrolysis. A range of drugs are known to induce 
this type of reaction including the penicillin antibiotics such as piperacillin and flucloxacillin, 
and sulfonamides such as sulfamethoxazole (SMX). The mechanism of drug antigen presentation 
of the exemplar drugs, SMX (Schnyder et al., 2000, Naisbitt et al., 1999), piperacillin (Whitaker 
et al., 2011) and flucloxacillin (Monshi et al., 2013), are thought to be similar and follow the 
pathway outlined by hapten hypothesis. However, it has also been reported that drug specific 
memory T-cells isolated from patients can respond to certain drug antigens in the absence of 
antigen presentation, indicating the potential for drugs to stimulate T-cells via the p.i concept; 
directly and without the need for processing (Schnyder et al., 2000, Wuillemin et al., 2013, El-
Ghaiesh et al., 2010). These before mentioned studies have focused on responses using allergic 
patient T-cells, allowing for the determination of the memory T-cell response to drug antigens. 
However, the use of patient T-cells provides little insight into the priming of naïve T-cells at the 
moment a susceptible individual is sensitized. Thus, to determine the mechanism of naïve T-cells 
activation by SMX-NO, piperacillin or flucloxacillin we utilized an established in vitro priming 
assay, whereby drugs are cultured with naïve T-cells and autologous mature dendritic cells 
isolated from healthy donors before secondary stimulation of the primed T-cells to perform a 
battery of readouts assays to determine antigen responsiveness. Furthermore, previous patient 
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studies have also reported that T-cell responses to piperacillin are highly specific in that 
piperacillin-specific T-cells do not cross-react with other antibiotics with similar chemical 
structures (El-Ghaiesh et al., 2010). Other studies report similar findings for SMX-NO specific 
T-cells, detailing a lack of cross-reactivity with alternative antibiotics (Schnyder et al., 2000). In 
contrast, flucloxacillin specific T-cells have previously been shown to cross react with several 
antibiotics including amoxicillin and piperacillin (Monshi et al., 2013). Therefore, using the 
naïve T-cell priming assay, we also investigate drug antigen cross-reactivity to determine 
whether highly structurally specific T-cells are readily primed in vitro.  
 
Several methods are available to investigate the mechanisms by which drugs activate T-cells (i.e., 
hapten mechanism or direct binding to MHC molecules). First, antigen presenting cell (APC) 
pulsing assays can be performed whereby cells are cultured with drugs for different durations. 
The drug-treated APCs are then washed repeatedly to remove free drug, reconstituted in drug-
free medium and added to T-cells as a source of antigen. If T-cells respond, they must be 
activated by a drug protein adduct. Secondly, APCs can be fixed with glutaraldehyde, which 
blocks protein processing, before pulsing with antigen. If T-cells are subsequently stimulated 
with the drug, the response is likely through a direct interaction of the drug with surface MHC 
molecules. Thirdly, T-cell assays can be performed with MHC class I and/or class II blocking 
antibodies to confirm that the drug-derived antigen is presented in the context of MHC. Finally, 
Glutathione (GSH) can be utilized to block SMX-NO protein binding to cysteine, and N-acetyl-
lysine (NAL) can be used to reduce the likelihood of piperacillin and flucloxacillin binding 
protein at lysine residues, thereby reducing the formation of drug-protein adducts. Thus 
glutathione or N-acetyl lysine can be added to T-cell assays to potentially block T-cell responses 
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to drug haptens. We have utilized each of these techniques to investigate the mechanism of 
SMX-NO, piperacillin and flucloxacillin-specific naive T-cell priming using cells from healthy 
donors. 
 
6.2 Methods  
To determine the propensity of drug antigen to prime naïve T-cells, we used different 
concentrations of SMX-NO, piperacillin and flucloxacillin. Western blotting was used to study 
whether SMX-NO could alter piperacillin or flucloxacillin protein binding when these three drug 
antigens are cultured with dendritic cells and naïve T-cells in one environment. T-cell clones 
were then generated from the initial priming cultures to assess whether priming to one drug 
antigen allows for cross reactivity to alternate drug antigens. To investigate the mechanisms of 
antigen presentation using the priming assay, several experiments were performed: APC fixation 
and pulsing assays were performed with T-cell clones to investigate whether the activation of the  
T-cells requires adduct formation and antigen processing. MHC blocking assays were used to 
determine whether T-cell activation was HLA restricted.   
6.2.1 T-cell priming assay. The priming assay model is described in 2.15.  
6.2.2 ELISpot. To test the specificity of drug primed T-cell clones ELISpot was applied 
following the protocol described in 2.14. 
6.2.3 T-cell cloning. To study the drug specificity and drug antigen presentation, drug specific T-
cells were generated using the protocol described in 2.5.  
6.2.4 T-cell proliferation assay. The concentration-dependent T-cell response was determined 
using [3H]-thymidine to measure proliferation as described in section 2.8.  
6.2.5 Western blotting. To test the drug protein binding in the serum and/or cells, western 
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blotting was applied following the protocol described in 2.13.  
6.2.6 APC fixation was applied following the protocol introduced in 2.18.  
6.2.7 SMX-NO, piperacillin, and flucloxacillin cross reactivity. SMX-NO, piperacillin and 
flucloxacillin specific activation of T-cell clones was tested following the protocol described in 
section 2.8. 
6.2.8 APC pulsing for proliferation assay was to study the mechanism of drug antigen 
presentation. The protocol is described in 2.10.  
6.2.9 MHC blockage experiment using blocking antibody was used to study the MHC restriction 
in drug specific T-cell response. The procedure is described in 2.9.  
6.2.10 Glutathione and N-acetyl lysine blocking assay was used to ascertain the drug-protein 
binding site in priming assay. 
6.2.11 Varied responses by T-cell clones are common due to a multitude of factors such as varied 
growth conditions, differing drug-antigen specificity or TCR affinity. Subsequently, Mann-
Whitney tests were performed to show the significance of data in comparison with control. 
P<0.05 was considered statistically significant.  
 
6.3 Results.  
6.3.1 Healthy donor naïve T-cell priming to SMX-NO, piperacillin, and flucloxacillin  
Healthy donor naïve (CD3+, CD45RO-) T-cells were cultured with autologous mature DCs and 
SMX-NO (50µM), piperacillin (2mM), or flucloxacillin (2mM) for 8 days before restimulation 
of T-cells using fresh mature autologous DCs and drug antigen. T-cell antigen-specificity and 
cross-reactivity was determined by analyzing T-cell proliferation and IFN-γ secretion in response 
to all three drug antigens irrespective of the drug-antigen present during initial priming culture.  
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As flucloxacillin- induced liver injury is strongly associated with the HLA-B*57:01 genotype 
(Daly, Donaldson et al., 2009), donors who were HLA-B*57:01+ were recruited in this study to 
assess comparative responses to those who were HLA-B*57:01-. Analysis of IFN-γ secretion 
using ELISpot showed that naïve T-cells from all four donors were successfully primed to SMX-
NO and piperacillin. These SMX-NO or piperacillin-primed T-cells showed no cross-reactivity in 
response to culture with piperacillin or SMX-NO, respectively, or the third alternate drug antigen 
flucloxacillin. Flucloxacillin failed to prime naïve T-cells from healthy donors, irrespective of the 
presence of HLA-B*57:01, as determined by cytokine secretion (Figure 6.1 and Table 6.1). Due 
to higher cell recovery from certain donors after priming, proliferative responses were able to be 
additionally measured in response to drug antigen by thymidine incorporation. Similar to 
ELISpot, proliferative studies revealed the successful priming of naïve T-cells from all drug-
naïve healthy donors to SMX-NO, and for 6/7 donors to piperacillin. In contrast to measuring 
cytokine secretion, naïve T-cells from 2/6 donors were successfully, albeit weakly, primed to 
flucloxacillin. As before, none of the drug-antigen primed T-cells proliferated upon re-challenge 
with SMX-NO, piperacillin or flucloxacillin (Figure 6.2).  In total 16 priming assays were 
conducted. The rate of positive priming tested by proliferation assay and ELISpot is summarized 
in Table 6.1 and Table 6.2. Figure 6.1 and 6.2 show representative data from donors who 
displayed positive responses to the different drug antigens.  
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Figure 6.1  S pecificity of drug  primed naïve T-cells from HLA-B*57:01 positive or negative donor tested by 
ELIS pot. Naïve CD3 T-cells were co-cu ltured with DCs at a ratio o f 25:1 in the presence of either SMX -NO (50 
μM), piperacillin (2 mM), or flucloxacillin (2 mM) for 8 days in a 24-well p late. 1×105 T-cells were then 
restimulated with 4×10
3
 fresh DCs and SMX-NO (50 μM) or p iperacillin (2 mM), or flucloxacillin (250 mg/ml) in 
an ELISpot plate pre-coated with IFN-γ capture antibody. Cells were cultured at 37°C under an atmosphere of 5% 
CO2 for 2 days and then developed according to manufacturer’s instructions and spots visualized under an AID 
ELISpot reader.  
 
 
Table 6.1 The summary table for the ELIS pot results in the Figure 6.1. 
The ELISpot results were semi quantified as follow: the numbers of spots in the non -stimulated control as -. +: 40 
spots more than the control.   ++:  80 spots more than the control. +++: 120 sports more than the control.  
 
 
Overall, SMX-NO and piperacillin were much more effective at priming naïve T-cells than 
flucloxacillin (table 6.2). These data highlight that measurement of proliferative response is a 
more sensitive technique to ascertain antigen-specific T-cell priming than IFN-γ secretion.  
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Figure 6.2 Drug s pecific induction of T-cell proliferation by S MX-NO and piperacillin but not flucloxacillin. 
The drug primed T-cells were challenged with particu lar drug. Donor 1 and donor 2 primed  naive T-cells were used 
for the pro liferation assay.  Drug primed naïve T cells (5×10
4
) were co-cu ltured with DCs (4×10
3
) with either SMX-
NO (50 μM), piperacillin (2mM) or flucloxacillin (2mM) in a similar manner as described in the ELISpot assay 
above in an U-bottomed 96-well plate. The p late was cultured for 2 days and [3H]-thymidine (0.5Ci/well) was added 
to each well in the final 16 hours of cu lture. T-cell p roliferat ion was measured by scintillation counting. The data 
shows mean and the standard deviation of triplicates. The SI>2 can be observed , indicating a drug specific response. 
 
 
Number of priming 
assay (numbers) 
SMX-NO piperacillin Flucloxacillin 
IFN-γ ELISpot 
Positive/Total 
7/16 6/16 0/16 
Proliferation 
Positive/Total 
7/7 6/7 2/6 
Table 6.2. Summary table showing the rate of positive priming  assays. Drug  reaction of primed T-cells was 
tested by proliferation assay and IFN-γ ELIS pot. The positive rate of priming assays is shown as: the number of 
positive assays / total assays. 
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Further analysis of drug-responsive T-cell phenotype and function warranted the generation of T-
cell clones. As previously stated, due to the association of HLA-B*57:01 with flucloxacillin-
induced hepatitis, two HLA-B*57:01 positive donors were recruited for priming and the 
subsequent generation of drug-specific T-cell clones. These two donors produced only weakly 
positive responses to flucloxacillin after priming, with proliferative SI of 1.8 and 1.2. In contrast, 
a third donor selected for T-cell cloning was HLA-B*57:01 negative. From the original priming 
cultures, a serial dilution was performed and after mitogen-driven expansion, T-cell clones were 
generated. Well growing T-cell clones were selected for further investigation of drug-antigen 
specificity and to assess the mechanisms of drug antigen presentation.  
Table 6.3 shows 1) the number of the SMX-NO, piperacillin and flucloxacillin-specific clones 
generated from 3 priming assays; 2) the phenotype of these drug specific T-cell clones; 3) the 
drug reaction of these clones. SMX-NO-, piperacillin- and flucloxacillin-specific T-cell clones 
were generated from all three donors irrespective of the HLA type. As has been previous ly 
described, the major phenotype of SMX-NO-specific T-cell clones were CD4+ T-cells, whereas 
for piperacillin-specific clones, the majority were CD8+. Flucloxacillin-responsive CD4+ and 
CD8+ T-cell clones were generated from all three donors.  
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Donor genotype & T-cell 
clone s pecificity 
Total 
clones (n) 
Reactive 
clones (n) 
CD4 
(% ) 
CD8 
(% ) 
Mixture of 
CD4 and 
CD8 T-cell 
Proliferation assay 
 (cpm) 
Donor ID 
and 
genotype  
Drug 
specificity 
Control Drug  
 
 
 
 
Donor 1 
HLA-
B*57:01+ 
SMX-NO 480 68 48% 40% 12% 6519 
±7063 
13797 
 ±9703 
PIP 426 49 15% 80% 5% 5682 
±3792 
23419 
±16374 
FLU 322 8 37% 63% 0 2351 
±504 
9372 
 ±1635 
 
 
 
 
Donor 2 
HLA-
B*57:01+ 
 
SMX-NO 546 57 55% 36% 9% 4638 
±6917 
16279 
 ±9028 
PIP 280 25 17% 79% 4% 5627 
 ± 4826 
19063 
±17352 
FLU 246 3 33% 67% N/A 3621 
±418 
8904 
 ±1395 
Donor 3  
HLA-B*57:01- 
 
SMX-NO 208 26 64% 28% 8% 3947 
±763 
16872 
±11372 
PIP 162 18 12% 84% 4% 3592 
±473 
8496 
±4281 
FLU 156 2 50% 50% N/A 2950 
±316 
5742 
±407 
Table 6.3. Generation of drug-s pecific T-cell clones and phenotypic characterization. The number of the total 
and the SMX-NO, piperacillin and flucloxacillin-specific clones generated from 3 priming assays were further 
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characterized. PIP: piperacillin, FLU: flucloxacillin.  
 
 
 
 
                           
Figure 6.3. Analysis of the time- and concentration- dependent binding  of S MX-NO, piperacillin and 
flucloxacillin to intracellular and extracellular proteins by western blotting . Various concentrations of 
piperacillin and flucloxacillin, from 0.5 mM to 2 mM and SMX-NO, from 10 M to 50 M were co-cultured with 
antigen presenting cells in serum containing medium for 1 hour or 16 hours under an atmosphere of 37
o
C/5% CO2. 
The proteins were separated by SDS-polyacry lamide gel and t ransferred onto nitrocellulose membrane and 
incubated with anti-SMX, anti-piperacillin or anti-flucloxacillin antibodies. Western blotting performed in triplicate 
after a 16-hour culture of flucloxacillin was not published due to overwhelming non -specific binding, including in 
the control. The protocol of flucloxacillin western blotting was described in section 2.13. However, our previous 
result detailing that flucloxacillin only binds to supernatant protein rather than to cell lysate protein was repeatable 
in the lab. Therefore, together with the 1h culture results, the result described above was reliable.   
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To determine whether any drug-protein complex is located in the serum and/or cells, western 
blotting was performed using cell culture supernatant or cell lysates, respectively. The drug-
protein complex was identified by the enhanced molecular weight (MW) of the drugs in the 
Western blotting assay. The MW of SMX-NO, piperacillin and flucloxacillin is 267.26 Da, 
517.55 Da, and 453.87 Da, respectively. Our data show that for all three drugs, the drug-protein 
MW is approximately 50K Da to 75K Da. We also show that while piperacillin and flucloxacillin 
bind selectively to protein in the serum, SMX-NO binds to both serum and cellular proteins 
(Figure 6.3). The binding of drug antigens to extracellular protein was found to be both time and 
concentration dependent. In contrast, while the binding of SMX-NO to B-cell APC lysate is also 
concentration dependent, it was not time dependent (Figure 6.3). In detail, our data highlights 
comparable signals between a culture length of 1 hour and 16 hours, but a marked difference 
between 10M and 50M SMX-NO when using cell lysates.  
To further study the mechanisms of drug-specific T-cell activation antigen specificity was 
assessed using thymidine incorporation assays to measure antigen-specific proliferation.  T-cell 
clones were found to proliferate significantly in the presence of the drug antigen to which they 
were originally primed, but displayed a complete lack of cross-reactivity to the two alternate 
drug antigens (Figure 6.4). These results mirror those obtained direct from the priming cultures.  
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 Figure 6.4 T-cell clones that are reactive to S MX-NO, piperacillin or flucloxacillin do not show cross 
reactivity against the other two drugs. 5 x 10
4 
T-cell clones were co-cultured with autologous B-cell APCs (1 x 
10
4
) in the presence of SMX-NO (from 12.5 mM to 50 mM) or piperacillin (from 0.5 mM to 2 mM) or flucloxacillin 
(from 0.5 to 2 mM) under an atmosphere of 5% CO2 at 37 
o
C for 3 days and [3H] thymid ine was added in the final 
16 hours. Pro liferat ion was measured by scintillation counting.  The data shows mean of triplicate or duplicate wells 
depend on cells availab ility. Mann-Whitney test was applied. *p<0.05 compared with control. 
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6.3.2 Mechanism of activation of drug-specific T-cell clones  
There are three main theories describing how drug-antigens can stimulate a TCR, namely the 
hapten theory, p.i. concept, and the more recently described altered peptide hypothesis. To 
determine the relevant mechanism of TCR activation for individual drug antigens we performed 
a series of assays. First, we assessed the requirement for antigen processing to stimulate antigen-
specific responses by comparing T-cell stimulation when using standard APCs in comparison to 
those pre-cultured in the fixative glutaraldehyde. While fixation renders the cell intrinsic antigen-
processing machinery non-functional, cell surface molecules including MHC remain intact and 
thus the cells maintain the ability to facilitate direct TCR-MHC interactions. SMX-NO, 
piperacillin and flucloxacillin-specific T-cell clones generated from drug-naïve donors were 
cultured with normal or glutaraldehyde-fixed APCs. T-cell proliferation in response to all three 
drug-antigens was abolished when using the fixed APCs compared with the irradiated APCs used 
as control (Figure 6.5). These data indicate that the activation of T-cells in response to SMX-NO, 
piperacillin and flucloxacillin-derived antigens requires the processing and subsequent 
presentation of antigen by functional APCs.  
Second, HLA restriction was performed. EBV-transformed B-cells which we utilize as 
immortalized APCs to assess antigen-specificity of T-cell clones express both MHC class I and II 
molecules at the cell surface which, if they respond to antigen, stimulate CD8+ and CD4+ T-cells, 
respectively. To explore the functional relevance of the MHC we cultured EBV-transformed B-
cells with MHC I or MHC II blocking antibodies for 30 minutes, so preventing their binding to 
antigen, before subsequent culture with antigen-responsive T-cell clones and assessment of 
proliferation in response to drug. As expected CD4+ T-cell clone responses were all inhibited by 
the presence of anti-MHC II antibodies, shown in Figure 6.6 and 6.7 where 2 representative 
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SMX-NO-specific T cell clones, 2 piperacillin-specific T-cell clones and 2 flucloxacillin-specific 
T-cell clones are shown. Two CD8+ flucloxacillin-specific T-cell clones were also studied which 
both showed MHC class I molecule restricted activation (Figure 6.7).  
Third, to further study the mechanisms of antigen presentation, drug antigen pulsing assays were 
performed. Pulsing in this context refers to the exposure of APCs to drug antigen for a defined 
time period, allowing any potential antigen uptake to occur, before performing multiple washing 
steps to remove free antigen prior to culture with T-cell clones. Any subsequent antigen-specific 
T-cell response, due to the lack of any additional free antigen added during the culture with T-cell 
clones, must be induced by antigen that has been taken up and processed by the APCs. 
Furthermore, to determine the length of culture period required for sufficient antigen uptake and 
processing, separate batches of APCs were co-cultured with drug antigen for 1 hour, 4 hours and 
16 hours. After an extensive washing procedure with HBSS, the now antigen pulsed APCs were 
cultured with T-cell clones for 3 days and proliferation measured using thymidine incorporation.  
Our data, displayed in figure 6.8, shows that all T-cell clones responsive to SMX-NO, 
piperacillin, or flucloxacillin proliferated in the presence of drug-antigen pulsed APCs without 
the presence of soluble antigen. For SMX-NO-specific clones, a highly proliferative response 
was seen when APCs had been cultured with SMX-NO for as little as 1 hour, suggesting that 
protein binding occurs rapidly (Figure 6.8). The response to flucloxacillin-specific T-cell clones 
was more varied. While some clones produced a weak response upon stimulation with pulsed 
APCs, other clones reached the maximum response when APCs were pulsed with flucloxacillin 
for 1 hour again indicating the potential for rapid protein binding and neoantigen formation 
(Figure 6.8). On the other hand, although piperacillin-specific T-cell clones produced responses 
when cultured with APCs that had been pulsed with antigen for 1 hour, longer pulses led to 
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increased proliferative responses with a pulse of up to 16 hours to reach the maximum response 
(Figure 6.9). 
Lastly, to form a drug antigen SMX-NO is known to bind to the cysteine residues of protein, 
whereas piperacillin and flucloxacillin bind to the lysine residues. To further characterize and 
confirm the propensity for SMX-NO, piperacillin and flucloxacillin to form protein conjugates 
before stimulating a drug antigen-specific response, we used glutathione and Nα-acetyl-L- lysine 
to block protein binding before culture with T-cell clones. Specifically, glutathione (GSH) which 
contains a reactive cysteine residue was utilized to block SMX-NO protein binding. Separately,  
Nα-Acetyl-L- lysine (NAL) was used to competitively bind to the β- lactam antibiotics thereby 
blocking protein binding. Our data shows that SMX-NO-mediated T-cell responses were totally 
inhibited by GSH but not NAL confirming a requirement for the binding o f SMX-NO to cysteine 
residues in proteins before T-cell stimulation (Figure 6.10). In stark contrast, piperacillin 
responses were down regulated by NAL but not GSH indicating a requirement for piperacillin-
protein conjugates to form at lysine residues (Figure 6.11). For flucloxacillin-specific clones, the 
antigen–induced T-cell response was decreased by NAL (Figure 6.12).  
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Figure 6.5 S MX-NO, piperacillin and flucloxacillin primed naïve T-cells do not proliferate when exposed to 
drug antigen in the presence of glutaraldehyde fixed APCs . Autologous EBV‐transformed B‐cells (2 x 106) were 
washed twice in HBSS and resuspended in 1ml HBSS. Glutaraldehyde (12.5μl, 2%) was then added and the cells 
agitated for 30 seconds. Glycine (1ml, 1M) was quickly added and cells were agitated for a fu rther 45 seconds. Th e 
cells were resuspended in 10ml T ‐cell medium after extensive washing (3 times, T‐cell medium). 
Glutaraldehyde‐fixed B‐cell APCs (1 x 104, 50μl) were then added to T‐cell clones (5 x 104) in the presence or 
absence SMX-NO (50mM), piperacillin (2mM) or flucloxacillin (2mM). Control APCs were the irradiated EBV-
transformed B-cells. Cells were cultured for 3 days at 37˚C with [3H] thymidine added for the final 16h. 
Proliferation was determined by scintillation counting. The data shows mean of trip licate or du plicate wells depend 
on cells availab ility. Mann-Whitney test was applied. *p<0.05 compared with control.  
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Figure 6.6 Activation of piperacillin and S MX-NO s pecific T-cell clones were HLA class II restricted.  MHC 
class I/II blocking antibodies (5µg/ml)  were incubated with 10
4 
cells/well of autologous APCs for 30 min at 37°C in 
an atmosphere of 5% CO2. 5 x 10
4
 T-cell clones/well and medium or drug solution (piperacillin 2 mM, SMX-NO 50 
M) was then placed in  each well. The cultures were incubated under atmosphere of 5% CO2 at 37
o
C for 3 days and 
[
3
H] thymid ine was added in the final 16 hours. Proliferation results were measured by scintillation counting. The 
data shows mean of triplicate or duplicate wells depend on cells availability.  
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Figure 6.7 CD4
+
 and CD8
+ 
flucloxacillin specific T-cell clones are MHC class II and I restricted, respectively.  
MHC class I/II b locking antibodies (5g/ml) were incubated with 104 cells/well of autologous APCs for 30 min at 
37°C with atmosphere of 5% CO2. 5 x 10
4
 T-cell clones/well and medium or drug solution flucloxacillin (2mM) was 
then placed each well. The cu ltures were incubated under atmosphere of 5% CO2 at 37
o
C for 3 days and [
3
H] 
thymid ine was added in the final 16 hours. Proliferation results were measured by scintillat ion counting. The data 
shows mean of t rip licate or duplicate wells depend on cells availability.  
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Figure 6.8 APCs pulsed with SMX-NO or flucloxacillin are able to generate strong proliferative responses in a 
time-dependent manner. APCs were incubated with flucloxacillin (2mM) and SMX-NO (50µM) for 1h, 4h, 16h and 
then extensively washed (3 times) to remove free drug. This is called pulsing the APCs. 5 x 10
4
 T-cell  clones/well 
were cultured with drug pulsed APCs (1 x 10
4 
cells/well) and drugs in duplicate in 96 well plates for 3 days at 37°C in 
an atmosphere of 5% CO2. Proliferation was measured by [
3
H]-thymidine incorporation. The data shows mean of 
triplicate or duplicate wells depend on cells availability. Mann-Whitney test was applied. *p<0.05 compared with 
control. 
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Figure 6.9 APCs pulsed with piperacillin for 16 hours are able to trigger antigen s pecific T-cell responses that 
are almost comparable with soluble drug. APCs were incubated with piperacillin (2mM) for 1h, 4h, 16h  and then 
extensively washed (3 times) to remove the free drug. 5 x 10
4
 T-cell clones/well were cultured with drug pulsed 
APCs (1 x 10
4
cells/well) and drugs in duplicate in 96 well p lates for 3 days at 37°C in an atmosphere of 5% CO2. 
Proliferation was measured by [
3
H]-thymidine incorporation. The data shows mean of triplicate or duplicate wells 
depend on cells availab ility. Mann-Whitney test was applied. *p<0.05 compared with control. 
 
 
 
Figure 6.10 SMX-NO specific T-cell activation was blocked by GS H but not by NAL. T-cell clones (5 × 10
4
 
cells, 50 μl) isolated from priming assay were cultured  with EBV-transformed B-cell APCs (1 x 104 cells, 50 μl)  in 
the presence of GSH and NAL under the atmosphere of 5% CO2 for 3 days and [
3
H]-thymid ine (0.5Ci/well) was 
added to each well in the final 16 hours of culture. T-cell p roliferat ion was measured by scintillation counting. The 
data shows mean of triplicate or duplicate wells depend on cells availability. Mann -Whitney test was applied. 
*p<0.05 compared with control.  
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Figure 6.11 Piperacillin specific T-cell activation was blocked by NAL but not by GS H. T-cell clones (5 × 10
4
 
cells, 50 μl) isolated from priming assay were cultured  with EBV-transformed B-cell APCs (1 x 104 cells, 50 μl)  in 
the presence of GSH and NAL under the atmosphere of 5% CO2 for 3 days and [
3
H]-thymid ine (0.5Ci/well) was 
added to each well in the final 16 hours of culture. T-cell p roliferat ion was measured by scintillation counting. The 
data shows mean of triplicate or duplicate wells depend on cells availability. Mann -Whitney test was applied. 
*p<0.05 compared with control.  
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Figure 6.12 Flucloxacillin s pecific T-cell activation was blocked by NAL but not by GS H. Flucloxacillin specific  
T-cell clones (5 × 10
4
 cells, 50 μl) isolated from priming assay were cu ltured with EBV-transformed B-cell APCs (1 
x 10
4
 cells, 50 μl) in  the presence of GSH and NAL under the atmosphere of 5% CO2 for 3 days and [
3
H]-thymid ine 
(0.5 Ci/well) was added to each well in the final 16 hours of culture. T-cell pro liferat ion was measured by 
scintillat ion counting. The data shows mean of triplicate or duplicate wells depend on cells availability. Mann -
Whitney test was applied and *p<0.05 compared with control.  
 
 
6.4 Discussion 
Currently, it is almost impossible to predict whether a novel chemical entity will cause 
hypersensitivity during the drug development process. This is because validated in vitro methods 
using lymphocytes from human donors to characterize the drug immunogenicity do not exist. 
Furthermore, animals do not develop hypersensitivity reactions that mimic the human condition. 
Thus, in vivo experiments provide very little information regarding a compounds sensitization 
potential. We have recently developed an in vitro T-cell priming assay using PBMC from healthy 
human donors, and SMX-NO as a model drug metabolite immunogen, to investigate naïve T-cell 
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responses to drug antigens (Faulkner, Martinsson et al. 2012, Monshi, Faulkner et al. 2013, 
Gibson, Ogese et al. 2014). The assay relies on the presentation of the drug antigen by 
autologous dendritic cells as these are the only professional APCs thought able to prime naïve T-
cells. These dendritic cells are generated through a week- long culture of CD14+ monocytes 
isolated from peripheral blood with GM-CSF and IL4-supplmented R9 medium. 24 hours prior 
to harvesting, the dendritic cells are additionally cultured with lipopolysaccharide from E.Coli 
and TNF in order to promote the establishment of a mature phenotype leading to an inc reased 
ability to engulf antigen and the upregulation of cell surface co-stimulatory molecules to promote 
T-cell stimulation. Therefore, this enforced maturation stage allows this in vitro assay to bypass 
the role played by danger signaling in vivo. Once primed, the T-cells can then be restimulated in 
vitro and T-cell responses measured using readouts for proliferation and cytokine release. 
Furthermore, individual T-cells can be expanded and tested for drug antigen specificity. This 
assay allows us to investigate mechanisms of drug antigen presentation using T-cells from 
healthy drug-naïve donors and determine how these naïve T-cell responses induced in vitro relate 
to responses seen in hypersensitive patients. In this study we focused on three drug-antigens, 
SMX-NO, piperacillin, and flucloxacillin, which are strongly linked with hypersensitivity 
reactions to explore mechanisms of T-cell activation and TCR cross-reactivity.  
Drug hapten-specific T-cell activation is presumed to occur via a classical hapten mechanism 
where the drug must first form a protein adduct. The drug antigen-protein conjugate is then 
presumed to be taken up by APCs and processed into peptide fragments. To activate T-cells, the 
peptides fragments must bind to endogenous MHC molecules before they are transported to the 
cell surface where they can be presented to passing T-cells. T-cells from patients with several 
forms of chemical sensitization and drug hypersensitivity have been shown to be activated via a 
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hapten mechanism (Brander, Mauri-Hellweg et al. 1995, Pickard, Smith et al. 2007, Castrejon, 
Berry et al. 2010, Jenkinson, Jenkins et al. 2010, El-Ghaiesh, Monshi et al. 2012). However, T-
cells may also be activated by drugs and chemicals through a direct interaction with surface 
MHC molecules via the pharmacological interaction (PI) pathway that does not require antigen 
processing (Schnyder, Mauri-Hellweg et al. 1997, Schnyder, Burkhart et al. 2000, Wu, Sanderson 
et al. 2006, Ko, Chung et al. 2011, Adam, Eriksson et al. 2012). This is the proposed mechanism 
of T-cell activation by sulfamethoxazole as it is able to do so in the presence of fixed APCs, 
which are incapable of processing antigen (Elsheikh et al., 2011). In recent years, some have 
argued that haptenic drugs might preferentially activate T-cells via this mechanism (Sieben, 
Kawakubo et al. 2002, Wuillemin, Adam et al. 2013, Wuillemin, Terracciano et al. 2014, Yaseen, 
Saide et al. 2015) but also that the PI pathway is likely more associated with the activation of 
memory rather than naïve T-cells as this mechanism suits responses dependent upon lower 
activation thresholds, i.e. those cells that have been previously stimulated (Adam et al 2011, 
Pichler et al 2011). Therefore the mechanism of TCR activation reported by the studies 
mentioned above, which refer to those in patients and thus memory T-cell responses, may be 
different to those during naïve T-cell priming. Thus, to investigate the mechanisms involved in 
naïve T-cell activation, T-cell priming assays were conducted using SMX-NO, piperacillin, and 
fluxcloxacillin, each of which has been shown to covalently modify proteins (Callan, Jenkins et 
al. 2009, Jenkins, Meng et al. 2009, Whitaker, Meng et al. 2011, Ogese, Jenkins et al. 2015) and 
induce T-cell responses in hypersensitive patients (Castrejon, Berry et al. 2010, Elsheikh, 
Castrejon et al. 2011, El-Ghaiesh, Monshi et al. 2012, Monshi, Faulkner et al. 2013) and so are 
ideal candidate antigens to investigate SMX-NO and piperacillin effectively primed naïve T-cells 
from heathy drug-naïve donors in 7/7 and 6/7 donors, respectively, as determined by measuring 
 155 
 
proliferation after antigen-specific restimulation of T-cells. While the secretion of IFN-γ was also 
assessed using a higher number of donors, a much lower proportion of donors showed antigen-
specific cytokine secretion after naïve T-cell priming indicating a known lack of sensitivity of the 
ELISpot compared to thymidine incorporation (Porebski et al 2011). Unlike piperacillin 
hypersensitivity, flucloxacillin- induced liver injury is associated with the expression of HLA-
B*57:01 (Daly, Donaldson et al. 2009) and a recent study from our lab has shown the ability to 
prime naïve T-cells from healthy donors expressing this alelle (Monshi, Faulkner et al., 2013). 
Despite this association, HLA-B*57:01 is clearly not the only predisposing factor as only 1 in 
500-1000 individuals who express this risk allele go on to develop flucloxacillin- induced 
hypersensitivity after drug administration (Daly et al., 2009). Nonetheless, T-cell priming with 
flucloxacillin was attempted using cells from both HLA-B*57:01 positive and negative donors. 
While no IFN-γ secretion was detected, similarly weak proliferative responses were detected in 
two donors after naïve T-cell priming. Interestingly, these responses occurred irrespective of the 
presence of HLA-B*57:01. Importantly, the lack of a flucloxacillin-specific T-cell response was 
not related to inadequate protein adduct formation as flucloxacillin-modified proteins were 
detected in our binding study. In order to characterize the phenotype and function of antigen-
responsive T-cells we subsequently generated T-cell clones from the priming cultures of two 
HLA-B*57:01 positive and one negative donor, allowing us to extract and utilize just the 
antigen-responsive cells. Both CD4+ and CD8+ T-cell clones were generated that responded to 
SMX-NO, piperacillin, or flucloxacillin from all three donors. However, those clones that were 
beta-lactam specific formed a predominantly CD8+ population, reflecting the major ity 
phenotype of T-cell isolated from the blood of beta lactam allergic patients (Hertl et al, 1993).  A 
plethora of published articles are available that detail the cross-reactivity, or lack of, between 
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drugs that bind directly to the MHC molecules (Pichler 2003, Pichler 2005, Schnyder and Pichler 
2009, Adam et al 2011). In the case of β-lactam antibiotics, Mauri-Hellweg and colleagues found 
that while some T-cell clones from allergic patients were cross reactive with other beta- lactams, a 
second subset were highly specific (Mauri-hellweg et al, 1996). More recently, Monshi et al 
detailed similar variability regarding cross reactivity in patient clones where some flucloxacillin-
specific T-cell clones proliferated strongly in response to piperacillin exposure (Monshi et al, 
2013). In our study using cells from healthy donor naïve T-cell priming, all clones were found to 
be highly specific with a distinct lack of cross reactivity between panels of SMX-NO, 
piperacillin, and flucloxacillin-responsive clones. 
 
In order to determine the mechanism of naïve TCR activation fo r each drug antigen, we first had 
to establish the propensity for each drug antigen in question to form a hapten by binding to either 
extracellular or intracellular protein. We found that SMX-NO was able to form haptens by 
binding to protein from either the cell lysates of the supernatant, while hapten formation 
regarding flucloxacillin or piperacillin was restricted to serum proteins. The formation of hapten 
intermediates by beta lactam antibiotics in vitro mirrors the scene depicted in vivo by early 
experiments in the 1960s detailing that the serum of allergic patients contained antibodies 
responsive to benzylpenicilloyl-modified protein structures (Levine and Price, 1964; Siegel and 
Levine, 1964). Attempts to identify these drug-protein conjugates as the culprit antigens that 
trigger the immune response were made. If the conjugates induced a T-cell response, mass 
spectrometry could then be employed to characterize the exact identity of the processed antigens 
that are formed during the priming assay, thus providing direct evidence of hapten- induced T-cell 
activation in vitro. However, when using established piperacillin-albumin conjugate synthesized 
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in our lab to stimulate piperacillin-specific T-cells, we were unable to maintain the T-cell clones 
due to either a time-dependent loss of antigenicity or poor growth.  We found that primed 
piperacillin-specific T-cell clones may lose their antigen-specificity in just one and a half months. 
Further work will be required to utilize this strategy.  
 
A battery of established assays were then utilized to determine the nature of the drug-specific T-
cell response including; the use of glutaraldehyde-fixed APCs to assess the requirement for 
antigen processing, HLA restriction using MHC class I and II blocking antibodies, antigen-
pulsing to determine the ability of free drug antigen to activate T-cells but also the length of 
exposure time required for sufficient processing of antigen by APCs, and the use of GSH and 
NAL to identify the specific binding of drug antigen to either protein cysteine or lysine residues, 
respectively. We found that all three drug antigen required uptake and processing by APCs in 
order to stimulate T-cells as no response could be detected in the presence of fixed APCs, and 
stimulation of CD4+ and CD8+ T-cells was MHC class II and I restricted, respectively. 
Interestingly, the SMX-NO responsive clones were activated with APCs pulsed with the drug for 
as little as 1 hour, which coincides with the previously reported almost instantaneous binding of 
the drug metabolite to protein (Naisbitt, Hough et al. 1999, Naisbitt, Farrell et al. 2002, Callan, 
Jenkins et al. 2009). In contrast, β- lactam antibiotics bind to protein in a time-dependent manner 
(Whitaker, Meng et al. 2011, El-Ghaiesh, Monshi et al. 2012) and in general, a longer (4-16 
hour) APC pulse was required to activate T-cells. Collectively these mechanistic studies indicate 
that T-cells responsive to all three drug antigens were activated by a hapten mechanism and that 
hapten formation was able to readily activate naïve T-cells in vitro. Hence, hapten formation in 
patients should be considered an important risk factor. However, this leads to the intriguing 
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puzzle as to why exposure to drugs such as paracetamol is not associated with a high incidence 
of hypersensitivity reactions. Paracetamol is metabolized in the liver to a reactive quinoneimine 
intermediate, which binds irreversibly to hepatic proteins and in overdose causes acute liver 
failure. However, these haptenated proteins are not “recognized” by the adaptive immune system 
and hypersensitivity reactions are reported infrequently.  
 
In summary, we show that highly structurally-specific T-cells are readily primed in vitro when 
autologous functionally mature dendritic cells present antigenic determinants, derived from 
haptenic structures bound covalently to protein, to naïve T-cells. The T-cell priming assays 
allows us to effectively determine the functional mechanisms by which distinct drug antigens 
activate the immune system by utilizing T-cells from healthy donors. This bypasses the difficulty 
of obtaining access to patient samples, and importantly allows for the investigation of the naïve 
T-cell response rather than the memory T-cell responses we detect in pre-sensitized responsive 
individuals. Furthermore, the availability of such an in vitro assay, once developed further to 
incorporate several donors on a single test plate, might represent an effective strategy for 
pharmaceutical companies to screen the immunogenicity of novel chemical entities thus 
enhancing the safety profile of future compounds.     
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Chapter 7 
 
7.1 Final discussion. 
 
Drug hypersensitivity represents an impediment to the drug development process and a burden 
on national health services. Although many reactions are mild and self- limiting, i.e., symptoms 
resolve after drug withdrawal, a limited number of patients develop serious and sometimes life-
threatening conditions. Drug hypersensitivity is described as an idiosyncratic or type B 
hypersensitivity reaction as mechanisms generally remain unresolved. In most cases, no simple 
relationship is apparent between the dose of drug administered and the development of clinical 
symptoms, due to the curve of therapeutic drug doses and the curve of drug doses induce 
hypersensitivity are not in the same range. Despite this, it should be noted that most drugs 
associated with a high incidence of hypersensitivity are administered at high mass doses.  
Immuno-histological studies of inflamed tissue of hypersensitive patients show an infiltra tion of 
T-cells. The T-cells have been isolated from the tissue, expanded in vitro, and shown to display 
reactivity against the drug the patient was exposed to at the time of the reaction. (Schnyder, 
Frutig et al. 1998, Yawalkar, Hari et al. 2000, Yawalkar, Shrikhande et al. 2000, Britschgi, 
Steiner et al. 2001, Nassif, Bensussan et al. 2002, Nassif, Bensussan et al. 2004, Ko, Chung et al. 
2011) In mild conditions, CD4+ T-cells are believed to be the primary mediators of tissue injury, 
potentially inducing cell death indirectly through the release of cytokines that recruit phagocytes, 
or directly through the production of apoptosis- inducing cytolytic molecules. In more severe 
conditions, i.e., Stevens-Johnson syndrome and toxic epidermal necrolysis, granulysin-secreting 
cytotoxic CD8+ T-cells predominate. Phenotypic and functional characterization of drug-specific 
T-cells from hypersensitive patients led to the development of an expanded Coombs and Gell 
classification of hypersensitivity (Pichler, Yawalkar et al. 2002, Pichler 2003, Pichler 2003). 
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Therefore, it was possible to describe different clinical conditions according to the CD phenotype 
of the drug-specific T-cells and the cytokines/effector molecules they secreted. Importantly, this 
classification is somewhat obsolete as it does not encompass the new populations of T-cell that 
have been discovered over the last decade.  
Identification of HLA alleles as important susceptibility factors for many forms of 
hypersensitivity has led to a renewed interest in understanding the nature of the drug interaction 
with immune receptors, in particular MHC molecules and specific T-cell receptors. The most 
progress has been made exploring whether HLA class I associations with particular forms of 
hypersensitivity relate to a specific fit of the drug-derived antigen within MHC class I molecules. 
For example, we now know that antigens derived from abacavir (HLA-B*57:01),  (Mallal, Nolan 
et al. 2002) allopurinol (HLA-B*58:01),  (Hung, Chung et al. 2005) carbamazepine (HLA-
B*15:02 & HLA-A*31:01) (Chung, Hung et al. 2004, McCormack, Alfirevic et al. 2011) and 
flucloxacillin (HLA-B*57:01) (Daly, Donaldson et al. 2009) interact with a degree of selectivity 
with the HLA risk allele to activate T-cells from hypersensitive patients. (Chessman, Kostenko et 
al. 2008, Ko, Chung et al. 2011, Monshi, Faulkner et al. 2013, Yun, Mattsson et al. 2013, 
Lichtenfels, Farrell et al. 2014) Furthermore, for each of the drugs highlighted above, it is 
possible to activate T-cells from healthy drug-naïve donors with the drug if they carry to risk 
allele. (Chessman, Kostenko et al. 2008, Farrell, Lichtenfels et al. 2013, Monshi, Faulkner et al. 
2013, Yun, Marcaida et al. 2014) Although genetic studies have identified several HLA class II 
associations with drug hypersensitivity e.g., amoxicillin-clavulanate,  (Donaldson, Daly et al. 
2010) lapatinib, (Spraggs, Budde et al. 2011, Spraggs, Parham et al. 2012) ximelagatran 
(Kindmark, Jawaid et al. 2008), as yet functional studies have not as yet been able to relate the 
activation of T-cells to restriction of the fit of the drug-derived antigen within the MHC molecule 
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encoded by the HLA risk allele.  
Does the association between specific hypersensitivity reactions and MHC proteins provide 
mechanistic information on how T-cells are likely to be triggered? The simple answer is no. 
Traditionally, drugs are thought to activate T-cells via 2 pathways. Pathway 1 (i.e., hapten 
hypothesis) involves the formation of drug-protein adducts as the initiation step. This is followed 
by protein processing and release of drug-modified peptides that are believed to bind directly to 
MHC molecules prior to triggering T-cells (Brander, Mauri-Hellweg et al. 1995, Padovan, Bauer 
et al. 1997). Pathway 2 (i.e., PI concept) involves direct binding of drugs to the peptide- loaded 
MHC molecules expressed on the surface of antigen presenting cells. The drug-MHC binding 
interaction is reversible, but sufficiently stable to trigger T-cell responses (Zanni, von Greyerz et 
al. 1998, Schnyder, Burkhart et al. 2000). From this brief discussion one can see that the species 
interacting with T-cell receptors is similar for both pathways (i.e., a MHC peptide drug complex). 
The main differences are (1) the nature of the drug peptide binding interaction and (2) the way in 
which the drug is transported to the MHC peptide binding groove.  
Studies using cells from healthy donors and hypersensitive patients who carry specific HLA risk 
alleles has enhanced our understanding of drug MHC binding interactions and go ne some way to 
address the suppositions associated with the hapten hypothesis and PI concept. Carbamazepine 
and allopurinol (or more precisely the metabolite oxypurinol) bind directly to surface MHC 
molecules and activate T-cells via a PI mechanism (Lichtenfels, Farrell et al. 2014, Yun, 
Marcaida et al. 2014).  Flucloxacillin, a β- lactam antibiotic that forms adducts with lysine 
residues on protein directly, activates T-cells from patients with liver injury via a classical hapten 
mechanism (Monshi, Faulkner et al. 2013). However, it should be noted that T-cells from healthy 
donors expressing HLA-B*57:01 are activated in vitro under conditions of excess antigen by 
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both hapten and PI pathways (Wuillemin, Adam et al. 2013, Yaseen, Saide et al. 2015). Finally, 
ground-breaking studies from 3 independent research groups exploring abacavir HLA binding 
devised a new pathway of drug-dependent T-cell activation. (Illing, Vivian et al. 2012, Norcross, 
Luo et al. 2012, Ostrov, Grant et al. 2012) The authors demonstrated that abacavir binds directly 
to endogenous HLA-B*57:01 (within antigen presenting cells) and alters the structure of the 
peptide binding groove. As such, with time, an altered repertoire of HLA binding self-peptides is 
displayed on the surface of the antigen presenting cell. It is assumed that a portion of these 
peptides cross-react with pathogen-derived peptides and activate pre-existing memory T-cells in 
susceptible patients and ultimately the clinical condition of abacavir hypersensitivity. Initially, it  
was assumed that many drugs might activate T-cells via this pathway; however, despite intensive 
studies as yet a second example has not been forthcoming. This is not so surprising as for most 
forms of drug hypersensitivity, even those with an HLA allele association, patients expressing 
multiple HLA alleles go on to develop hypersensitivity indicating that the presence of the risk 
allele increases the likelihood of developing hypersensitivity, but is not the sole predisposing 
factor.       
Notwithstanding the above discussion several forms of drug hypersensitivity are not linked to 
expression of a particular HLA allele. Most forms of β- lactam and sulphonamide hypersensitivity 
reactions can be included in this list. The sulphonamides have been studied most extensively and 
to date HLA risk alleles have not been identified.  (Alfirevic, Vilar et al. 2009) One explanation 
for this might be the high incidence of reactions seen in patients exposed to these classes of drug. 
For example, sulfonamide reactions are seen in 30-50% of patient with HIV infection,  
(Pirmohamed and Park 2001) whereas β-lactam reactions are observed in up to 30% of patients 
with cystic fibrosis (Whitaker, Naisbitt et al. 2012). In both instances patients are exposed to 
 163 
 
high doses of drug, often for a prolonged duration.    
In this thesis I focused on three drugs associated with a high incidence of hypersensitivity 
reaction: the sulfonamide sulfamethoxazole and the β- lactam antibiotics piperacillin and 
flucloxacillin. Sulfamethoxazole is a pro-hapten that requires metabolism to generate a hapten. It 
is metabolized preferentially by CYP2A9 to a hydroxylamine intermediate.(Gill, Tjia et al. 1999) 
This metabolite circulates unchanged in the periphery. However, under pro-oxidative conditions 
it is spontaneously oxidized to nitroso sulfamethoxazole (SMX-NO), (Naisbitt, ONeill et al. 
1996, Naisbitt, Hough et al. 1999) which binds covalently to cysteine residues on 
protein.(Callan, Jenkins et al. 2009, Ogese, Jenkins et al. 2015) Fortunately, SMX-NO can be 
synthesized (Naisbitt, ONeill et al. 1996) and when added to aqueous buffers has a half- life of 5-
10mins. (Naisbitt, Hough et al. 1999, Naisbitt, Gordon et al. 2001, Castrejon, Lavergne et al. 
2010) This timeframe is sufficient to generate drug protein adducts that activate dendritic 
cells,(Sanderson, Naisbitt et al. 2007, Elsheikh, Lavergne et al. 2010) and T-cells from (1) 
hypersensitive patients, (Schnyder, Burkhart et al. 2000, Castrejon, Berry et al. 2010) (2) drug 
naïve donors (following priming) (Engler, Strasser et al. 2004, Faulkner, Martinsson et al. 2012) 
and (3) in animal models of immunogenicity. (Naisbitt, Gordon et al. 2001, Naisbitt, Farrell et al. 
2002, Farrell, Naisbitt et al. 2003) The β- lactam antibiotics piperacillin and flucloxacillin both 
form adducts through a direct interaction with lysine residues on protein; however, they differ in 
terms of (1) the nature of the hypersensitivity reaction: flucloxacillin, liver injury; piperacillin, 
skin injury, (2) the dominant phenotype of drug-specific T-cell: flucloxacillin, CD8+;(Monshi, 
Faulkner et al. 2013) piperacillin, CD4+ (Whitaker, Meng et al. 2011, El-Ghaiesh, Monshi et al. 
2012) and (3) whether reactions are associated with an HLA risk allele: flucloxacillin, HLA-
B*57:01;(Daly, Donaldson et al. 2009) piperacillin, no known associations (unpublished data). T-
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cell clones responsive to the drugs were generated from blood and skin of hypersensitive patients 
to study the functionality of T-cells, focussing specifically on the cytokines IL-17 and IL-22. 
PBMC from healthy donors were subjected to drug-specific dendritic cell T-cell priming to 
assess whether T-cells with a similar phenotype can be generated in vitro. Finally, clones 
responsive to the 3 drugs were used to assess T-cell cross reactivity and mechanisms of drug-
specific T-cell activation. 
In initial studies, piperacillin-responsive T-cells were cloned from peripheral blood of 
hypersensitive patients. In agreement with published data, the vast majority of piperacillin-
responsive clones were CD4+. Clones proliferated in concentration-dependent manner following 
drug stimulation, with concentrations above 4 mM inhibiting the response due to cytotoxicity 
(results not shown). ELISpot was used to visualize the cytokines released by piperacillin-specific 
clones. T-cell activation resulted in secretion of a mixed panel of Th1 and Th2 cytokines with 
IFN-γ, IL-5 and IL-13 secreted by individual clones. Importantly, the availability of antibodies 
for IL-17 and IL-22 allowed us to investigate for the first time whether these cytokines are 
secreted by drug-specific T-cells. Many piperacillin-specific clones were found to secrete IL-22 
alongside Th1 and Th2 cytokines. However, IL-17 was not detected. 
One question that is frequently asked by researchers in the field of drug hypersensitivity is  
whether clones isolated from blood accurately reflect what occurs is skin at the time of the 
hypersensitivity reaction. To address this issue, through a close collaboration with the clinical 
team at the Leeds cystic fibrosis unit, skin biopsies were obtained from two patients following a 
positive piperacillin skin prick challenge. The hypothesis we were testing is that T-cells that 
migrate into the inflamed skin are the primary mediators of the hypersensitivity reaction. These 
biopsies were transferred to Liverpool to isolate and characterize the infiltrating T-cells. Skin was 
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digested and T-cells were allowed to migrate from the tissue to culture supernatant containing IL-
2. The T-cells were stimulated non-specifically with the mitogen PHA and cloned directly 
without any requirement for a round of drug-specific expansion. Piperacillin-specific CD4+ 
clones were successfully isolated from both biopsy specimens and subjected to the same analysis 
as the blood-derived clones. Importantly, the cyotkine profile of the skin-derived and blood-
derived piperacillin-specific clones was similar, with Th1 and Th2 cytokines detected alongside 
IL-22. These data are in agreement with the elegant studies of (Gaide, Emerson et al. 2015) who 
found that for every abundant skin resident memory T-cell generated from a naïve precursor, an 
abundant central memory T-cell bearing the same T-cell receptor can be found. They suggested 
that the tissue resident cells respond rapidly following antigen exposure, whereas the central 
memory cells produce a delayed response that extend the duration of the allergic reaction. The 
discovery of IL-22 as an important mediator of piperacillin hypersensitivity might explain why 
patients exposed to piperacillin rarely develop severe forms of hypersensit ivity reaction as IL-22 
has been shown to promote keratinocyte proliferation and wound repair in several forms of skin 
disease.(Eyerich, Eyerich et al. 2010, Cavani, Pennino et al. 2012, Avitabile, Odorisio et al. 
2015) 
Based on these findings, in the next component of the thesis I choose to explore whether it was 
possible to prime naïve T-cells from healthy donors to piperacillin and if so explore the nature of 
the induced response. To fulfil this objective, a recently developed dendritic cell T-cell priming 
assay was utilized. The assay relies on culture of highly purified naïve T-cells with autologous 
monocyte-derived dendritic cells and piperacillin for 8 days to prime the T-cells. Drug-antigen 
responses are then measured through assessment of proliferation and/or cytokine secretion by 
restimulating the now primed T-cells with a second batch of autologous dendritic cells and 
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piperacillin. Piperacillin effectively activated naïve T-cells from the healthy donors. Through the 
cloning of T-cells from the priming assay it was possible to show that piperacillin-specific T-cell 
activation was associated with secretion of Th1 and Th2 cytokines alongside IL-22, which 
mirrored the responses observed in hypersensitive patient skin. The one intriguing difference 
between healthy donor and patient T-cells was that many healthy donor T-cells expressed the 
CD8 co-receptor. This may relate to differences in the provision of piperacillin antigens in vitro 
and in patient skin; however, further investigation in this area was beyond the scope of this 
thesis.  
All of the experiments investigating piperacillin-specific T-cell priming utilized SMX-NO as a 
positive control. Hence, the cytokines secreted from SMX-NO-responsive T-cells was also 
profiled and related to T-cells from sulfamethoxazole hypersensitive patients. Similar to 
piperacillin, SMX-NO-responsive clones secreted Th1 and Th2 cytokines and IL-22, but IL-17 
was not detected. These data lead to the possibility that IL-22 secretion from drug-specific T-
cells is a common feature of drug hypersensitivity reactions in patients. Obviously further 
experiments using T-cells from patients with mild and severe forms of hypersensitivity are 
needed to confirm this possibility.   
The ability of CD4+ T-cells to initiate hypersensitivity is often questioned. The clones generated 
from piperacillin and sulfamethoxazole hypersensitive patients secreted IFN-γ following drug 
stimulation and as such will have the capacity to recruit and activate phagocytes; thus, providing 
an indirect pathway to tissue injury. Furthermore, several clones secreted cytolytic molecules 
including perforin, granzyme B and FasL. Hence, the T-cells might also damage keratinocytes 
directly through induction of the apoptotic cascade.                            
The final objective of my project was to explore mechanisms of drug-hapten-specific T-cell 
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activation and cross-reactivity between 3 different drug antigens: piperacillin, flucloxacillin and 
SMX-NO. Clones responsive to all 3 drugs were activated via a hapten mechanism. Several 
pieces of evidence support this conclusion. First, drug-pulsed antigen presenting cells activated 
all of the clones. In these experiments, the antigen presenting cells are cultured with drug for 
different durations. This is followed by repeated washing with drug-free medium. Finally, the 
antigen presenting cells are added to the T-cell assay in the absence of soluble drug. Second, 
fixation of antigen presenting cells with glutaraldehyde blocked the activation of the T-cell 
clones. Glutaraldehyde inhibits antigen processing but not the presentation of drug bound 
directly to MHC expressed on the surface of antigen presenting cells. Third, addition of 
exogenous glutathione (SMX-NO) and N-acetyl lysine (piperacillin and flucloxacillin) to culture 
medium reduced the strength of the drug-specific T-cell response. These mediators reduce drug 
hapten protein binding but will not alter the ability of the drug to bind directly to surface MHC. 
(Schnyder, Burkhart et al. 2000, Burkhart, von Greyerz et al. 2001, Jenkins, Meng et al. 2009, 
Meng, Jenkins et al. 2011) Finally, MHC blocking antibodies inhibited the drug specific T-cell 
response. Collectively, these data indicate that clones responsive against all 3 drugs are activated 
via a pathway involving formation of drug protein adducts, uptake of the adducted proteins by 
antigen presenting cells, protein processing and binding of the derived peptides to MHC.  
The availability of hapten-responsive clones with specificity for 3 drugs provided the unique 
opportunity to study T-cell cross reactivity. To date, several studies have addressed T-cell cross 
reactivity with parent drugs that bind directly to MHC, but knowledge of the drug-hapten-
specific response was limited. Clones responsive against SMX-NO, piperacillin and 
flucloxacillin haptens were not activated with the alternative compounds, which suggests that the 
hapten structure is important for the T-cell receptor binding interaction and triggering of the T-
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cell response.  
In summary, this thesis describes a series of investigations that explore the way in which T-cells 
are activated by drug haptens and the nature of the induced response. Two areas of interest 
deriving from these studies: specifically, (1) the role of IL-22 in drug hypersensitivity reactions 
and (2) the preferential generation of piperacillin-responsive CD4+ and CD8+ T-cells in patients 
skin and in vitro, respectively, warrant further investigation.     
 
Appendix 
 
 
Appendix Figures showed the piperacillin specific cytokine correlat ions in chapter3, which includes (A) Drug 
specific IL-22 secretion (showed by stimulatory index) and drug specific IFN-, (B) Drug specific T-cell 
proliferation and IL-13, (C) Drug specific T-cell proliferation and IFN-, and (D) Drug specific IFN-and IL-13.  
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